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ABSTRACT 
The utility of the dissolution test has broadened from a simple quality control tool to have a 
more developmental and predictive role. Consequently, it has been realised that compendial 
dissolution media may not adequately represent the environment in the gastro-intestinal tract 
(GIT), resulting in poor in vitro-in vivo correlations (IVIVC). Biorelevant media are being 
developed in which oral dosage forms may be studied. Of particular interest is the effect of 
biorelevant media on poorly soluble and highly permeable drugs (Biopharmaceutics 
Classification System Class II), which may suffer from dissolution rate-limited bioavailability. 
In addition to pH and secretory changes between the fasted and fed state, the composition of the 
ingested meal may influence drug dissolution through surfactant, complexation and 
micellization effects. 
The dissolution behaviour of the acidic drugs ibuprofen and naproxen was investigated in 
compendial media, in 50/50 milk/O. IN HCI mixtures and, where appropriate, in mono 
component media based on milk (4.8% w/v lactose, 1.475% w/v casein). The dissolution of the 
basic drug loratadine was investigated in a pH-shift experiment (pH 1.2 - 7.3) using buffer 
media and in Fasted state simulated intestinal fluid (FaSSIF) and Fed state simulated intestinal 
fluid (FeSSIF). Loratadine solubility was assessed in a range of surfactant media in an attempt 
to develop less expensive replacement media for FaSSIF and FeSSIF. Consequently dissolution 
tests were carried out using varying concentrations of sodium dodecyl sulphate (SDS) and 
hexadecyltrimethyl ammonium bromide (CTAB) media to match profiles obtained from the 
biorelevant media. The dissolution of a second basic drug, trimethoprim, was investigated in 
phosphate buffer pH 6.8. 
Tablet dissolution tests were performed using the USP 28 Apparatus 2 under test conditions of 
37°C, 50 rpm and 500mL (gastric) or 1000mL (intestinal) volume. Intrinsic dissolution rate 
(IDR) studies were carried out for ibuprofen and naproxen using the USP28 Rotating Disk 
Method fitted with 10 mm dies. 24 h solubility studies were completed for all the drugs in the 
relevant media and disintegration tests were performed on ibuprofen, naproxen and loratadine 
tablets. All samples were analysed by HPLC. 
The solubility of ibuprofen and naproxen was improved in the milk media. Casein, the major 
bovine milk protein, was identified as a food component that increased the release of ibuprofen 
and naproxen from tablets through interactions with the excipients. The amount of loratadine 
dissolved in the dissolution vessel decreased when the pH was increased from 1.2. to 7.3. The 
dissolution profiles of three loratadine tablet brands (A, B and C) containing the same excipients 
differed significantly in FeSSIF over lh and in FaSSIF over 4h. The neutral and zwitterionic 
surfactants tested were poor solubilisers of loratadine. The dissolution profiles in FaSSIF and in 
FeSSIF were matched for one product (Brand B) by using SDS and CTAB media but the profile 
similarity was not maintained when another product (Brand C) was tested in the same media. 
Variations in the manufacturing formulae and processes of these brands may be implicated in 
the differences observed. Despite being placed in BCS Class II, trimethoprim dissolution in 
phosphate buffer pH 6.8 was high (100% in 15min). 
The use of milk as a biorelevant gastric medium highlighted a food effect on drug solubility and 
dissolution from tablets for ibuprofen and naproxen. Loratadine solubilisation in both biological 
and synthetic surfactant systems appears to be sensitive to formulation factors. The BCS criteria for solubility classification are inappropriate for trimethoprim in the physiologically relevant pH 
range 1.2-6.8, 
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"It is the mark of an educated mind to be able to entertain a 
thought without accepting it. " 
Aristotle (384BC -- 322BC) 
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1. INTRODUCTION 
The process of dissolution and the methods of dissolution testing are fundamental 
topics that need to be appreciated in order to further probe dissolution phenomena 
occurring in pharmaceutical compounds. Scientific and technological advances in 
discovery and development programmes in the industry have instigated a need to 
characterise dissolution behaviour earlier in the product development lifecycle. 
Such information could lead to the synthesis of more soluble compounds or the 
formulation of more soluble products to improve bioavailability. From a viewpoint 
of dissolution, the aims are to assess changes in the dissolution behaviour and hence 
potential bioavailability of candidate drugs, to formulate a drug product from which 
drug absorption is not dissolution rate limited, and further, to be able to predict in 
vivo drug dissolution performance using in vitro methods. This chapter introduces 
the basic concepts and theory of dissolution and dissolution testing, together with 
the factors that affect them and related issues, leading to the aims and objectives of 
this research project. 
1,1. Drug dissolution 
1.1.1. Solubility and dissolution 
Unless a drug is administered directly into the blood stream intravenously, it must 
be absorbed into the systemic circulation from its site of administration. On reaching 
the systemic circulation a drug may partition between erythrocytes and blood 
plasma. Furthermore, the drug in blood plasma may bind to plasma protein or 
remain in plasma water. The unbound drug is free to be distributed to tissues and 
sites of action (Proudfoot, 1988a). The absorption, and thus bioavailability, of drugs 
from oral dosage forms depend on a variety of drug and formulation factors as well 
as the physiological condition of the gastro-intestinal tract (GIT). Essentially, for a 
drug to be absorbed into the blood stream it must first dissolve in the gastric or 
intestinal fluid and then cross the mucosal membrane via para- or trans-cellular 
1 
mechanisms that range from passive diffusion to complex carrier mediated 
transport. Thus, the dissolution rate of a drug in these fluids can be the rate-limiting 
step to absorption, especially for poorly water-soluble drugs. 
Before considering the factors that affect dissolution, it is important to clarify what 
is meant by solubility and to understand the dissolution process itself. Solubility can 
be defined as the number of molecules or ions that move from the solid state into 
solution until equilibrium is reached under a given set of experimental conditions. 
The process of transfer is termed dissolution. Carstensen (2001) confirmed concerns 
about the definition of solubility, assuming that when solubility is referred to, it is 
meant to be the equilibrium solubility. This is when a solid and solvent are agitated 
together for a sufficiently long period of time for the concentration of solute in the 
solvent to have reached a constant level. 
Solubility is temperature dependent and small fluctuations in the experimental 
temperature can affect the solubility results for a compound. Also, solubility may be 
a function of the particle size (surface area increases with decreasing particle size) 
(Atkinson et al., 1962; Fincher, 1968) and the existence of polymorphs and 
amorphates (Shaw et al., 1973). Literature also refers to degrees of solubility e. g. 
poorly soluble. What does this mean? The United States Pharmacopoeia 28 (2005) 
describes some of these subjective terms (Table 1.1). 
Table 1.1. Quantitative description of commonly used solubility terms 
Solubility term weight of solvent (g) required 
to dissolve 1g of solute 
Very soluble <1 
Soluble 10-30 
Sparingly soluble 30-100 
Slightly soluble 100-1000 
Very slightly soluble 1000-10 000 
Practically insoluble >10 000 
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Aqueous solubility is a function of the ability of a non-ionic compound to form 
hydrogen bonds with water molecules and generally is directly proportional to the 
number of bonds that can be formed with water (Martinez et al., 2002). 
Dissolution requires bond-breaking and bond-forming processes to allow drug 
molecules to move away from the solid structure and interact with the solvent. The 
energy changes associated with such processes are the thermodynamic basis of 
dissolution. 
1.1.2. Thermodynamics of dissolution 
Heat is usually absorbed when a solid dissolves. This is called the enthalpy of 
solution (AHs) and is defined as the heat absorbed at constant temperature and 
pressure when 1 mole of solid dissolves in a very large amount of solvent. 
AH, = lattice enthalpy + enthalpy of solvation (Eq. 1.1} 
The lattice enthalpy is the heat absorbed (at constant temperature and pressure) to 
separate completely the molecules or ions of I mole of crystalline solid from their 
mutual attraction in the crystal lattice and is an endothermic process. The enthalpy 
of solvation is the heat absorbed (at constant temperature and pressure) when 1 mole 
of the separated molecules or ions become immersed and interact with a very large 
volume of solvent, i. e. water. This is an exothermic process. Solubility usually 
increases with temperature because AH, is positive since the endothermic lattice 
enthalpy is higher than the exothermic enthalpy of solvation. In rare cases where the 
affinity of the solute for solvent is so great that the enthalpy of solvation is higher 
than the lattice enthalpy e. g. anhydrous sodium sulphate in water, increasing 
temperature will decrease solubility according to Le Chatelier's principle (Wallwork 
& Grant, 1977). 
For dissolution to occur spontaneously, there must be a decrease in the free energy 
of the system, known as Gibbs free energy (AG). Gibbs free energy is a measure of 
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the energy available in a system to do work (Richards, 1988). In this case it would 
be the work done to overcome the lattice energy of a solid, 
OG = OH$ -TAS { Eq. 1.2 } 
where T is the thermodynamic temperature and AS is the change in entropy. Entropy 
is a measure of the randomness of the system and for a process like dissolution, 
where molecules are no longer held in a solid structure, the randomness increases. It 
follows then that if AG has to be negative for spontaneity and AS is positive for 
dissolution then AH, must be negative, zero or very slightly positive (Aulton, 2002). 
At a molecular level, if a solute is to be soluble in a solvent, the intermolecular 
attractive forces between solute and solvent must be equivalent to or stronger than 
the attractive forces between solute-solute and solvent-solvent molecules 
themselves. Ionic compounds and salts dissolve in polar solvents because the 
dielectric constant of the solvent weakens the attractive forces between oppositely 
charged solute ions. Furthermore, the permanent dipole of the solvent results in the 
introduction of new electrostatic attractions such that the ions will be surrounded by 
interacting solvent molecules. In cases where non-ionic compounds have shown 
aqueous solubility it is the result of hydrogen bonding of the -OH, -NH2 and -COOH 
groups with the solvent with the possibility of dipole-dipole attractions at other parts 
of the molecule (Wallwork & Grant, 1977). 
1.1.3. Mechanisms of dissolution 
Dissolution experiments were first cited in the work by Noyes and Whitney (1897) 
who expressed the law : "The rate at which a solid substance dissolves in its own 
solution is proportional to the difference between the concentration of that solution 
and the concentration of the saturated solution. " 
Further investigations by various workers led to the theories of dissolution described 
below. 
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Film Theory (Nernst & Brunner, 1904). This is a widely utilised theory in literature. 
It states that if a solid is immersed in an agitated liquid and allowed to dissolve, bulk 
liquid will move past the solid at a certain velocity but a layer of liquid, with 
thickness hi, will surround the solid (Figure 1.1). This boundary layer is static due to 
intermolecular forces at the solid/liquid interface. The concentration in the boundary 
layer adjacent to the solid is the saturation solubility C and that in the bulk solution 
is C. Hence, there is a concentration gradient across this layer, which obeys Fick's 
first law of diffusion. This theory is the basis of the Nernst-Brunner equation that 
has been extensively used in dissolution rate studies and which is described later in 
this section. 
Static boundary layer with thickness h, 
0 
1)illmiun ul dlssulred drug mulceulc Blood 
lhnnilh the ssmantcunud enm ", circulation 
z 
I 
N 
ýýý 
Gastrointestinal membrane 
(site of absorption) 
Figure I. I. Schematic illustration of the dissolution of a drug particle in 
gastrointestinal fluids 
Sur/We Renewal Theory/ Penetration Theory (Danckwerts, 1951). In the event that 
the reaction rate at the solid surface is the rate-limiting step to dissolution, then the 
concentration at the solid/liquid interface will actually be less than the Cs. This led 
Danckwerts (1951) to disregard the existence of a stagnant boundary layer and 
propose that turbulence reaches the solid surface, which is then continually being 
replaced with fresh liquid. Carstensen (1974) suggested that this renewal could be 
looked at as solvent molecules from the bulk diffusing through the boundary layer 
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as being the rate-limiting step. The Danckwerts equation equivalent to the Nernst- 
Brunner equation is: 
dC/dt = A. Sv'. Dv' . (CS-C) {Eg. l. 3 } 
where dC/dt is the change in concentration with time; A is the surface area of the 
solid; S is the mean rate of production of fresh surface and D is the diffusion 
coefficient (Higuchi, 1967). 
Interfacial Barrier Theory. In the case where the interfacial reaction at the solid 
surface is much slower than the transport process to the bulk solution, the 
dissolution rate is `surface controlled'. It is difficult to derive a relationship for the 
dissolution rate in this situation since different crystal faces will have different 
interfacial barriers (Higuchi, 1967). A general equation can be presented as: 
dC/dt = A. kj. (Cs - C) {Eg. 1.4) 
where k1 is the effective interfacial rate constant (Higuchi, 1967) 
Double Barrier Theory. When both the interfacial reaction rate and transport rate are 
of similar magnitude both processes may control the dissolution rate. Combining the 
interfacial barrier and boundary layer concepts gives the equation: 
dC/dt = A. D. (C1-C) {Eq. 1.5} 
hl. [1 +D/hiklj 
where h, is the boundary layer thickness (Higuchi, 1967) 
Combining the interfacial barrier and surface penetration concepts gives the 
equation: 
dC/dt = SV2. D". (Cs- .Q{ 
Eq. 1.6 } 
[1 + (S". Dy')/kt] 
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Returning to the film theory, the Nernst-Brunner equation (Nernst & Brunner, 1904) 
can be used to describe the diffusion-controlled dissolution of a solid: 
dC = D. A (C, - C) {Eq. 1.7 } 
dt h, 
It follows then, that the factors which influence the terms of this equation will 
consequently affect the dissolution rate. 
During dissolution the surface area of dissolving particles will continuously change. 
Hixson and Crowell (1931) derived a law which related the dissolution rate to 
surface area and concentration. They expressed the particle surface as proportional 
to weight and introduced the Hixson-Crowell cube root law equation (Hixson & 
Crowell, 1931). For a spherical particle under sink conditions (see below) the 
equation is written as: 
k2t = Woiý_Wýh {Eq. l. 8} 
where wo is the initial weight of the particle, w is the weight of the particle at time t 
and k2 is the cube root dissolution rate constant. 
Plotting the cube root difference (wo 1/3 - w) against time shows a linear 
relationship, the slope of which gives the constant k2. For non- spherical particles 
the assumptions are: 
a) The dissolution characteristics of all the crystal faces are identical i. e. particles 
dissolve in an isotropic fashion 
b) Particles are isometric, which implies that the shape factor (a) of a particle is 
independent of time. 
If the bulk concentration (C) is less than 10 % of the saturated concentration i. e. 
when the solute is removed from the dissolution medium at a faster rate than it 
passes into solution or when the dissolution volume is sufficiently large, then `sink' 
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conditions are said to operate (Richards, 1988). The Nernst-Brunner equation 
(Equation 1.7) can then be approximated to: 
dC = D. A. Cý (Eg. 1.9) 
dt ht 
However, during the dissolution of tablets, disintegration, deaggregation and 
dissolution causes the effective surface area to continuously change therefore the 
dissolution rate is measured as the total amount of drug dissolved per unit time 
(mg/min) (Wells & Aulton, 1988). 
1.1.4. Intrinsic Dissolution Rate 
The intrinsic dissolution rate (IDR) of a pure substance is the rate at which it 
dissolves from a constant surface area whilst the temperature, agitation, pH and 
ionic strength of the dissolution medium are kept constant. Thus, for a drug 
substance, the IDR is independent of formulation factors and measures the inherent 
dissolution rate of the drug in the dissolution medium. IDR determinations can be 
used to characterise bulk drug substances and excipients and to test the chemical 
equivalence of active pharmaceutical ingredients synthesised by different processes. 
They can also provide an important insight into the dissolution behaviour of a drug 
in physiological conditions or distinguish whether changes in the dissolution profile 
of a drug product in various biorelevant media are due to interactions between the 
medium and formulation excipients or medium and drug substance or both. 
Subsequently, this test has a place in the screening of drug candidates for further 
development. Yu et al (2004) discussed the feasibility of using IDR (as opposed to 
saturation solubility data) to place drugs in a Biopharmaceutics Classification 
System (BCS) class (see Section 1.5) since in vivo drug dissolution is a dynamic rate 
controlled process rather than an equilibrium process. 
The IDR is a key indicator of the potential bioavailability of a candidate drug before 
formulation, where an IDR z1. Omg/min/cm2 suggests that drug dissolution will not 
be the rate-limiting step to absorption whilst an IDR 50.1mg/min/cm2 suggests that 
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drug dissolution will be the rate-limiting step to absorption. An intermediate value 
suggests that drug dissolution ma be the rate-limiting step to absorption. This guide 
is based on stirring at 50 rpm, 37°C, pH 1-8 under sink conditions (Kaplan, 1974). 
Maintenance of a constant surface is a critical requirement for IDR studies. Levy 
and Sahli (1962) fixed a flat disk perpendicular to a rotating shaft exposing a single 
surface to the dissolution medium. An improved rotating disk apparatus was 
introduced by Wood et al (1965) and is described in Section 1.1.4.2.1. 
The transport of solute in a moving liquid is governed by molecular diffusion due to 
concentration differences and also by entrainment of solute molecules in the moving 
liquid (Levich, 1962). Combination of the two mechanisms is termed convective 
diffusion of a solute in a liquid. Levich (1962) proposed a convective diffusion 
theory for the rate of mass transport to and from the face of a rotating disk. Fluid in 
the dissolution vessel moves towards the rotating disk and a thin layer adjacent to 
the disk surface acquires a rotating motion with angular velocity equal to that of the 
rotating disk. Also, the thickness of the diffusion boundary layer is constant over the 
disk surface such that transport of matter to and from any point on the disk is 
identical (Levich, 1962). The Levich equation for the IDR is: 
IDR = 0.62. Dý. (oy'. Cý 
t) 
1/6 
tEq. 1.10} 
where w is the angular velocity of the rotating disk and u is the kinematic viscosity 
of the medium. 
1.1.4.1. Factors affecting the intrinsic dissolution rate 
The IDR assumes a constant surface area and boundary layer thickness. Hence, the 
Nernst-Brunner equation (Equation 1.7) simplifies to: 
IDR = D. C5 } Eq. 1.11 } 
Therefore, the properties of the dissolution medium that influence diffusivity and C. 
will determine the IDR. 
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It is well established that the conditions in the GIT such as pH, buffer capacity, 
surfactant concentration, viscosity, etc. affect the dissolution rate of drugs and 
changes to these conditions including the presence of food consequently affect 
absorption of a drug. Pharmacopoeial dissolution tests are not realistic 
representations of the in vivo environment and there has been a move towards the 
development of biorelevant media for use in dissolution testing to improve in vitro- 
in vivo correlations (IVIVC) (Dressman et al., 1998; Galia et al., 1998). This is 
discussed further in Section 1.3.5. The factors that influence the IDR of drugs based 
on the film theory of dissolution are discussed below. 
1.1.4.1.1. Polymorphism and solvation 
The existence of different crystal lattices for a particular drug (polymorphism) can 
have important consequences on bioavailability, especially if the drug is poorly 
water-soluble. In a monotropic system, only one polymorph is stable below the 
melting point of the drug, therefore reversible transitions between polymorphic 
forms are not observed below the melting point. Conversely in an enantiotropic 
system, reversible transitions occur at a specific transition temperature below the 
melting point, because different polymorphic forms are the most stable above and 
below the transition temperature (Grant, 1999). For an enantiotropic system, the 
most stable polymorph at room temperature usually has the lowest solubility and 
slowest dissolution rate, however, when little energy is required to convert from one 
form to another it is likely that these will interconvert in vivo such that 
administration of either form will not impact upon the bioavailability of the drug 
(Florence & Atwood, 1988). 
An appropriate metastable polymorph with suitable solubility can be acquired by 
manipulation of the recrystallisation process and choice of solvent but it must be 
emphasised that an enhanced dissolution rate does not necessarily translate to 
improved bioavailibility (Haleblian et al., 1971) .A major problem with the use of 
metastable polymorphs is the risk of interconversion during manufacture and 
storage (Horter & Dressman, 2001). Manufacturing processes such as 
recrytallisation, comminution, granulation, drying and compaction can change the 
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crystal structure of a drug and its solubility (Brittain & Fiese, 1999). For example, 
milling digoxin increases the surface area and the drug becomes amorphous, both of 
which increase the saturation solubility of the drug. (Florence & Salole, 1976). 
Anhydrous crystals show greater solubility and increased dissolution rates compared 
to hydrates because in the hydrate the drug has already interacted intimately with 
water and the energy released for crystal break-up is less when the hydrate is in 
contact with the water (Florence & Atwood, 1988). Non-aqueous solvates tend to be 
more soluble in water than non-solvates e. g. the n-amyl alcohol solvate of 
fludrocortisone is five times more soluble than the parent compound (Shefter & 
Higuchi, 1963). 
1.1.4.1.2. Wetting 
Prior to dissolution the solvent must wet the surface of solid particles. When the 
solid is first immersed in the liquid the initial wetting is referred to as `immersional 
wetting'. The extent of this wetting is measured by the contact angle between the 
solid and liquid (Figure 1.2). For complete wetting the contact angle will be zero. 
This occurs when the attractive forces between solid and solvent are equal to or 
greater than the attractive forces between the solvent and solvent (Florence & 
Atwood, 1988). The attractive surface forces are referred to as surface tensions. The 
solid surface tension (ys/A) in Figure 1.2 will tend to spread the liquid but this will be 
opposed by the solid-liquid interfacial tension ('Ysn. ) and the surface tension of the 
liquid in the plane of the solid (? UA). 
TS/A 
liquid 
S 
Figure 1.2. Illustration of the forces acting on a solid partially immersed in liquid. 
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This gives rise to Young's equation: 
7S/A ='YS/L +'YUA COSB 
where 0 is the contact angle. 
IEq. 1.12) 
According to Florence and Attwood (1988) once the solid is submerged in the 
solvent `spreading wetting' becomes important, during which the liquid will spread 
over the solid. 
Surfactants are important wetting agents that can increase the solubility of drugs. 
They work by lowering the surface tension of the liquid and also by adsorbing onto 
the powder surface thus reducing the surface tension of the solid. Both these events 
reduce the contact angle (Florence & Atwood, 1988). 
According to the Nernst-Brunner equation a decrease in particle size and the 
subsequent increase in surface area will result in an increase in the dissolution rate. 
However, this may not be the case if the drug is hydrophobic and/or the dissolution 
medium has poor wetting characteristics. In such situations a decrease in particle 
size causes a decrease in effective surface area (Finholt, 1974). Air is adsorbed onto 
the hydrophobic surface of a drug powder, which then remains floating on the top of 
the dissolution medium. If the surface tension of the dissolution medium is reduced 
by the presence of surface-active components in the GIT or by the addition of 
synthetic surfactants then the contact angle between the drug particle and liquid 
medium is reduced and the drug particle is more readily wetted. Finholt and Solvang 
(1968) illustrated an increase in the dissolution rate of paracetamol using 
polysorbate 80 as a surfactant. They found that increasing polysorbate 80 
concentration from 0.001 to 0.1% w/v had little effect on the solubility of 
paracetamol. The improved dissolution rate was mainly due to the ability of 
polysorbate 80 to reduce the interfacial tension between the solid and liquid and due 
only to a small extent to the solubilising power of the surfactant. For hydrophilic 
drugs (e. g. aspirin) addition of a surfactant to the dissolution medium only increased 
the dissolution rate when the particle size was small (0.2-0.3mm) (Finholt, 1974). 
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For larger particles (0.71-1.00mm) no significant change in dissolution rate was 
observed because the hydrophobic properties were so insignificant that a decrease in 
surface tension was of little importance except when the specific surface area was 
large. 
For IVIVC, an important dissolution medium to consider is gastric fluid because it 
is the first in vivo fluid the drug comes into contact with. Finholt and Solvang 
(1968) and Efentakis and Dressman (1998) confirmed the surface tension of fasted 
human gastric fluid (35- 45 mN/m) is lower than water (= 70mN/m) and that 
surface tension is independent of pH. Various surfactants have been used to lower 
the surface tension of water to this range in dissolution testing e. g. Tween 80, 
dioctyl sulfosuccinate and Triton X-100R amongst others (Luner et al., 1996). 
Dressman et al (1998) suggested an aqueous solution of sodium dodecyl sulphate as 
being physiologically representative of gastric fluid. 
1.1.4.1.3. Solubilisation 
There has often been debate as to whether the increased dissolution rate of drugs by 
surfactants has been due to wetting or solubilisation. The two processes are related. 
When the surfactant concentration is high enough to reach the critical micelle 
concentration (cmc) then the solubility of the drug can be enhanced by its 
incorporation into micelles in the dissolution medium. This is solubilisation. 
Physiologically, the presence of bile can increase the absorption of poorly water- 
soluble drugs by increasing their solubility or dissolution rate. Bile is amphiphilic 
and reduces the surface tension of the dissolution medium allowing better wetting of 
drug particles and a greater effective surface area for dissolution. Naylor et al (1993) 
proposed that the dissolution of hydrocortisone was improved by wetting in simple 
sodium taurocholate (NaTC) micelles and by solubilisation in NaTC/lecithin mixed 
micellar systems. Furthermore, the concept of wetting versus solubilisation by bile 
salts has been reported to be compound specific (Horter & Dressman, 2001) leading 
to a lack of predictability of the solubility/dissolution behaviour of poorly water- 
soluble drugs. 
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1.1.4.1.4. Complexation 
This is a method used to enhance the solubility/dissolution rate of poorly soluble 
drugs (Truelove et al., 1984; Tinwalla et al., 1993). The question that arises here is 
at what stage of the dissolution process do these different complexing agents take 
effect. In terms of the intrinsic dissolution rate, complexing agents that actively 
remove molecules from the solid surface and take them into the bulk solution are of 
particular interest. Unfortunately there is little differentiation as to whether the 
interactions proposed are occurring between the complexing agent and solid surface, 
such that there is a direct effect on the intrinsic solubility (C0), or between 
complexing agent and drug particles in the boundary layer, such that there is an 
increase in Cs. Two types of complexes, II donor/ 11 acceptor and cyclodextrin 
complexes, are discussed below. 
Ildonorl Tlacceptor complexes 
These are charge transfer interactions where one molecule is usually aromatic and 
the other has a lone pair of electrons (donor atom) or an acidic hydrogen (acceptor 
atom). Nicotinamide, a 11 acceptor, increased the solubility of poorly soluble 
diazepam and progesterone via a 1TI donor/ 11 acceptor complex (Rasool et al., 
1991). The greater solubilisation of benzoic acid by caffeine compared to 
theophylline implicated the role of the methylated imidazole nucleus to form 
hydrophobic bonds with the other component as a factor in the interaction (Higuchi 
& Zuck, 1952,1953). 
Cyclodextrin complexes 
Cyclodextrins (CDs) have received a great deal of attention over the last 20 years 
(Tokumura et al., 1986; Okada et al., 1988; Woodcock et al., 1993; Loftsson, 2002; 
Magnusdottir et al., 2002; Loftsson et al., 2003; Loftsson & Masson, 2004). The 
parent compounds consist of glucose molecules arranged in a a-1,4-linked toroid, 
where the hydrophilic hydroxyl groups are arranged around the outside of the 
molecule whilst the internal cavity is essentially hydrophobic. Cyclodextrins form 
inclusion complexes with poorly soluble drug by taking up a guest molecule into the 
central cavity (Loftsson & Brewster, 1996; Horter & Dressman, 2001). The drug- 
14 
CD complexation does not involve breaking or forming any covalent bonds. Instead 
the driving force for complexation is a combination of removal of enthalpy-rich 
water molecules from within the CD cavity, van der Waals interactions, hydrogen 
bonding, hydrophobic interactions, release of ring strain in the CD molecule and 
changes in the solvent-surface tensions (Loftsson & Brewster, 1996). 
a, ß and y-cyclodextrin contain 6,7 and 8 glucose units respectively. The internal 
diameter of a-CD is too small for the inclusion of pharmaceutical compounds and 
ß-CD has poor water solubility due to intramolecular hydrogen bonding (Loftsson & 
Brewster, 1996). y-CD has been well documented as being able to significantly 
increase the rate of dissolution but recently the derivative hydroxypropyl ß-CD (HP- 
ß-CD) has won favour because of its higher aqueous solubility and lower toxicity 
compared to methylated derivatives, e. g. in the solubilisation of 
thiazolobenzimadole (Tinwalla et al., 1993). The aqueous solubility of compounds 
such as the fat soluble vitamins may be enhanced further by substituting ß-CD with 
maltosyl or glucosyl groups (Okada et al., 1990). Also, maltosylated CDs are less 
toxic than unsubstituted CDs. CDs increase the rate of dissolution of solid drugs but 
their effect on bioavailability depends on whether dissolution is the rate-limiting 
step to absorption. 
1.1.4.1.5. The effect of pKQ, pH and buffer capacity 
75% of all drugs are weak bases, 20% are weak acids and 5% are non-ionic or 
amphoteric (Wells & Aulton, 1988). Thus the majority are ionisable and their 
aqueous solubility will depend on their ionisation constant (Ka). It has been 
established that the IDR is dependent on C$ of the drug in the dissolution medium. In 
turn, the CS is dependent on the intrinsic solubility of the drug (CO), which is defined 
as the solubility of a compound in its free acid or base form. For a weak acid, Co is 
approximated as the solubility at more than 1 pH unit below its pKa (Hotter & 
Dressman, 2001). The pH at the surface of the dissolving solid will influence the 
dissolution rate of ionisable drugs. It follows that the pH of the boundary layer and 
the pKa of the drug are significant in determining its C. The pH in the bulk solution 
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can be considerably different to that in the boundary layer depending on the Co and 
pKa of the drug and the buffer capacity of the bulk solution, 
Ozturk et al (1988) demonstrated that the pH at the surface of dissolving drug 
particles was considerably different to the pH in the bulk solution using the three 
weak acids indomethacin, 2-napthoic acid and benzoic acid in unbuffered media. 
An increase in the Co of the drug (weak acid in this case) suppresses the pH at the 
surface of the dissolving drug. 
Horter and Dressman (2001) commented that intestinal juice contains such a 
significant amount of bicarbonate buffer that in-vitro testing in unbuffered or 
weakly buffered medium does not reflect in-vivo dissolution of ionisable drugs. An 
increase in the buffer concentration would increase the solubility of weakly acidic 
drugs because the pH at the drug surface would be nearer to the bulk lumenal pH. 
McNamara et al (2003) were able to maintain stable bicarbonate buffer media at pH 
5.0 and 6.8 by continuous gas sparging of CO2 into the media 
1.1.4.1.6. Salt form of the drug 
The pH in the boundary layer (microclimate pH) around drug particles is affected by 
a) the pKa and Co of the drug 
b) the pKa and Co of the buffers in the bulk solvent/GI fluids 
It is also known that the dissolution rate of weakly acidic drugs in the gastric fluid 
will be relatively low (Proudfoot, 1988b). If the pH in the boundary layer were 
increased then C. and dissolution rate would increase. This can be done by changing 
the weakly acidic drug from the free acid to basic salt e. g. Na+ or K' salts, which 
have a strong neutralising effect and would increase the pH to 5-6. However, as the 
drug diffuses through the boundary layer and arrives at the bulk solution of lower 
pH, it may precipitate (Proudfoot, 1988b). The extent of this precipitation depends 
on the Co of the drug. The precipitated free acid drug usually consists of very fine 
wetted particles that aid rapid re-dissolution as soon as more gastric fluid is 
available. This occurs when: 
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a) drug is absorbed, therefore the gastric fluid is no longer saturated 
b) precipitated particles move into the intestine 
c) additional fluid enters the stomach 
For weakly basic drugs, a salt of a strongly acidic anion can be made e. g. Cl-. This 
ensures dissolution occurs prior to gastric emptying. If absorption is fast enough, 
precipitation in the intestine will not occur and bioavailability will not be affected. 
Unfortunately, the Cl- ions already present in the stomach may cause a common ion 
effect, competing for hydration by the gastric fluid therefore suppressing drug 
dissolution. 
1.1.4.1.7. Electrolytes in the dissolution medium and the common ion effect 
Electrolytes in the dissolution medium can impact on various aspects of the ionic 
dissolution process (Wells & Aulton, 1988). They may alter the pH of the medium, 
which as discussed earlier, might affect the solubility of weak acids and bases based 
on the drugs' pKa values and the buffer capacity of the medium. Electrolytes can 
also reduce the solubility of salts through the common ion effect. This drives the 
dissociation equilibrium of the salt in the opposite direction such that precipitation 
(salting out) or reduced solubility occurs. Various inorganic ions can be arranged in 
a series based on their ability to `salt out' different proteins which depends on ion 
characteristics such as size, hydration and charge. For univalent cations the series 
order was K+ < Na+ < Li' and common anions followed the order CNS" < I'< Br '< 
N03" < Cl'< S04 < PO43- (Heyman et al., 1938) 
1.1.4.1.8. Experimental variations 
The IDR will be affected by experimental parameters such as temperature, speed of 
agitation and turbulence. For IVIVC, these variables need to mimic the GI 
conditions as closely as possible. 
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1.1.4.1.9. Physiological factors affecting IDR 
Brief references have been made to physiological conditions that will affect the 
IDR. Considerations for IVIVC include the changing pH down the GIT and the 
effect of co-ingested food on transit time, pH and solubilisation capacity of the 
stomach and intestine. Drugs whose physicochemical properties are affected by 
these changes will result in changes in the rate and extent of absorption. The effect 
of age and disease states on the gastric secretions also needs to be considered. 
1.1.4.2. Methods of determining the IDR 
1.1.4.2.1. Intrinsic Dissolution Method (USP <1087>) 
Two variations of the IDR apparatus exist - the rotating disk apparatus (Woods 
Apparatus, Figure 1.3) and the stationary disk apparatus (Figure 1.4). Both types of 
apparatus employ a compacted pellet of pure drug, produced by compressing an 
aliquot of powder in a stainless steel punch & die (Figure 1.5). The die is mounted 
onto a smooth polished base plate and the punch is driven into the die using a 
hydraulic press. The United States Pharmacopoeia states a compression dwell time 
of I min at the minimum compression force required to form a non-disintegrating 
compacted pellet. The base plate is then detached to expose a smooth and constant 
pellet surface at the face of the die and it is this pellet surface that is subjected to the 
dissolution test. 
In the rotating disk apparatus the die is then inverted and screwed onto a customised 
shaft on a dissolution tester, which is then lowered into the dissolution medium until 
the face pellet is 2.54 cm from the bottom of the vessel (Figure 1.3). The shaft is 
then rotated in the same way as the USP apparatus I and 2. In the stationary disk 
apparatus the die containing compressed pellet is placed face up into a flat- 
bottomed dissolution-vessel (Figure 1.4), prefilled with the appropriate volume of 
dissolution medium. The medium is stirred by means of a rotating paddle (e. g. USP 
apparatus 2) positioned 6 mm above the pellet surface. 
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Dissolution Vessel 
('ý (Round Bottom) 
Figure 1.3. Schematic of rotating disk IDR apparatus (Woods apparatus). 
Flat-bottomed Vessel 'ý--º 
Paddle 
Dissolution medium 
c Drug pellet (in die) 
Figure 1.4 Schematic of a stationary disk IDR apparatus 
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Figure 1.5. Tooling used to produce disks for IDR testing. From United States 
Pharmacopoeia 28 (USP, 2005) 
Disadvantages of the rotating disk apparatus include the risk of air bubbles forming 
on the surface of pellet, which could affect the dissolution rate, and heat loss of 
approximately 2°C through the shafts when the dies are first lowered into the 
dissolution medium. Using the stationary disk apparatus significantly reduces the 
formation of air bubbles, whilst heat losses are eliminated since the dies are totally 
submerged in the dissolution medium (Viegas et al., 2001). 
The IDR is calculated by plotting the cumulative amount of substance dissolved per 
unit area of the exposed pellet surface against time until 10% of the drug pellet has 
dissolved (limit of sink conditions). Linear regression should be applied to data 
points up to this point and the slope of the regression line gives the IDR of the 
substance under test in mg/min/cm2 (United States Pharmacopoeia 28,2005). 
However, this compendial calculation may prove difficult to apply to poorly soluble 
compounds where 10% dissolution may not be achieved. In these instances, it may 
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be practical to use an analytical method with sufficiently high sensitivity to be able 
to plot 6-8 data points before 10% dissolution and apply linear region. 
1.2. Disintegration as a prerequisite for dissolution from solid oral 
dosage forms 
The IDR of a drug substance is a measure of the inherent drug solubility and does 
not take into account formulation factors that may affect dissolution (Section 1.1.4). 
During the determination of the IDR, maintenance of a constant surface of the 
exposed disk is required. Conversely, for solid oral dosage forms such as tablets and 
capsules, drug exposure to the dissolution medium requires the collapse of the unit. 
The disintegration of tablets and the disintegration test method are described in this 
section. 
1.2.1. Tablet disintegration 
The disintegration of a tablet is a fundamental requirement for release of the drug 
from the dosage form and to promote dissolution. When immersed in liquid, the 
solid surface is wetted and liquid penetrates the tablet pores causing a break up of 
the dosage form. In practice, this process is usually aided by the addition of a 
disintegrating agent to the formulation, which performs its function by swelling, 
capillary action or generation of a gas (Lowenthal, 1973). The initial fragments 
produced may be large agglomerates that disintegrate further into primary drug 
particles. Deaggregation into these primary drug particles provides the largest 
surface area for dissolution (Wagner, 1969; Wells & Rubinstein, 1976). The 
mechanism is related to dissolution diagrammatically in Figure 1.6. 
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Figure 1.6. Mechanism of the drug release process from a tablet by 
disintegration and dissolution. From Rubinstein (1988) 
1.2.2. Disintegration Testing 
The pharmacopoeia) disintegration test for tablets and capsules determines whether 
these dosage forms disintegrate within the time prescribed in the individual 
monograph. The test is not intended for sustained release and chewable dosage 
forms. The United States Pharmacopoeia 28 and British Pharmacopoeia (2004) 
22 
describe a similar apparatus for disintegration testing. The description below is 
taken from the British Pharmacopoeia 2004. 
The apparatus consists of a basket-rack assembly (Figure 1.7) holding six 
cylindrical transparent tubes 75.0 to 80.0 mm long, 21.5 mm in internal diameter 
and with a wall thickness of about 2 mm. The tubes are held vertically by two 
separate and superimposed rigid plastic plates 90 mm in diameter and 6 mm thick, 
perforated by six holes. The holes are equidistant from the centre of the plate and are 
equally spaced from one another. Attached to the under side of the lower plate is a 
piece of woven gauze made from stainless steel wire 0.635 mm in diameter and 
having mesh apertures of 2.00 mm. The plates are held rigidly in position and 
77.5 mm apart by vertical metal rods at the periphery and a metal rod is also fixed to 
the centre of the upper plate to enable the assembly to be attached to a mechanical 
device capable of raising and lowering it smoothly through a distance of 50 to 
60 mm at a constant frequency of between 29 and 32 cycles per minute. The 
assembly is suspended in the specified liquid medium in a 1000-m1 beaker. The 
volume of liquid is such that when the assembly is in the highest position the wire 
mesh is at least 15 mm below the surface of the liquid and when the assembly is in 
the lowest position the wire mesh is at least 25 mm above the bottom of the beaker 
and the upper open ends of the tubes remain above the surface of the liquid. The 
temperature of the liquid is maintained at 35° to 39°. The design of the basket-rack 
assembly may be varied provided that the specifications for the tubes and wire mesh 
are maintained. Where stated in the monograph, a plastic disk may be added to each 
tube to aid immersion of floating dosage forms. The disk specifications are 
described in the pharmacopoeias. 
To run a test, one tablet or capsule is placed into each of the six tubes, the assembly 
is suspended in the beaker containing the specified liquid and the apparatus operated 
for the specified time. The tablets or capsules pass the test if all six have 
disintegrated. The United States Pharmacopoeia 28 defines complete disintegration 
as: 
"that state in which any residue of the unit, except fragments of insoluble coating or 
capsule shell, remaining on the screen of the test apparatus is a soft mass having no 
palpably firm core. " 
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Stainless steel gauze 
(mesh apertures 2.00mm) 
Liquid medium held 
between 35-39°C ýý 
Figure 1.7. Schematic diagram of the basket rack assembly of the 
Disintegration Test apparatus. 
1.3. Dissolution Testing 
Dissolution tests are one of the most commonly used tests in the characterization 
and quality control (QC) of oral dosage forms. They are vital if dissolution is the 
rate-limiting step in drug absorption, e. g. in rapidly disintegrating tablets or 
capsules. From a QC perspective, dissolution testing is mainly used to confirm 
batch-to-batch consistency, site and manufacturer variation, product stability and to 
identify good and bad formulations (Hanson, 1991a). Dissolution tests are used to 
confirm compliance with compendial specifications and are therefore needed as part 
of a marketing authorisation. Additionally, they are used during product 
development and stability testing as part of the development specification for the 
product. Critically, from an R&D perspective, there is the potential to correlate in 
vitro dissolution data with in vivo bioavailability, which would greatly facilitate 
product development. 
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1.3.1. Compendia) Testing Methods 
The general principle of dissolution tests is that the powder or solid dosage form is 
tested under uniform agitation, which is accomplished by either passing the medium 
over the sample or by agitating the sample in the medium. Two general methods, 
using the basket or paddle apparatus, are currently included in the United States 
Pharmacopoeia 28 and the British Pharmacopoeia 2004 to measure dissolution from 
immediate-release oral tablets and capsules whilst there are several variants used in 
the testing or modified-release oral dosage forms and other, non-oral types of 
dosage form. The compendial dissolution tests for oral dosage forms are described 
below. 
1.3.1.1. Basket Apparatus (USP Apparatus 1) 
Essentially, in this method, the dosage form is placed in a basket that is lowered 
into the dissolution medium and rotated at a specified speed. 
The apparatus consists of a motor, a metallic drive shaft, a cylindrical basket and a 
covered vessel made of glass or other inert transparent material. The latter should be 
made of materials that do not sorb or react with the sample tested. The contents are 
held at 37 ± 0.5°C. There should be no significant motion, agitation, or vibration 
caused by anything other than the smoothly rotating stirring element. Ideally, the 
apparatus should provide observation of the stirring element and sample. The vessel 
is cylindrical with a hemispherical bottom and sides that are flanged at the top. It is 
160 to 175 mm high and has an inside diameter of 98 to 106 mm, and a nominal 
capacity of 1000 mL. A fitted cover may be used to retard evaporation but should 
provide sufficient openings to allow ready insertion of a thermometer and allow 
withdrawal of samples for analysis. The shaft is so positioned that its axis is no 
more than 2 mm at any point from the vertical axis of the vessel and should rotate 
smoothly, without significant wobble. The shaft rotation speed should be 
maintained within ± 4% of the rate specified in the individual monograph. The shaft 
and basket should be constructed of stainless steel, type 316 or equivalent. Other 
specifications for the basket apparatus are given in Figure 1.8. A 2.5 tm thick gold 
coating on the basket may be used for acidic media. For testing, a dosage unit is 
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placed in a dry basket at the beginning of each test. The distance between the inside 
bottom of the vessel and the basket is 25 ±2 mm (Ford & Rajabi-Siahboomi, 2002). 
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Figure 1.8. The basket stirring element of USP 28 (Apparatus 1) 
Apart from apparatus design, certain practical issues can potentially be problematic. 
For example, corrosion of the wire basket when placed in acidic media; obstruction 
of fluid flow through the basket mesh due to adhering substances; variation in 
agitation conditions produced by the rotating basket leading to poor reproducibility 
and the risk of particles falling from the basket to the bottom of the vessel and 
consequently being subjected to different agitation conditions to those within the 
basket (Hanson, 1991b; Ford & Rajabi-Siahboomi, 2002). Finally, there is the 
possibility of dissolution being accelerated due to abrasion of the surface of the 
dosage form as it rubs against the basket mesh, the so-called `cheesegrater effect'. 
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1.3.1.2. Paddle Apparatus (USP Apparatus 2) 
In Apparatus 2, the paddle apparatus, a paddle is used as the source of agitation. As 
with the basket apparatus, the shaft should position no more than 2 mm at any point 
from the vertical axis of the vessel and rotate without significant wobble. Figure 1.9 
gives the shaft specification. The paddle should be rotated at a fixed depth of 25 ±2 
mm from the bottom of the vessel throughout the test. The metallic blade and shaft 
may be coated with a protective inert coating to prevent corrosion. The dosage form 
is dropped into the vessel and the paddle rotated when the dosage form has reached 
the bottom of the vessel. 
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Figure 1.9. The paddle stirring element of USP 28 (Apparatus 2) 
In the case of hard-gelatin capsules and other floating dosage forms, a `sinker' is 
required to weight the sample down until it disintegrates and releases its contents at 
the bottom of the vessel. The sinker has to hold the capsule in a reproducible and 
stable position directly below the paddle, but it needs to be constructed in such a 
fashion that it does not significantly affect hydrodynamic flow within the vessel nor 
should it appreciably reduce the surface area of the capsule available to the 
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dissolution medium. Two designs have predominated, the three-fingered clip and 
the helical spring. The former comprises a small circular disc with three short, 
parallel rods sticking out from it, into which the capsule is wedged. The device is 
typically plastic, but the disc contains metal, which gives it the necessary weight to 
fall to the bottom of the vessel. The latter is a stainless steel or plastic-coated 
stainless steel helix (coil, spring) down the middle of which the capsule is inserted. 
However, with this design, as the thickness of the wire used and the number of turns 
in the spring increase, the available surface area of the capsule decreases, leading to 
a concomitant decrease in the observed rate of dissolution (Soltero et al., 1989; 
Avgoustakis et al., 1992). The United States Pharmacopoeia allows for `a small, 
loose piece of non-reactive material such as not more than a few turns of wire 
helix... ' whilst the Japanese Pharmacopoeia (JP) actually prescribes a specific 
sinker (Figure 1.10). 
(a) 3-Prong sinker (b) JP Basket Sinker (c) Helical-spring sinker 
Figure 1.10. Typical sinker designs. (a) 3-prong sinker, (b) Japanese 
Pharmacopoeia basket sinker, (c) helical-spring sinker 
1.3.1.3. Reciprocating Cylinder Apparatus (USP Apparatus 3) 
An apparatus comprising vertically reciprocating tubes, sealed with mesh discs at 
each end to restrain the dosage form is official in United States Pharmacopoeia 28 
as the Reciprocating Cylinder Apparatus. This has been commercially developed as 
the Bio-Dis apparatus® which allows tubes containing the sample to be plunged up 
and down in a small vessel containing the dissolution medium (Figure 1.11). It has 
been designed to allow the tubes to be dipped sequentially in up to six different 
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media vessels, using programmes that vary the speed and duration of immersion. It 
allows automated testing for up to 6 days and the manufacturers advocate its use in 
the testing of extended-release dosage forms (Dyas & Shah, 2006). 
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Figure 1.11. The reciprocating cylinder apparatus of USP 28 (Apparatus 3) 
1.3.1.4. Flow-through Cell Apparatus (USP Apparatus 4) 
The previously described limited-volume apparati operate under non-sink 
conditions, which can restrict the study of poorly soluble drugs. A flow-through 
system and reservoir may be used to provide sink conditions by continually 
removing solvent and replacing it with fresh solvent. Alternatively, continuous re- 
circulation may be used when sink conditions are not required. The disadvantages 
of limited-volume apparati (Tingstad & Riegelman, 1970) are [1] lack of flexibility, 
[2] lack of homogeneity, [3] the establishment of concentration gradients, [4] their 
semi-quantitative agitation, [5] the obscuring of details of the dissolution processes 
and [6] their variable shear. 
29 
Consequently, the flow-through apparatus has been developed which features a 
dissolution cell of low volume (often less than 30 mL) and a reservoir to provide 
fresh solvent. The apparatus is now official in the United States Pharmacopoeia as 
USP Apparatus 4 (Figure 1.12), where it is prescribed for testing extended-release 
dosage forms. The basic components are reservoir, pump, heat exchanger, column 
(cell), tablet support, filter system and analytical method. The systems enable 
solvent to be taken from a suitable reservoir and passed straight through the 
apparatus containing the dosage form to be either assayed and removed (effluent 
system) or recirculated (recycling system) (Ford & Rajabi-Siahboomi, 2002). The 
design of the pump to remove the solvent from the reservoir is crucial to the results 
obtained from such systems. The pump used may be either a displacement 
(oscillating or peristaltic) or a momentum (centrifugal) type. However, peristaltic 
pumps may create oscillations that might result in faster dissolution rates than might 
otherwise have occurred. Factors such as the volumetric flow rate, the cross- 
sectional area of the cell, the initial drug quantity, liquid velocity and drug 
concentration affect dissolution (Ford & Rajabi-Siahboomi, 2002) . 
Figure 1.12. Schematic diagram of a flow-through dissolution cell. From Ford 
and Rajabi-Siahboomi (2002) 
The maintenance of a controlled flow is crucial to column methods and can be 
influenced by the inlet system. Glass beads are often inserted at the bottom of the 
cell to ensure laminar flow of the solvent and allow similar disintegration of all the 
surfaces of the dosage form. However, attrition of the dosage form by the glass 
beads may influence disintegration and give erroneous dissolution rates. In order to 
generate reproducible results the tablet must be supported and positioned in the 
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fluid flow in a consistent manner. Consequently, attempts have been made to set the 
tablet in glass wool or glass beads. 
Laminar flow conditions are typically used for tablets, hard gelatin capsules, 
powders and granules. Suppositories and soft gelatin capsules are placed in the cell 
without beads for turbulent flow. Nicolaides et al (2000) reported differences in the 
dissolution rate of a poorly soluble drug, tiaglitazone, from an immediate release 
tablet formulation based on the presence or absence of a tablet holder and/or beads 
in the flow through cell. 
Flow-through facilities can be constructed from cylindrical chromatographic 
columns with flow-rates as low as 1 mUmin. Ascending flow minimises the 
problems associated with air bubbles and allows laminar flow of the solvent and 
ascending columns are the most common types of flow-through apparatus. The 
columns may be short with tapered inlet and outlet sections but generally are long 
sections of straight-sided tubing to provide hydrodynamic stability to the liquid 
flow. The material under test is placed in the vertically mounted dissolution cell 
which permits solvent at 37° ± 0.5 °C to be pumped in from the bottom. The cell 
type selected is dependent on the dosage form being tested. Standard cells used for 
tablets and capsules have an internal diameter of 12mm but may show a higher 
dissolution rate when compared to 26mm cells due to higher flow velocity. For 
testing powders and granules a modified cell containing 2 screen plates is used 
where the sample is placed between the screen plates. 
The flow rate of the dissolution medium through the cell must be specified for each 
product. The USP recommends a flow rate between 4-16mUmin with an allowance 
of ±5%. Manual operation and sampling for this type of test can be tedious and the 
system can be automated to control the pump, heat exchanger and test procedure 
and deliver samples to a fraction collector. The system can be programmed to 
switch between different media at predetermined time points to allow pH changes 
during the test. 
31 
Further advantages of the flow through method (Looney, 1996) include (1] selection 
of laminar or turbulent solvent flow conditions, [2] simple manipulation of medium 
pH to match physiological conditions, [3] application to a wide range of dosage 
forms e. g. tablets, hard and soft gelatin capsules, powders, granules, implants and 
suppositories. 
Whilst the applicability of the flow through apparatus to biorelevant dissolution 
tests still requires further investigation and optimisation, a Level A IVIVC has been 
reported with this apparatus using physiologically relevant media and a flow rate of 
8 mUmin (Sunesen et al., 2005). 
1.3.1.5. Reciprocating HolderApparatus (USP Apparatus 7) 
There are several variants to this apparatus, which is based on a sample holder that 
oscillates up and down in the medium vessel. The sample holder may take the form 
of a disk, cylinder or a spring on the end of a stainless steel or acrylic rod, or it may 
simply be the rod alone. The sample is attached to the outside of the sample holder 
either by virtue of being self-adhesive (e. g transdermal delivery system) or is glued 
in place using a suitable adhesive. This apparatus may be used for transdermal 
products, coated drug delivery systems or other suitable products (e. g osmotic pump 
devices). It is prescribed for the drug-release testing of Psuedoephedrine 
hydrochloride extended-release tablets USP where the tablets are enclosed in a5 cm 
x5 cm square of nylon, which is then attached to the rod (Dyas & Shah, 2006). 
1.3.2. Sample Collection and Analysis 
1.3.2.1. Sample collection 
The United States Pharmacopoeia 28 and the British Pharmacopoeia 2004 both state 
that samples should be drawn from a region equidistant between the surface of the 
dissolution medium and the top of the rotating basket or paddle, not less than 1 cm 
from the vessel wall. The volume of sample withdrawn should be replaced with an 
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equal volume of fresh medium or the reduced volume should be accounted for in 
the dissolution calculation. Samples taken should be filtered using appropriate inert 
filters that do not adsorb the drug nor liberate materials that could interfere with the 
analytical procedures. The filter pore size should not be greater than 1 µm. When 
capsule shells interfere with the analysis, the contents of a minimum of six capsules 
should be removed as completely as possible and the shells dissolved in the 
dissolution medium. This allows calculation of correction factors, which should be 
no greater than 25% of the labelled content. 
The advent of sophisticated, programmable autosamplers allows samples to be 
removed automatically into tubes or vials for off-line spectroscopic or 
chromatographic analysis. However, care has to be taken to ensure in-line filters do 
not become blocked after repeated use. Autosamplers that can pump liquid samples 
from the dissolution vessel through a spectrophotometer and back into the vessel 
offer combined on-line sampling and analysis. Again, care has to be taken to ensure 
particles do not enter the tubing system and cause blockage. Also, excessive lengths 
of tubing can lead to a significant lag-time before the sample reaches the 
spectrophotometer or pools of cool, stagnant fluid causing precipitation of dissolved 
solute. A typical on-line UV dissolution system is depicted in Figure 1.13. 
Figure 1.13. Typical apparatus set-up for on-line UV measurement of 
dissolution. From Ford and Rajabi-Siahboomi (2002) 
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1.3.2.2. Assay methods 
Whatever assay technique is chosen, it must be specific to the drug being studied. 
For single-drug entities, UV spectroscopy is often the method of choice as it is 
quick, simple and easily lends itself to on-line automation. The use of UV 
photodiode array spectrophotometry has become popular in the testing of multidrug 
dosage forms. Where analytical sensitivity or selectivity is an issue, HPLC assays 
are commonly resorted-to as these allow low-level quantitation of high-potency 
(low-strength) drugs. In the case of multidrug dosage forms, more complicated 
assay techniques may be required, which makes HPLC useful since more than one 
drug can be analysed in the same chromatogram. Whilst HPLC can be automated it 
is essentially off-line and on-line strategies are often preferred. 
1.3.2.2.1. Fibre-optic technology 
Fibre optic technology for in-situ UV assay has received particular interest as it 
offers significant labour, time and cost savings by eliminating the sampling and 
filtering stages of the dissolution test (Martin, 2003). A fibre optic probe is 
positioned in each vessel in the same fashion as a sampling probe. Light is then 
transmitted from a linked spectrophotometer into an open-sided reflectance cell in 
the vessel, reflecting back to the detector where absorbance is measured (Bynum & 
Kraft, 1999). The dissolution profiles are calculated in real time allowing the direct 
scrutiny of product performance. This technology is also capable of rapid 
measurements of a series of vessels allowing intervals of less than 1 min between 
sampling time points during a dissolution run. A multiplexing arrangement is 
required to selectively transmit the signal from each vessel, in turn, to the 
spectrophotometer. 
Proposals for a new general chapter on dissolution in the USP (Gray et al., 2001) 
have highlighted the use of this technology and a regulatory perspective has also 
been published (Gray, 2003). These developments suggest that fibre optic 
technology is likely to emerge as a common analytical tool as long as the following 
considerations are addressed: 
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1. The spectrum of each component of the formulation needs to be evaluated to 
ensure there is no excipient interference. Spectra should be determined in the 
dissolution media to be used and at concentrations expected in the dissolution 
vessel. (Minor interference can be corrected for using software algorithms. ) 
2. The absorbance of the active ingredient at 100% release from the dosage 
form being tested must be below the photometric range maxima since sample 
dilutions are not possible, A shorter path-length cell will be required if the 
absorbance is too high. 
3. The limit-of-detection for fibre optics is higher than for conventional 
spectrophotometry because the loss of signal down the fibre decreases the 
Signal: Noise ratio. This loss of sensitivity may be overcome with a longer path 
length cell. 
4. Turbidity and light scattering caused by undissolved drug or excipients 
interfere with spectral measurement and increases noise (Martin, 2003). The 
interference should be limited to 2-3% and if this is not achievable, 
conventional discrete sampling and off-line measurement may be required. 
5. Formation of air bubbles on the fibre optic probe can affect the accuracy of 
the analysis (Lu et al., 2003). The dissolution medium should always be 
properly degassed prior to the test. 
Furthermore, prolonged transmission of far-UV radiation leads to degradation of the 
fibre and increasing opacity whilst fouling of the external surface of the fibre by 
some media components e. g. enzymes, surfactants etc. can be a problem in some 
cases. 
1.3.3. Data Presentation and Interpretation 
The data generated from dissolution tests are usually presented as dissolution 
profiles of the amount released plotted as a function of time. Drug release is 
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monitored at several time-points or, where possible, continuously until 100% of the 
dose is dissolved. Values equivalent to the times for 10,50,70 or 85% drug release 
are often cited as t10%, t50%, t70%, or t85% (Figure 1.14). The dissolution profiles from 
tablets and capsules are often sigmoidal in shape. 
Whilst pharmacopoeias do not require a dissolution profile to be generated, they do 
state the amount of drug that must dissolve (or not dissolve in the case of enteric- 
coated products) within a specified time. When a single-time specification is stated, 
the test can be stopped earlier if the requirement for a minimum amount dissolved is 
met. If two or more times are specified, then the samples should be withdrawn with 
a tolerance of ± 2% of the stated time. 
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Figure 1.14. Hypothetical dissolution profile showing the determination of tjo% 
t5O% t70% and tss% 
The United States Pharmacopoeia 28 assesses dissolution in a three-stage series of 
tests with the amount of drug dissolved after a specified time being expressed as a 
percentage of the nominal content of the dosage form. The time at which the sample 
is to be tested is specified in the monograph as is the so-called Q-value, the 
minimum percentage-dissolved at that time. In the first stage (Si), six units are 
tested and the pass criteria are that the amount of drug dissolved from each unit at 
the specified time should be no less than Q+ 5%. Failure at Si requires a second 
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stage test (S2) to be performed on an additional six units. To pass the test at this 
stage the average content dissolved, from the combined two stages (i. e. 12 units) 
should be equal to or greater than Q with no unit being less than Q-15%. Failure 
leads to stage 3 where a further 12 units are tested. These results are combined with 
the results from the previous stages. The average of the total of the 24 units thus 
tested should be equal to or greater than Q. No more than two units should be less 
than Q- 15% and no unit should be less than Q- 25% (USP, 2005) 
In the testing of delayed-release products there is a similar three-tiered approach for 
both the acid-dissolution (Al, A2 & A3) and buffer-dissolution (B1, B2 & B3) 
stages. For extended-release the levels are denoted Li, L2 and L3. 
1.3.4. Operational factors that may affect the dissolution test 
The British Pharmacopoeia 2004 and the United States Pharmacopoeia 28 each give 
considerable guidance about external factors that may affect dissolution. The more 
significant factors are referred to in this section. 
1.3.4.1. Vibration 
Vibration is a source of energy that is transmitted to the dissolution medium and can 
therefore significantly affect dissolution data. It was Beyer and Smith (1971) who 
first reported a six fold increase in the dissolution rate of tolbutamide tablets due to 
increased vibration of the dissolution vessel. Therefore, to minimize the effects of 
vibration, the distance from the stirring drive motor to the stand supporting it and 
the distance from the rotating basket to the point connecting the shaft to the 
dissolution motor should be specified. Vibrations may arise from various sources 
including equipment such as the water bath and pump. There is anecdotal evidence 
that vibration transmitted through building fabric (floors, walls) and furnishings 
(benches) from more distant sources such as lifting-gear, air-conditioning and 
heating systems may also have an effect. The net result is that equipment should be 
heavily insulated and clamped into position to effectively increase the mass of the 
vessels and thereby decrease vibration. 
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1.3.4.2. Alignment of the Stirrer Shaft 
Misalignment of the stirring element can be the cause of variation in the dissolution 
rate of a drug. According to compendial limits, the shaft should be positioned such 
that its axis is no more than 2 mm at any point from the vertical axis of the vessel. 
Significant wobble should also be eliminated. Bending of the stirring rod has been 
reduced by increasing the acceptable diameter from 6.0 to 6.5 mm to approximately 
10 mm. Minor changes in physical alignment of the paddle may produce large 
variations in results. 
1.3.4.3. Vessel Design and Construction 
Rosalia et al (1972) discovered that flask shape affected the hydrodynamics of the 
system through differences observed in the dissolution rate of hydrochlorthiazide 
tablets using flasks from two manufacturers. The use of a hemispherical flask 
allows some variation in construction. Minor changes in vessel shape may 
considerably alter the dissolution rates determined by the paddle method (Cox et al., 
1982) due to changes in the hydrodynamics created by the different shapes. Plastic 
vessels provide closer dimensional tolerances than glass vessels (Cox & Furman, 
1984) and should be preferred to glass vessels so long as drug does not sorb to them 
and that the dissolution fluid does not interact with the plastic (Cox et al., 1982). 
However, plastic vessels also have practical disadvantages. Plastic has a lower 
thermal conductivity than glass, therefore, the warm up time for the medium is 
longer and the temperature of the medium may be difficult to maintain as heat may 
radiate faster from the surface of the medium than from the vessel wall (Hanson, 
1991b). During dissolution, some tablets may become more centred in glass vessels 
than in plastic vessels, which is probably attributable to friction between the tablet 
and the wetted vessel surface being greater for plastic than for glass. Even the 
method of cleaning the vessel may result in different dissolution properties. 
Differences have been obtained from glass containers when cleaned with soap and 
water or 95% ethanol, the former method leaving a residual film (Cox & Furman, 
1984). 
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1.3.4.4. Sampling Procedures 
Flow-through facilities usually allow on-line ultraviolet (UV) analysis of drug 
dissolved or collection of samples for subsequent analysis. The sample must be 
filtered prior to analysis to reduce turbidity problems caused by undissolved drug 
and excipients and to help eliminate false results caused by particles dissolving 
following removal. 
A sampling probe used for continuous sampling must not disturb the 
hydrodynamics of the system. When continuous monitoring is accomplished by 
flow-through systems, the flow rate should not be too high or some of the 
suspended drug will adhere to the filter, resulting in a percolation effect and 
artificially high estimates of the amount of drug released (Ford & Rajabi- 
Siahboomi, 2002). The sampling probe should be as small as possible because the 
displacement volume of the probe may modify dissolution rates. Savage and Wells 
(1982) described an apparatus that allows removal of the probes giving a maximum 
of 40 s immersion in the dissolution fluids. Capillary sampling probes of 1.5 mm 
diameter were used, their size being reduced to minimize their influence on fluid 
hydrodynamics. 
Adsorption of the drug onto the filter should be avoided when sampling and the 
release of iso-octylphenoxypolyethoxyethanol, which is often included in 
membrane filters as a wetting agent, may be a potential problem as this surfactant 
has significant absorption in the range 220 to 240 nm. Hence, selection of an 
appropriate filter material is important to avoid selective loss of drug through 
adsorption. Selection of a suitable pore size is also important, as it should be small 
enough to retain undissolved particles of a significant size but without restricting 
flow and impeding sample withdrawal. Replacement of sampled fluid must be by 
fluid of the same temperature as that inside the dissolution vessels. 
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1.3.4.5. Temperature Control 
The Unites States Pharmacopoeia directs that the thermometer should be removed 
before the test and that the temperature should be checked periodically. The 
dissolution fluids should be maintained at 37 ± 0.5°C as even slight temperature 
variations may have a significant effect on tablet dissolution (Hanson, 1991c). It is 
important, therefore, to prevent evaporation of the medium both to reduce heat loss 
and maintain the volume of the liquid for dissolution. This is accomplished through 
the use of plastic covers, placed over the opening of the vessels. 
1.3.4.6. Deaeration of the Dissolution Medium 
Cox et al (1983) investigated the dissolution of prednisolone tablets in water 
presaturated with air. These authors found that the higher air content in the medium 
resulted in more drug being dissolved using the paddle method. In water 
presaturated with air, air bubbles attached to particles of the disintegrating tablets 
owing to sorption of air. Instead of sinking to the bottom of the vessel, the particles 
were suspended by the air bubbles and thus subjected to greater conditions of 
agitation. 
Failure to deaerate media used with the basket apparatus results in the clogging of 
the pores of the basket by air, causing different flow characteristics (Cartwright, 
1979) and often a decrease in dissolution rates. This has even greater influence 
when gel forming extended release dosage forms are being tested (Ford & Rajabi- 
Siahboomi, 2002). Bubbles attached to tablets or capsules may cause the dosage 
form to relocate near to the top of the basket, thereby reducing dissolution rates or 
amounts dissolved (Cartwright, 1979). The basket is intended to hold the tablet in a 
fixed position. Disintegration of the dosage form will occur in the basket and fluid 
must flow through the basket sufficiently to disperse the tablets and sweep 
dissolved drug into the bulk of the dissolution fluid (Ford & Rajabi-Siahboomi, 
2002). 
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The United States Pharmacopoeia 28 and the British Pharmacopoeia 2004 each 
state that media should be deaerated before use. The United States Pharmacopoeia 
recommended method of heating the medium and filtering under vacuum is labour 
intensive and time consuming and other validated methods may be used. Inert gas 
purging is a popular alternative. Current media preparation stations available can 
dispense heated and deaerated medium based on the vacuum principle. They also 
reduce foaming problems encountered during deaeration when surfactants are used 
in the media. Degenhardt et al (2004) compared these methods of deaeration and 
found helium sparging to be the most effective and efficient. They recommended 
that media be sparged for 30 s per litre of container volume at a helium flow rate of 
40 mLls, using an inlet filter pore size between 2 and 10 µm. 
However, there is a risk of re-aeration when the medium is transferred to the 
dissolution vessels. A 275% increase in the level of oxygen has been reported after 
deaeration and dispensing of media into dissolution vessels (Diebold & Dressman, 
1998). An alternative approach to deaeration would be to sparge the medium in-situ 
with helium. Dissolution testers with an on-line deaeration facility are available 
commercially. 
1.3.4.7. Variation in Speed of Agitation 
Agitation speed must be kept constant during the test. The compendia specify a 
speed tolerance of ± 4%. Technological advancements have led to electronic control 
of motors that allows speed to be checked throughout the test period by means of a 
digital display. 
1.3.5. Standardisation and Calibration 
All apparati must be calibrated and the variables standardized and known. Variation 
in dissolution data between individual vessels and between experimental runs can 
be determined through appropriately designed experiments. Errors in experimental 
set-up are minimised by using mean dissolution times and partial balancing. 
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Standardization of equipment and experimental conditions should remove all 
variable factors. 
The United States Pharmacopoeia 28 specifies apparatus suitability tests, based on 
the operating conditions, involving the USP Dissolution Calibrator, Disintegrating 
Type or the USP Dissolution Calibrator, Non-disintegrating Type. The apparatus is 
deemed suitable if the obtained results are within the accepted range stated for that 
type of calibrator. 
Equipment problems such as chain looseness, tilting of stirrer motor, excessive 
vibration, or misalignment of the flasks with the stirrers have been identified using 
calibrators (Hanson, 1991d). Non-disintegrating calibrators are composed of 300 
mg salicylic acid, whereas disintegrating calibrators contain 10 mg prednisone. The 
dissolution rates obtained from the calibrants should fall within established ranges 
at both 50 and 100 rpm. 
There has been a growing realisation of late that modern dissolution testers are 
high-performance instruments, which if subjected to a regular programme of 
maintenance and mechanical calibration, can perform very accurately and precisely. 
This has led to a growing body of opinion that appropriate electromechanical 
calibration regimes may offer far more confidence than chemical calibrators (Shah, 
2004). 
1.3.6. Other Variables in Compendia] Methods 
The British Pharmacopoeia 2004 usually specifies 900 mL of dissolution fluid, but 
for digoxin tablets the volume is 600 mL. Variation in the volume of dissolution 
medium to be used is more prevalent in the United States Pharmacopoeia 28, for 
example, 500 mL for alprazolam tablets, 750 mL for metyrosine capsules, 900 mL 
for ampicillin capsules and 1000 mL for dicumarol tablets. In addition, different 
volumes may be specified for various strengths of the same product, as in the case 
of phentermine hydrochloride capsules, where 500 mL of medium is used if the 
strength is 15 mg or less, but 900 mL is used for preparations containing in excess 
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of 15 mg. The same volumes are specified for prednisone tablets where the cut-off 
point is 10 mg and for cinoxacin capsules where 500 mL is used for capsules 
containing 250 mg or less but 1000 mL is used for capsules containing in excess of 
250 mg. 
1.3.7. Dissolution Media 
The selection of an appropriate dissolution medium is a critical stage of the 
dissolution test. As previously described the dissolution test has numerous roles that 
must be taken into account during media selection. For the quality control of a drug 
product, the chosen medium must be able to distinguish between batch-to-batch 
variability, scale up and post approval changes (SUPAC) and stability issues. This 
discriminating ability is built in during dissolution test method development. In 
general, physiological media are preferred to water-organic solvent mixtures or 
solutions incorporating surfactants. For a New Drug Application (NDA) it is 
recommended that, during dissolution method development, dissolution profiles in 
at least 3 media should be generated i. e. pH 1.2,4.5 and 6.8. Water can be used as 
an additional medium. If the drug is poorly soluble, appropriate concentrations of 
surfactants are recommended (CDER, 2003). All the in vitro and in vivo data 
generated can then be used to select a dissolution medium (and agitation speed) 
with adequate discriminating ability. 
Ideally, a dissolution medium should be formulated as close as possible to that pH 
anticipated in in vivo fluids; for example, dissolution media based on 0.1N HC1 are 
used to mimic gastric pH. Simulated gastric fluid is similarly used. Food can 
increase the gastric pH to as high as 3 to 5. Many compendia) dissolution fluids are 
at a pH near neutral despite the fact that tablets, when swallowed, will meet a lower 
gastric pH. Both the United States Pharmacopoeia 28 and the British 
Pharmacopoeia 2004 indicate that the pH of dissolution fluid should be within 0.05 
of that specified in the relevant monograph. The use of surfactants and enzymes 
may also be a coarse approximation of the intestinal fluids, although surfactants 
may be included to increase drug solubility by solubilization into micelles. 
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Complex biorelevant media are being used more frequently during the drug 
development stages to mimic the physicochemical characteristics of the 
gastrointestinal tract in the fasted and fed states. The aims are to highlight potential 
bioavailibility issues and attempt to achieve IVIVC that would aid candidate 
selection and predict product performance without resorting to in vivo studies. Thus 
far, it has not proved viable to extend their utility to quality control applications. 
Klein et al (2004) characterised the physicochemical properties of homogenised 
standard breakfasts administered during pharmacokinetic studies and compared 
them to several commercially available liquid meals in an attempt to propose a 
biorelevant medium. Examples of biorelevant media include fasted state and fed 
state simulated intestinal fluids (FaSSIF and FeSSIF) consisting of bile salt- 
phospholipid mixed micelle systems (Tables 1.2. a and 1.2. b), which significantly 
increase the cost of the test. Bovine milk has also been investigated (Macheras et 
al., 1987; Galia et al., 1998). Diluted Intralipid® emulsions have been suggested as 
an alternative to milk because they are not subjected to biological variation. Aiache 
et al (1989), suggested that drug release from controlled-release formulations 
should be studied following a2h contact with peanut oil by a dissolution test 
involving increases in pH (peanut oil resembles a heavy fatty food). 
Table 1.2a. Typical FaSSIF Medium. From Vertzoni et al (2004) 
Component Content 
Sodium taurocholate 3 mM 
Lecithin 0.75 mM 
NaOH (pellets) 0.174 g 
NaH2PO4. H20 1.977 g 
NaC1 3.093 g 
Purified water q. s. 500 mL 
Medium pH = of 6.50; osmolality - 270 mOsm/kg 
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Table 1.2b. Typical FeSSIF Medium. From Vertzoni et al (2004) 
Component Content 
Sodium taurocholate 15 mM 
Lecithin 3.75 mM 
NaOH (pellets) 4.04 g 
Glacial acetic acid 8.65 g 
NaCI 11.874 g 
Purified water q. s. 1000 mL 
Medium pH = 5.00; osmolality - 635 mOsm/kg 
1.3.8. Dissolution Testing of Selected Dosage Forms 
1.3.8.1. Dissolution Testing versus Drug Release Testing 
The United States Pharmacopoeia distinguishes dissolution from drug-release. 
Dissolution testing is applied to dosage forms where the drug content is considered 
to be readily available for dissolution, i. e. the dosage forms have not been 
formulated to retard the passage of the drug into solution in any substantial way. In 
contrast to this, products that have been formulated to retard the dissolution in 
specific media or for a pre-determined period of time are considered to be modified 
release products and are subjected to drug release testing. Modified release products 
include extended-release (sustained or slow-release) products and delayed-release 
(enteric-coated) products. The former are described as allowing at least a twofold 
reduction in the dosing frequency as compared with that drug presented as a 
conventional dosage form. A delayed-release product is one that releases the drug at 
a time other than promptly after administration. 
1.3.8.2. Immediate-release Tablets & Capsules 
For immediate-release tablets and capsules, the only barrier to drug release is a 
simple disintegration or erosion stage, which is generally accomplished in less than 
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1 h. For such dosage forms the dissolution test is based on the straightforward 
basket or paddle apparatus with a single sample being taken before quantitation. 
The United States Pharmacopoeia test specification is typically Q= 75% in 45 min 
although this may vary. For example, for Calcium Carbonate Tablets USP the time 
specificed is 30 min but for Calcium Gluconate Tablets USP it is 45 min. 
Nitrofurantoin Capsules USP present a special case where capsules containing 
macrocrystals dissolve slowly (to reduce GI irritation) and Q at 1,3 and 8h is 
between 20-60%, ? 45% and >_60% respectively. Capsules containing both 
macrocrystals and the monohydrate form are subjected to a two phase test in an 
acidic then basic medium as described in the relevant monograph (United States 
Pharmacopoeia 28,2005). 
For immediate-release formulations of highly water-soluble drugs (e. g. BCS Class 
I) the United States Pharmacopoeia monograph may omit the dissolution test and 
rely solely on disintegration testing. This is the case for a number of well- 
established preparations such as Apomorphine Hydrochloride Tablets USP. 
Otherwise, the only practical modification that may be required for immediate- 
release drugs is for floating dosage forms where a sinker is required (Figure 1.10) 
1.3.8.3. Delayed-release (Enteric-coated) Tablets & Capsules 
For enteric-coated (gastroresistant) dosage forms designed not to release their drug 
content in an acidic environment, a two-stage test is prescribed in both the United 
States Pharmacopoeia and British Pharmacopoeia, which can take one of two forms. 
In Method A, the dosage form is tested using the basket or paddle apparatus initially 
containing 750 ml of 0.1 N hydrochloric. After 2h exposure a sample is removed 
for analysis and 250 ml of phosphate buffer is immediately added and the mixed 
contents of the dissolution vessel adjusted to a pH of 6.8 ± 0.05. The test is 
continued for 45 min, or whatever time is prescribed in the relevant monograph 
before a further sample is taken for analysis. 
In Method B, the dosage form is tested using the basket or paddle apparatus 
containing 1000 ml of 0.01 N hydrochloric acid. After 2h exposure a sample is 
removed for analysis and the remaining contents of the vessel are discarded and 
1000 ml of a phosphate buffer having a pH of 6.8 ± 0.05 added. The test is 
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continued for 45 min, or whatever time is prescribed in the relevant monograph 
before a further sample is taken for analysis. 
In both instances, six units are initially tested and no more than 10% of the labelled 
content of drug should be released after 2 h. If these conditions are not met, a 
further six units are examined; the average released for the 12 units tested should 
not exceed 10% with no individual unit being greater than 25%. Failure leads to 
testing of a further 12 units; the average of the 24 units tested should not exceed 
10% released and no unit should exceed 25%. For the studies at pH 6.8, none of the 
initial six units tested should release less than Q+ 5% after the prescribed time; 
failure leads to testing a further six units where the average of the 12 tested is equal 
to or greater than Q and no unit is less than Q- 15%. Failure leads to the evaluation 
of another 12 units; of the 24 units examined, the average must be equal to or 
greater than Q; no more than 2 units can be less than Q- 15%, and no unit can be 
less than Q- 25%. Here Q is defined as the total amount of active ingredient 
dissolved in both the acid and buffer stages expressed as a percentage of labelled 
content. 
The official tolerances for delayed-release products have been given above and 
commercial manufacturers will have their own in-house specifications. Standards 
for enteric-coated forms ensure the integrity of the coat, but consideration should be 
given to a pH change method for evaluating extended-release medications. This 
evaluation should ensure that dose dumping does not occur at a specific pH, as 
might be a problem with certain delayed-release dosage forms, for example those 
using hydroxypropylmethylcellulose phthalate as a coat. 
1.3.8.4. Drug Release From Modified-release Dosage Forms 
Various methods have been used to study the influence of pH changes on drug 
dissolution, e. g. media change from 0.1 N HCl to pH of 7.5 or a progressive rise 
from pH 1.5,4.5,6.9,7.2 to 7.5 over 22 h. Such methods are aimed at mimicking 
the pH changes that a dosage form is subjected to during transit through the 
gastrointestinal tract. Skelly et al (1986) developed topographic profiles of the 
matrix tablets to determine the dissolution profiles at a variety of pHs where an 
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apparent three-dimensional profile of amount released versus time versus pH was 
produced. Such information may help to identify the pH range over which the drug 
dissolution rate is faster than intended, thus avoiding the problem of dose dumping 
at a particular narrow pH range. Additionally, they lead to the suitable single pH for 
testing; for example, phosphate buffer pH 5.4 was most meaningful for quinidine 
gluconate controlled-released products 
Apart from being used for QC purposes, dissolution testing can also be used as a 
predictive tool during the development of modified release dosage forms to 
discriminate the in vivo effect of good and bad formulations. Therefore, one needs 
to understand the mechanism of drug release from the dosage form in order to 
utilise the dissolution testing effectively. For extended-release reservoir 
formulations, where the drug is dissolved and released by diffusion through a 
barrier coat, factors such as the influence of medium on solubility of the drug needs 
to be established (Ford & Rajabi-Siahboomi, 2002). 
Drug release from hydrophilic matrix sustained release formulations occurs via 
diffusion through and erosion of the hydrated viscous surface polymer (Alderman, 
1984; Ford et al., 1987). Factors that hinder these processes or provide additional 
support to the surface polymer must be minimised to avoid false results. For 
example, dissolution testing of a large swelling matrix using the basket apparatus 
may be inappropriate because the basket wall may support the matrix, which, when 
combined with a slow speed of rotation, leads to unrealistically slow drug release 
(Ford & Rajabi-Siahboomi, 2002). Conversely in vivo, faster drug release may 
occur due to gut contractions and the presence of food enhancing matrix erosion. A 
second example involves matrix-sustained release tablets sticking to the walls of the 
dissolution vessel, resulting in a reduction in the surface area exposed to the 
dissolution medium. Hence, the choice of apparatus is critical and a discriminating 
dissolution test would aid the accomplishment of the desired in vivo drug release 
profile, through manipulation of the formulation variables. 
Osmotic pump devices, where a microscopic orifice is laser-drilled into the surface 
of the tablet coating, are not suitable for testing by USP dissolution Apparati 1-4 
as the tablet may lie in such an orientation as to obscure the hole, In this case, drug 
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release is determined using USP Apparatus 7 with the tablet glued onto the end of a 
reciprocating rod. 
Pellets, beads and other particulate systems intended to provide prolonged release 
are probably best tested by column methods that facilitate changes in pH or 
dissolution fluids. With compendial apparati, problems arise; for instance, it is 
difficult to capture dispersed particles when the paddle method is used, and small 
particles may pass through the mesh of the basket in the basket method (Ford & 
Rajabi-Siahboomi, 2002). 
Moore and Flanner (1996) described a simple model using mathematical indices to 
define a similarity factor f2, to compare dissolution profiles as in Equation 1.8: 
f2=50 log {[1+1/n Et`1 (Rt - Tt)2] 
°. 5 X 100} {Eq. 1.13 } 
where R, and Tt are percent dissolved at each time point for the reference product 
and the test product, respectively. Using the f2 values, dissolution profiles are 
considered dissimilar if these values were less than 50 with average difference 
between any dissolution samples not being greater than 50%. The similarity factor 
and similarity testing have been recommended for dissolution profile comparison in 
the FDA's Guidance for Industry (CDER, 1995,1997a, b). 
1.3.8.5. Granules & Suspensions 
Release of drug from particles in granules and suspensions is usually intended to 
occur rapidly in vivo and testing of such dosage forms is not common. However, 
United States Pharmacopoeia 28 includes dissolution testing of Flunixin Meglumine 
Granules (Apparatus 2, Q= 75% in 60 min), Cefuroxime Axetil for Oral suspension 
(Apparatus 2, Q= 60% in 30 min) and Indomethacin Oral Suspension (Apparatus 2, 
Q= 80% in 20 min). The flunixin granules are tipped into the filled vessel, the 
indomethacin suspension is simply poured onto the surface of the dissolution 
medium whilst the cefuroxime powder is reconstituted before being poured onto the 
medium. 
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1.3.9. Robotics and Automation 
Dissolution testing by manual methods is very labour-intensive and time- 
consuming, particularly during critical stages of product development, such as 
stability studies or plant trials and also when modified or sustained-release dosage 
forms are involved. It is also costly to implement on a 24 hour-a-day, 7 day-a-week 
basis. Therefore, computerised systems have been developed which control many 
features of the test procedure, from sample introduction, through instrument 
operation to data capture and reporting. The additional cost of such systems is easily 
justified where the test may take up to 24 h. The use of robotic systems is 
particularly valuable in busy development laboratories where the robot can also 
remove samples for off-line testing. Complicated samples may require off-line 
clean-up by liquid-liquid extraction or solid-phase extraction followed by 
chromatographic analysis. Rapid insertion and withdrawal of a small sample probe 
controlled robotically, produces minimum disturbance of the hydrodynamic 
conditions, with a sampling time as low as 40 s. The use of robotics increases the 
speed of assay, the throughput and the productivity of dissolution testing although 
the speed of assay may then be the rate-limiting step to productivity. Consequently, 
short (2 -5 cm) HPLC columns may be used to increase assay speed, increasing 
productivity by as much as 75%. 
1.4. In Vitro - In Vivo Correlation 
The QC functions of dissolution tests were established in Section 1.3. In addition, 
one may consider the in vitro dissolution test as a prognostic tool for in vivo 
performance during the drug development stages. In this respect, dissolution tests 
are used at preformulation stages to characterise candidate drug properties and 
select suitable excipients to optimise drug release. Dissolution testing is then 
applied to candidate formulations to determine which formulation produces the 
most desirable and reproducible dissolution profile (Dressman et at., 1998). Later in 
the development life cycle dissolution test data are used to establish in vitro - in 
vivo correlations (IVIVC) between drug release from the dosage form and 
absorption. In such studies the dissolution test conditions must be physiologically 
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relevant otherwise the prediction of which drug and which dosage form will provide 
the most favourable release profile in vivo will be invalid (Dressman et al., 1998). 
In situations where in vitro results do not adequately predict in vivo performance of 
a drug product, the size and number of clinical trials have to be increased, at 
significant cost. 
For poorly soluble drugs where dissolution is the rate-limiting step to absorption, 
the presence of food may improve bioavailability. However, current pharmacopeial 
dissolution tests do not account for this. The dissolution test should mimic the 
conditions in the G1T as closely as possible to be meaningful (Anon., 1997). In 
relation, a crucial factor that needs to be considered is the composition of the 
dissolution medium and its biorelevance (see Section 1.3.7). 
For some drugs, simple test conditions have allowed dissolution rate to be related to 
bioavailability. Kingsford (1984) showed a linear relationship between the 
percentage frusemide dissolved from tablets in 30 min and drug bioavailability 
relative to an oral solution when frusemide was examined using the rotating basket 
apparatus and buffer at pH 5.0. Therefore, in certain cases, it may be appropriate to 
apply dissolution testing data to evaluate biopharmaceutical implications of a 
product change rather than an automatic bioequivalence study (CDER, 1995). 
1.5. Biopharmaceutics Classification System (BCS) 
Biopharmaceutics is the study of how the physico-chemical properties of drugs and 
formulations and the physiology of the route of administration affect the rate and 
extent of drug absorption. Bioavailibility and bioequivalence are two elementary 
terms used in biopharmaceutics. 
Bioavailablity can be defined as "the rate and extent to which the active drug 
ingredient or therapeutic moiety is absorbed from a drug product and becomes 
available at the site of drug action" (Lobenberg & Amidon, 2000), or " ... the extent 
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and the rate to which a substance or its therapeutic moiety is delivered from a 
pharmaceutical form into the general circulation" (EMEA). 
Bioequivalence is "the absence of a significant difference in the rate and extent to 
which the active ingredient or active moiety in pharmaceutically equivalent dosage 
forms becomes available at the site of action when administered at the same molar 
dose under similar conditions in an appropriately designed study in human 
subjects" (Kanfer, 2002), or "two medical products are considered to be 
bioequivalent when their concentration vs. time profiles, from the same molar dose, 
are so similar that they are unlikely to produce clinically relevant differences in 
therapeutic and/or adverse effects" (Anon, 1994). 
As part of the safety and efficacy assessment of a generic drug product, regulatory 
agencies require a bioavalability (BA) study and a bioequivalence (BE) study 
versus the innovator product whose safety and efficacy will have been established 
through expensive clinical trials. Such studies require in vivo comparisons of the 
plasma drug concentration in healthy human subjects between the test and reference 
products. As a result, the BCS was introduced with guidance from the FDA. The 
regulatory aim of the BCS is to make the drug development and review process 
more efficient by recommending a strategy for replacing certain BE studies with 
surrogate in vitro dissolution tests. In addition, biowavers that exempt a product 
from in vivo BA and BE studies may be granted for lower strengths of immediate 
release (IR) and modified release (MR) drug products, based on formulation 
proportionality and dissolution profile comparison (CDER, 2000a). 
The three major factors that determine the rate and extent of drug absorption from 
solid oral dosage forms are solubility, dissolution rate and permeability. Solubility 
and permeability are recognised in the BCS, which categorises drugs into four 
classes based on their aqueous solubility and intestinal permeability (Table 1.3). 
Dissolution rate is recognised in the BCS biowaver criteria. 
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Table 1.3. The Biopharmaceutics Classification System 
BCS CLASS DRUG SOLUBILITY DRUG PERMEABILITY 
I High High 
II Low High 
III High Low 
IV Low Low 
The following ranges are required when estimating the drug solubility and 
permeability classification as high or low in Table 1.3 (CDER, 2000b): 
>A drug substance is considered HIGHLY SOLUBLE when the highest dose 
strength is soluble in 5 250m1 water over a pH range 1 to 7.5. 
>A drug substance is considered HIGHLY PERMEABLE when the extent of 
absorption in humans is determined to be > 90% of an administered dose, based 
on mass-balance or in comparison to an intravenous reference dose. 
At present, biowavers for in vivo BA and BE studies can be requested if the drug 
falls into BCS Class 1, is formulated as an IR solid oral dosage form and shows 
rapid and comparable dissolution (f2 similarity factor > 50) in pH 1.2,4.5,6.8 with 
the innovator product (Lennernas & Abrahamsson, 2005). The BCS definition for 
`rapid' dissolution is as follows (CDER, 2000b): 
AA drug product is considered to be RAPIDLY DISSOLVING when z 85% of 
the labelled amount of drug substance dissolves within 30 min using USP 
apparatus 1 (100rpm) or apparatus 2 (50rpm) in a volume S 900m1 of 0.1N HCl 
or simulated gastric fluid, pH 4.5 buffer and pH 6.8 buffer or simulated 
intestinal fluid. 
However, certain restrictions are applied when applying for a biowaiver: 
I. The drug must have a wide therapeutic index; 
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2. The drug must be chemically stable in the gastrointestinal tract; 
3. Excipients used must have previously been used in FDA approved IR dosage 
forms and must not have a significant effect on the rate and extent of oral drug 
absorption; 
4. The product must not be designed for absorption from the buccal cavity. 
1.5.1. The Impact of the BCS Solubility and Dissolution Rate Criteria on Drug 
Discovery and Development 
The BCS provides criteria for determining the rate-limiting factor for drug 
absorption from oral dosage forms. Therefore, it may influence the choice of drug 
candidate(s) for further development, the prediction and elucidation of food 
interactions, the choice of formulation and IVIVC in the dissolution testing of oral 
dosage forms. 
Furthermore, pharmacokinetic factors such as absorption, distribution, metabolism 
and excretion (ADME) affect drug bioavailability, efficacy and safety and thus are 
vital considerations in the selection process of oral drug candidates in development 
pipelines. Since solubility, permeability and the fraction of dose absorbed are 
fundamental BCS parameters that affect ADME, their knowledge should prove 
useful in drug discovery and development. In particular, the classification can be 
used to make the development process more efficient (Yazdanian et al., 2004). For 
example, in the case of a drug placed in BCS Class II where dissolution is the rate- 
limiting step to absorption, formulation principles such as polymorph selection, salt 
selection, complex formation and particle size reduction (i. e. nanoparticles) could 
be applied earlier in development to improve bioavailability. 
However, it must be acknowledged that the current BCS class boundaries are too 
conservative in certain aspects, which could lead to the loss of promising 
compounds in early development stages or prevent biowavers from being granted 
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for drugs that exhibit Class I behaviour in physiologically relevant conditions (Polli, 
2004). 
Suggestions have been made to further improve the applicability of the BCS in 
industry and were summarised in a BCS workshop report by Polli et al (2004). Of 
particular importance to the topic of this thesis are the suggestions that are likely to 
affect the future solubility and dissolution classifications of the BCS. They are as 
follows: 
1. The pH range for solubility studies should be limited to only include pH 1.2,4.5 
and 6.8. 
2. The solubility of amphoteric compounds should be determined at the isoelectric 
point if it occurs between pH 1.2 and 6.8. 
3. An intermediate solubility class should be introduced given the tendency of many 
acids and bases to be highly soluble at pH 6.8 and 1.2 respectively. 
4. The dose: solubility ratio for determining the solubility class boundary should be 
increased from 250 mL to 500 mL, particularly at pH values of 4.5 and 6.8 which 
are representative of the small intestine where the fluid volume is greater than in the 
stomach. 
5. The dissolution classification should be broadened from at least 85% dissolved in 
30 min to at least 85% dissolved in 60 min. 
The implementation of BCS guidance to utilise in vitro dissolution tests as a 
surrogate for in vivo BE studies and the incorporation of the BCS into drug 
development strategies exemplifies the rapidly evolving function of the dissolution 
test. 
55 
1.6. Regulatory Developments 
The previously contrasting views of dissolution testing held by pharmaceutical 
scientists and regulators led to constant development and review of the technology. 
The industrial drive has been to improve the IVIVC, so speeding up the 
identification and development of new therapeutic products and elimination of 
unworkable drug candidates, whilst the regulatory focus was traditionally on the use 
of dissolution testing as a quality control tool to confirm product safety & efficacy. 
However, regulatory perspectives are now changing, signalled by the emergence of 
the dissolution test as a surrogate in vitro bioequivalence test. Several aspects of 
dissolution testing are receiving particular attention in various industry-government 
fora (Williams et al., 2004) 
1.7. Harmonisation 
Discussions within the Pharmacopoeial Discussion Group under the auspices of the 
International Conference on Harmonisation (ICH) process have led to some 
harmonization of compendia) approaches. There is an agreement by all to adopt the 
United States Pharmacopoeia three-tiered system of testing and specification where 
appropriate. However, some differences are further from resolution. For example, 
the Japanese Pharmacopoeia does not recognise USP Apparatus 3 and maintains a 
different approach to delayed release products. The European Pharmacopoeia (2001) 
prescribes three apparatuses for oral solid dosage forms, the basket, the paddle and 
the flow-through along with a flow-through device for suppositories and three 
systems for testing transdermals which equate to the USP paddle-over-disk, 
diffusion cell and rotating cylinder. 
1.8. Aim and Objectives 
The overall aim of this project is to gain a better understanding of the effect of the 
dissolution medium on the drug release profile in vitro, so that in vitro dissolution 
testing can be used more effectively in the early stages of formulation development. 
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This aim is to be achieved through in vitro dissolution testing of drugs using media 
that are a closer representation of the gastric and intestinal environment than 
compendial media. Consequently, insight into possible interactions between drugs 
and/or excipients and biorelevant media would be useful to understand some of the 
physicochemical factors affecting dissolution into these complex media. Hence, a 
more accurate prediction of in vivo dissolution performance would be provided, 
progressing to the concept of achieving IVIVC. 
In order to discriminate between differences in drug dissolution in various media, 
the model drugs selected in this project have to be poorly soluble. Also, to 
investigate drug dissolution as a barrier to drug absorption the chosen drugs must be 
highly permeable for absorption to be dissolution rate limited. According to the 
BCS these criteria would fall under Class H. Drugs that are acids will be poorly 
soluble in an acidic environment such as the stomach but on movement into the 
intestinal region, where the pH is higher, rapid dissolution is likely occur. 
Conversely, basic drugs will be more readily soluble in the stomach with the 
possibility of precipitation in the fed state or as the stomach contents empty into the 
small intestine. 
The Objectives of this project are to: 
> Investigate the dissolution of two acidic BCS Class II drugs in milk, which 
is a more realistic representation of the fed state stomach, in comparison to 
compendial media 
> Devise and conduct a pH shift experiment (from acidic to neutral) using 
simple media to assess the extent of any reprecipitation of a basic drug on 
exposure to intestinal pH and the utility of such a test 
> Investigate the dissolution of two basic BCS Class II drugs in the proposed 
FaSSIF and FeSSIF media and their constituents in comparison to 
compendial media 
> Compose and assess the use of alternative, less expensive, surfactant based 
media to replace FaSSIF and FeSSIF media. 
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2. MATERIALS AND GENERAL METHODS 
2.1. Materials 
A list of the materials and suppliers used throughout the project is provided below. 
Where necessary, specific details are described in the relevant chapter. 
2.1.1. Drug substances 
As stated in Section 1.8, the model drugs chosen for investigation in this project 
would have to be poorly soluble so that differences in the dissolution behaviour of 
each drug in various media could be distinguished. Also, for drug dissolution to be 
the rate-limiting step to absorption, drug permeability through the gut wall would 
have to be high. Consequently, two acidic drugs (ibuprofen and naproxen) and two 
basic drugs (loratadine and trimethoprim) were selected (Table 2.1. ). All four drugs 
are categorised in BCS Class II, i. e. they are poorly soluble and highly permeable. 
Table 2.1. Drug substances used. 
Drug Source Batch 
Number 
Ibuprofen Knoll Pharma Chemicals, Nottingham, 453408 
(particle size 25 µm) U. K. 
Loratadine Kindly donated by Ranbaxy Laboratories 1459651 
(particle size 10 µm) Ltd, Hamachal Pradesh, India. 
Naproxen Sigma-Aldrich Chemie GmbH, Steinheim, 02230LB-024 
(particle size 20 µm) Germany. 
Trimethoprim Kindly donated by Alpharma Ltd, 39423 
(particle size 50 µm) Barnstaple, U. K. 
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2.1.2. Marketed drug products 
Tablets are the most common and preferred oral dosage form. It was decided to 
investigate a marketed tablet formulation of each drug for its dissolution behaviour 
in various media. Brand selection was random. However, for loratadine, poor 
disintegration of the selected product (Brand A) in biorelevant media led to the 
investigation of two further products (Brand B and Q. The products selected are 
listed in Table 2.2. 
Table 2.2. Marketed drug products used. 
Marketed Product Source Batch Number 
Ibuprofen 400mg tablets The Boots Company PLC, 1SS 
Nottingham, U. K. 
Loratadine 10mg tablets Ranbaxy (UK) Ltd, London, U. K. 140 9665 
(Brand A) 
Loratadine 10mg tablets APS Ltd, Eastbourne, U. K. 4T27LT 
(Brand B) 
Loratadine 10mg tablets Boots Brand, PL Holder Schering- 05B 1607 
(Brand C) Plough Ltd, Hertfordshire, U. K. 
Naproxen 250mg tablets Roche Products Ltd, Hertfordshire, El 171 
(Naprosyn®) U. K. 
Trimethoprim 200mg Alpharma Ltd, Barnstaple, U. K. TG 424 
tablets 
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2.1.3. Ingredients used in solubility screens and dissolution media 
All the materials used in the preparation of the dissolution media and the surfactants 
investigated for their solubilising capacity for loratadine are listed in Table 2.3 
below. 
Table 2.3. List of materials used. 
Material Source Batch Number 
Brij 35. Polyoxyethylene Sigma-Aldrich Chemie GmbH, 025KO055 
23 lauryl ether. Steinheim, Germany. 
Casein (Technical grade) Sigma-Aldrich Chemie GmbH, 013KO162 
Steinheim, Germany. 
CHAPSO. 3- [(3- Sigma-Aldrich Chemie GmbH, 015K5315 
Cholamidopropyl) Steinheim, Germany. 
dimethylammoniol -2- 
hydroxyl -1- 
propanesulfonate (98%) 
Cremophor EL®. Castor oil Sigma-Aldrich Chemie GmbH, 103K2521 
polyoxyethylene ether Steinheim, Germany. 
CTAB. Hexadecyltrimethyl Sigma-Aldrich Chemie GmbH, 113KO092 
ammonium bromide. Steinheim, Germany. 
DDAO. N, N- Sigma-Aldrich Chemie GmbH, 063K2607 
Dimethyldodecylamine N- Steinheim, Germany. 
Oxide. 
Glacial acetic acid (-100%, BDH, Poole, U. K. K23898917 
AnalaR®) 
Hydrochloric Acid (GPR®) BDH, Poole U. K. K32540451 343 
Lactose (Lactopress®, Borculo Domo Ingredients, 204022 
spray dried monohydrate, Chester, U. K. 
USP) 
Continued......... 
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Table 2.3 (contd). List of materials used. 
Material Source Batch Number 
Lecithin. Lipoid GmbH, Ludwigshafen, 108015-1/88; 
Egg phosphatidylcholine. Germany 108015-1/124; 
(EPC S) 108015-1/911 
Potassium dihydrogen Rectapur®, Prolabo, Bois, 1188 
phosphate France. 
Skimmed, Semi-Skimmed ASDA, Liverpool, U. K. -- 
and Whole Milk 
Sodium acetate (AnalaR®) BDH, Poole, U. K. K91214705 339 
Sodium chloride Rectapur®, Prolabo, Bois, N020 
France. 
Sodium dihydrogen BDH, Poole, U. K. A856721 
orthophosphate (AnalaR®) 
Sodium dodecyl sulphate BDH, Poole, U. K. 6744110 
Sodium hydroxide pellets GPR®, BDH, Poole, U. K. 260494H16S 
Sodium Taurocholate Sigma-Aldrich Chemie GmbH, 084K5301 
(95%) Steinheim, Germany. 
Sodium Taurocholate Alfa Aesar, Lancaster, U. K. 10109329 
hydrate (97%) 
Triton® X100. Sigma-Aldrich Chemie GmbH, 024KO025 
Polyethylene glycol tert- Steinheim, Germany. 
octylphenyl ether (Sigma 
Ultra) 
Tween®80 Sigma-Aldrich Chemie GmbH, 052KO144 
Polyoxyethylenesorbitan Steinheim, Germany. 
Monooleate (Sigma Ultra) 
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2.1.4. Drug extraction and mobile phase solvents 
Organic solvents used to extract drug from milk-based media and in the preparation 
of mobile phases fro HPLC analyses are listed in Table 2.4. 
Table 2.4. Drug extraction and mobile phase solvents used. 
Solvent Source 
Acetonitrile (HiPerSolv for HPLC®) BDH, Poole, U. K. 
Cyclohexane (HiPerSolv for HPLC®) BDH, Poole, U. K 
Ethyl acetate (HiPerSolv for HPLC®) BDH, Poole, U. K 
Methanol (HiPerSolv for HPLC®) BDH, Poole, U. K. 
Orthophosphoric acid (85%) J. T. Baker, Deventer, Holland. 
Sodium perchlorate BDH, Poole, U. K. 
Water (HiPerSolv for HPLC®) BDH, Poole, U. K. 
2.1.5. Filters 
Samples collected during solubility, dissolution and intrinsic dissolution rate 
experiments were passed through the appropriate filters listed in Table 2.5. 
Table 2.5. Filters used for sample collection procedures. 
Filter size and type Source 
0.45µm syringe filters Millipore Corp, Bedford, U. S. A 
Millex®-LCR, PTFE, 25mm 
20µm cannula filters Science Marketing International Ltd, 
Erweka style, UHMW polyethylene Maisemore, U. K. 
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2.2. General Experimental Methods 
2.2.1. Solubility determinations 
2.2.1.1. Ibuprofen and naproxen 
10 mg of drug substance was placed into a 20 x 42 mm screw cap vial followed by 6 
mL of medium. The vial was then capped and agitated in a heated shaker (Model 
AM89B, Dynex Technologies Ltd, Worthing, U. K) for 24 h at 37°C. At 1,5 and 24 
h 1.5 mL of the bulk suspension was sampled and passed through a 0.45 gm filter, 
into a2 mL glass autosampler vial. For solubility studies in milk media, the samples 
were excessively particulate for filtration and therefore, 1.5 mL of sample was 
transferred to a2 mL Eppendorf tube instead and spun at 14,000 rpm (G force = 
9878 g) for 1h in a mini centrifuge (Model Z160M, Hermle Labortechnik, 
Wehingen, Germany). 1 mL of the supernatant was then removed and added to 1 
mL of cylohexane (ibuprofen) or to 1 mL of ethylacetate (naproxen) in a test tube. 
This mixture was then shaken for 20 s before 500 µL of the organic layer was 
removed, mixed with 1 mL of phosphate buffer pH 10 and shaken for 20 s. 800 µL 
of the phosphate buffer was then transferred to a2 mL glass autosampler vial for 
analysis. The pH of the bulk suspension was measured at 1,5 and 24 h using a 
digital pH meter (Delta 350, Mettler Toledo, Leicester, U. K. ). 
2.2.1.2. Loratadine 
10 mg of drug substance was placed into a 20 x 42 mm screw cap vial followed by 2 
mL of medium. A magnetic stirrer bar was then inserted into the vial containing the 
bulk suspension and the vial capped before being placed in a Variomag Telemodul 
40CT heated stirrer (H+P Labortechnik GmbH, Oberschleissheim, Germany) at 
37°C for 24 h. 600 µL samples were withdrawn from the vial at 1,5 and 24 h and 
transferred to an Eppendorf tube using an auto pipette and spun at 40,000 rpm (G 
force = 80,640 g) for 15 min in a Beckman Optima TL ultracentrifuge (Beckman 
Coulter Inc, California, USA). 450 µL of the supernatant was transferred to a second 
Eppendorf tube and spun again at 40,000 rpm for a further 15min. 300µL of the 
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supernatant was then transferred to a2 mL glass autosampler vial for dilution or 
direct analysis. The pH of the bulk suspension was measured at 1,5 and 24 h using a 
digital pH meter. 
2.2.1.3. Trimethoprim 
100 mg of drug substance was placed into a 20 x 42 mm screw cap vial followed by 
4 mL of medium. The vial was then capped and a similar procedure as ibuprofen 
and naproxen was used except that 1 mL samples were removed from the bulk 
mixture instead of 1.5 mL and no extractions were required, as milk media were not 
used. 
The samples were assayed as described in Section 2.3. 
N. B. Whilst samples were assayed at 1,5 and 24h, where drug `solubility' is 
referred to throughout this thesis it is with reference to 24h data. 
2.2.2. Disintegration testing 
A Pharma Test PTZ (Pharma Test Apparatebau GmbH, Hainburg, Germany) 
disintegration tester was used throughout. Three tablets were placed in the basket 
rack assembly without disks (see Section 1.2.2) and lowered into the relevant 
medium held at 37°C. The tester was operated and the time taken for complete 
disintegration of all the tablets was noted. 
For ibuprofen and naproxen, tablet disintegration tests were carried out in 0. IN HCI, 
0.003N HCI containing 0.017%v/w sodium dodecyl sulphate, the filtrate of 1.475% 
w/v dispersion of casein in O. O1N HCI and in 50/50 mixtures of O. 1N HC1 with 
whole, semi-skimmed or skimmed milk (see Section 4.2.2 for media preparation). 
For loratadine, tablet disintegration tests were carried out in O. 1N HCI, FaSSIF 
blank and FeSSIF blank (see Section 6.2.2 for media preparation). 
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Disintegration tests were not conducted for trimethoprim for reasons explained in 
Chapter 7. 
2.2.3. Dissolution testing 
Experiments were conducted in a Pharmatest PTW S2C (Pharma Test Apparatebau 
GmbH, Hainburg, Germany) or a Distek 2100C (Distek Inc, New Jersey, USA) 
dissolution tester using Apparatus 2 (paddle method) described in General Chapter 
<711> of the United States Pharmacopoeia 28 (see Section 1.3.1.2). Six tablets were 
tested for each experiment. 500 mL or 1000 mL of dissolution medium was placed 
in each of six vessels, the paddles lowered to 25 mm from the base of the vessels 
and the vessels covered with plastic lids. After lowering, the paddles were rotated at 
50 rpm to agitate the dissolution medium. The dissolution medium was heated to 
37°C by a water bath. Each tablet was then dropped into a separate vessel containing 
the dissolution medium. 5 mL samples were taken at 15,30,45,60,90 and 120 min 
or designated time points using 0.45 µm syringe filters for non- particulate media 
and 20 µm cannula filters for milk media. The pH of the medium was measured at 
the start and end of the test using a digital pH meter (Delta 350, Mettler Toledo, 
Leicester, U. K. ). 
2.2.4. Intrinsic dissolution rate determinations 
IDR was measured by the rotating disk method of the United States Pharmacopoeia 
28, using the Woods apparatus (Figure 1.3). The test preparation was as follows: 
Each stainless steel die (10 mm diameter) was bolted to a base plate made from 
hardened polished steel. 200 mg of ibuprofen or 400 mg of naproxen drug substance 
was weighed and added to each die. The drug powder was then compressed into a 
disk using a hydraulic press (Model M-30, Research and Industrial Instrument 
Company, London, England) and hardened steel punch (Figure 1.5) at a 
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compression force of 8x 106 N/m2 (80 bar). The base plate was removed after 
compression to expose a smooth drug surface. Screw threads on the top of the die 
allowed attachment to a specially designed shaft that could be interchanged with the 
paddle on the Pharmatest PTW S2C dissolution apparatus. Experimental conditions 
and sampling times were identical to those used for tablet dissolution tests (see 
Section 2.2.3). 
2.2.5. Procedures for drug extraction from milk based media 
A significant challenge to dissolution testing in food-based media was the extraction 
of dissolved drug into a suitable matrix for analysis, which can be both time and 
labour intensive. For HPLC, the dissolved drug had to be extracted from the various 
milk media (50/50 mixtures of whole, semi-skimmed or skimmed milk with 0.1N 
HCl) into an aqueous medium that could be injected directly onto the column. A 
back extraction method was developed and applied to each drug as described below. 
2.2.5.1. Extraction of ibuprofen 
Dissolution and solubility studies: After removal and filtering, 2 mL of the sample 
solution was mixed with 2 mL of cyclohexane and the mixture was shaken for 20 s. 
The mixture was allowed to settle before 1 mL of the (upper) cyclohexane layer was 
transferred to a second tube and 2 mL of phosphate buffer pH 10 added. This 
mixture was shaken for 20 s, allowed to settle and 1 mL of the (lower) aqueous layer 
transferred to a2 mL glass autosampler vial for analysis. Method validation studies 
using each of the three milk-HCI media spiked with an ibuprofen standard (n = 6) 
indicated this process recovered >90% of the available ibuprofen in the sample. For 
solubility studies, a similar procedure was used except that it was scaled down such 
that half of all the volumes stated above were used. 
IDR studies: After removal and filtering, 2 mL of the sample solution was mixed 
with 2 mL of cyclohexane and the mixture was shaken for 20 s. The mixture was 
allowed to settle before 1 mL of the (upper) cyclohexane layer was transferred to a 
second tube and 1 mL of phosphate buffer pH 10 added. This mixture was shaken 
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for 20 s, allowed to settle and 800 µL of the (lower) aqueous layer transferred to a2 
mL glass autosampler vial for analysis. 
2.2.5.2. Extraction of naproxen 
Dissolution and solubility studies: After removal and filtering, 2 mL of the sample 
solution was mixed with 2 mL of ethyl acetate and the mixture was shaken for 20 s. 
This mixture was allowed to settle before 500 µL of the (upper) ethyl acetate layer 
was transferred to a second tube and 2 mL of phosphate buffer pH 10 added. This 
was shaken for 20 s, allowed to settle and 1 mL of the (lower) aqueous layer 
transferred to a 2mL glass autosampler vial for analysis. Method validation studies 
using each of the three milk-HCI media spiked with a naproxen standard (n=6) 
indicated this process recovered >85% of the available naproxen in the sample. For 
solubility studies, a similar procedure was used except that it was scaled down such 
that half of all the volumes stated above were used. 
IDR studies: After removal and filtering, 2 mL of the sample solution was mixed 
with 2 mL of ethyl acetate and the mixture was shaken for 20 s. The mixture was 
allowed to settle before 500 pL of the (upper) ethyl acetate layer was transferred to a 
second tube and 1 mL of phosphate buffer pH 10 added. This mixture was shaken 
for 20 s, allowed to settle and 800 µL of the (lower) aqueous layer transferred to a2 
mL glass autosampler vial for analysis. 
2.3. Analytical Method 
2.3.1. HPLC 
2.3.1.1 Ibuprofen 
For dissolution and solubility studies, quantitation was carried out using a Hewlett 
Packard HP1090 liquid chromatograph (Agilent Technologies U. K. Ltd, Stockport, 
U. K. ). 25 µL of sample for assay was injected into a mobile phase consisting of 
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0.3% v/v orthophosphoric acid, 24.7% v/v water and 75% v/v methanol flowing 
through the column at a rate of 1 mU min. A 5µm Nucleosil C18 column (25 cm x 
4.6 mm) (Hichrom Ltd, Reading, U. K. ) was used and eluting peaks were detected at 
a wavelength of 264 nm. Quantitation was based on the use of an external ibuprofen 
calibration standard and peak area measurement. 
For IDR studies, quantitation was carried out using a Waters 2695 liquid 
chromatograph connected to a Waters 474 fluorescence detector (Waters S. A. S., 
Cedex, France). The injection volume, mobile phase and flow rate were unchanged 
from the dissolution and solubility studies. A5 pm Hypersil C18 column (10 cm x 
4.6 mm) (Hichrom Ltd, Reading U. K. ) was used fitted with a Phenomenex C18 
guard cartridge (4 mm x3 mm) (Macclesfield, U. K. ). Eluting peaks were detected at 
excitation and emission wavelengths of 222 nm and 285 nm respectively. 
Quantitation was based on the use of an external ibuprofen calibration standard and 
peak area measurement. 
2.3.1.2. Loratadine 
Quantitation was carried out using either a Hewlett Packard HP1090 or Agilent 
1100 (Agilent Technologies U. K. Ltd, Stockport, U. K. ) liquid chromatograph. 10 
µL of sample was injected into a mobile phase consisting of 1% v/v orthophosphoric 
acid, 8%v/v potassium dihydrogen phosphate (0.5M), 44%v/v acetonitrile and 48% 
v/v water flowing through the column at a rate of 1.8 mUmin. A5 . tm Hypersil 
BDS C18 column (15 cm x 4.6 mm) (Hichrom Ltd, Reading, U. K. ) fitted with a 
Phenomenex C18 guard cartridge (4 mm x3 mm) was used and eluting peaks were 
detected at a wavelength of 200 nm. Quantitation was based on the use of an 
external loratadine calibration standard and peak area measurement. 
2.3.1.3. Naproxen 
Dissolution samples were analysed using a Hewlett Packard HP 1090 liquid 
chromatograph whilst solubility and IDR samples were analysed using an Agilent 
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1100 liquid chromatograph. 25 µL of sample was injected into a mobile phase 
consisting of 32% v/v orthophosphoric acid (0.01M) and 68% v/v methanol flowing 
through the column at a rate of 1.5 mL/min. A5 µm Spherisorb C18 column (10 cm 
x 4.6 mm) (Hichrom Ltd, Reading, U. K. ) fitted with a Phenomenex C18 guard 
cartridge (4 mm x3 mm) was used and eluting peaks were detected at a wavelength 
of 262 nm. For IDR studies, the injection volume was increased to 50 gL for all 
media tested except O. 1M HCl where the injection volume was increased to 100 µL. 
Quantitation was based on the use of an external naproxen calibration standard and 
peak area measurement. 
2.3.1.4. Trimethoprim 
Dissolution samples were analysed using a Hewlett Packard HP1090 liquid 
chromatograph whilst solubility samples were analysed using an Agilent 1100 liquid 
chromatograph. 5µl of sample was injected into a mobile phase consisting of 30% 
v/v methanol and 70%v/v sodium perchlorate (0.01M), adjusted to pH 3.6 with 
phosphoric acid, flowing through the column at a rate of 1.3 mlJmin. A5 µm 
Hypersil BDS C18 column (15 cm x 4.6 mm) (Hichrom Ltd, Reading, U. K. ) was 
used and eluting peaks were detected at a wavelength of 280 nm. Quantitation was 
based on the use of an external trimethoprim calibration standard and peak area 
measurement. 
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3. DETERMINATION OF THE SURFACE TENSIONS 
OF THE DISSOLUTION MEDIA INVESTIGATED 
3.1. Introduction 
As previously explained in Section 1.1.4.1, the surface tension of the 
solvent/dissolution medium can affect the dissolution of a drug particle through its 
influence on the wetting phenomena at the solid surface. Hence, it is an important 
parameter to consider when comparing the effect of different media on drug 
dissolution. For example, Chen et al (2003) found that decreasing the surface 
tension of 0.1N HCl by addition of Tween 80 reduced the IDR of the hydrophobic 
drug, CI-1041. The lower surface tension promoted nucleation of the insoluble 
chloride salt onto the disk surface causing the reduction in IDR. Also, the 
dissolution rate of the poorly soluble drug, griseofulvin, from a solid dispersion was 
correlated to the surface tensions of carrier aqueous solutions (Saito et al., 2002). An 
assessment of the wetting properties of physiological concentrations of bile salt 
solutions versus compendial media was conducted by Luner (2000). The study 
revealed that the bile salt solutions had lower surface tensions and contact angles 
compared to compendial media and that individual bile salts differed in surface 
tension lowering effect and contact angles. These findings are important in 
establishing an IVIVC for drug dissolution because they illustrate that drug wetting 
may differ between compendial media and physiological fluids. 
In terms of tablet formulations, wetting of the tablet surface is an elementary 
requirement for disintegration, therefore, the surface tension of the medium can 
influence the drug release rate. Anwar et al (2005) investigated tablet disintegration 
in relation to the liquid penetration rate, which is dependent on the surface tension 
and viscosity of the liquid, the contact angle and the tablet pore size. 
The purpose of this chapter is to obtain definitive in-house surface tension data for 
the variety of dissolution media used throughout the project. No literature values 
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were available for some of the unique media used whilst those reported for other 
media were inconsistent. Also, by using the same method and conditions for all the 
media, more accurate and meaningful comparisons of surface tensions were possible 
through reduced experimental variability. 
3.2. Methods 
3.2.1. Density measurements 
For the method used to determine surface tension, the densities of the dissolution 
media were required to resolve their surface tensions. The densities of the all the 
dissolution media were determined using a Paar Model DMA 55 density meter 
(Anton Parr Ltd, Hertford, U. K. ). The measurement is based on the oscillating U- 
tube principle whereby the resonant frequency of the sample is inversely 
proportional to the square root of its mass. Since the volume of the U-tube is 
standardised, the resonant frequency measured is used to automatically calculate and 
display the density (p) of the sample. The instrument was first calibrated using two 
fluids of accurately known densities at the same temperature and pressure to be used 
for the unknown samples. 17.53% w/v sodium chloride solution (p = 1.1058 g/cm3) 
and methanol (p = 0.7866 g/cm3) were used for this purpose. After calibration, a 
sample of medium was injected into the U-tube and the density at 25°C recorded. 
The mean of three determinations was used for the surface tension calculation. 
3.2.2. Surface tension measurements 
The drop shape technique was used to determine surface tension (Satherley et al., 
1990; Miller et al., 2001; Miqueu et al., 2001). Fundamentally, the opposing forces 
of surface tension and gravity determine the shape assumed by a pendant drop of 
liquid. Surface tension makes the drop spherical while gravitational forces elongate 
the drop. Advances in video digital techniques have allowed highly accurate 
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detection of the droplet edge enabling drop profile coordinates to be mapped by 
computer programmes. Hence working backwards from the acquired droplet shape 
and known force of gravity, the surface tension can be determined. 
A pendant drop of the sample medium was formed at the tip of a capillary 
positioned inside a glass cell with optically flat windows (Figure 3.1). Zoom lens 
and a silicon charge-coupled device (CCD) camera were used to capture an image of 
the drop and a digital image processor captured the profile coordinates of the drop. 
Axisymmetric drop shape diagnostic software utilised the Laplace-Young equation 
(Equation. 3.1) and the measured sample density to compute the surface tension: 
ep gh=y (1/Rl + 1/R2) { Eq. 3. l} 
where Ap is density difference between the droplet and substance surrounding it, g 
is the acceleration due to gravity, h is the height in the drop measured from its apex, 
y is the surface tension and R1 and R2 are radii of curvature determined from the 
drop profile coordinates. 
A schematic diagram of the apparatus is shown in Figure 3.1. For each medium 
tested, three drops were analysed and the results reported in Table 3.1. For each 
drop, the software reported the mean data from 10 simultaneously captured images. 
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3.3. Results 
The density and surface tension measurements for the media used are presented in 
Table 3.1 below. Numerous SDS concentrations were used in the project. 2.5 
mg/mL SDS was used to lower the surface tension of 0.1M HC1 to that of gastric 
fluid. 0.17 mg/mL SDS was used to lower the surface tension of 0.003M HCl to 
match that of the 50/50 milk/HCl mixtures (Chapter 4 and 5) but as determined in 
Table 3.1. Density and surface tension data for dissolution media investigated. 
Medium 
Density (g/cm3) 
@ 25°C 
Mean Surface 
tension (mN/m) 
n=3 
± S. D. 
(mN/m) 
Purified water (Milli Q®) 0.99262 66.02 0.13 
Distilled water 0.99268 68.08 0.40 
0.1M HCl 0.99424 68.48 2.99 
O. 1M HCl + 2.5 mg/mL SDS 0.99461 32.03 0.16 
0.003M HC1 0.99230 67.43 0.33 
0.003M HCl + 0.17 mg/mL SDS 0.99256 40.35 1.26 
Simulated Intestinal Fluid (SIF) 0.9980 63.35 0.22 
50150 Whole milk/0.1M HC1 1.00670 47.80 0.83 
50/50 Semi-skimmed milk/0.1M HCl 1.00800 47.94 0.27 
50/50 Skimmed milk/0.1M HCl 1.00873 47.52 0.74 
Casein filtrate in 0.01M IICI 0.99358 48.95 0.78 
FaSSIF Blank 0.99957 66.98 0.74 
FaSSIF 0.99984 49.28 0.53 
FeSSIF Blank 1.00491 65.95 0.99 
FeSSIF 1.00683 46.12 0.49 
CTAB 1.82 mg/mL 1.00493 33.42 0.11 
CTAB 0.1365 mg/mL 0.99965 35.29 0.12 
SDS 1 mg/mL 1.00543 27.66 0.10 
SDS 0.225 mg/mL 0.99982 31.90 0.94 
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Table 3.1 the surface tension of this medium was lower than the 50/50 milk/HCl 
media. The 1 mg/mL and 0.225 mg/mL SDS media at the bottom of Table 3.1 were 
used to match loratadine dissolution profiles in FeSSIF and FaSSIF respectively 
(Chapter 6). 
3.4. Discussion 
The surface tension of pure water is reported as 72 mN/m at 25°C (Weast, 1976). 
Repeated determinations using 2 different sources of Milli-Q® purified water (John 
Moores University and University of Liverpool) gave similar results (- 66. N/m). 
Satherley, J (personal communication) revealed that his group saw the same 
discrepancy. It is believed that there is some impurity passing through the Milli-Q 
filtration system that is responsible for the reduced surface tension, and it is not an 
error in the experimental procedure. The surface tension recorded for distilled water 
was slightly higher at 68 mN/m. i. e. the disparity in surface tension with literature 
values is related to the source of the water used. 
Table 3.1. shows that the milk and casein filtrate media had similar surface tensions 
to each other and therefore differences in drug dissolution between these media 
should not be attributed to this factor. It must be noted that complete wetting of solid 
particles may not be governed solely by the surface tension of the liquid phase. Fell 
and Mohammad (1995) and Luner et al (1996) demonstrated differences in the 
wetting of solid surfaces by different media at similar surface tensions. The nature 
of the surface-active components and their interaction at the liquid-vapour and solid- 
liquid interfaces may control wetting as opposed to surface tension itself (Luner & 
VanDer Kamp, 2001) 
FaSSIF and FeSSIF blanks (i. e. without bile salt and lecithin) had surface tensions 
approximately 19mN/m higher than the complete FaSSIF and FeSSIF media. The 
difference can be explained by the addition of the surface-active components 
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sodium taurocholate (NaTC) and lecithin to the complete media. Interestingly, there 
was only a small difference in surface tension between FaSSIF and FeSSIF (Table 
3.1. ) despite large differences in concentration of NaTC and lecithin between the 
two media. The critical micelle concentrations (cmcs) of NaTC and lecithin are 1.6 
mg/mL and 0.076 ng/mL respectively (Leng et al., 2003). Lecithin does not form 
micelles easily in aqueous media and floats on the liquid surface until it can form 
mixed micelles. This implies that at the concentrations of NaTC and lecithin used 
mixed miceller systems were formed. Consequently, dissolution enhancements from 
tablets observed in these media are probably micelle solubilisation effects as 
opposed to improved wetting effects. 
CTAB and SDS-containing media had lower surface tensions than FaSSIF and 
FeSSIF media. For the SDS media, the two concentrations used were well below the 
cmc of SDS, which is 2.37 mg/mL. For the CTAB media (cmc = 0.36 mg/mL) only 
the higher of two concentrations used was above the cmc. The fact that these 
synthetic surfactant media were able to match dissolution profiles generated by 
FaSSIF and FeSSIF suggests that profile matching was the result of improved 
wetting of the drug. In support of this, Luner and VanDerkamp (2001) found that 
0.25% w/v SDS and 0.1% w/v Triton X-100 were significantly better wetting agents 
for a model surface, poly(methyl methacrylate), than various physiologically 
representative media. 
The data generated show there were no significant surface tension differences 
between the aqueous media without surfactants i. e. Water, HCI, SIF, FaSSIF blank 
and FeSSIF blank. Hence it can be postulated that factors other than surface tension, 
such as pH and other variables, may account for any differences observed in drug 
dissolution using these media. 
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4. IBUPROFEN 
4.1. Introduction 
Ibuprofen ((RS)-2-(4 isobutylphenyl) propionic acid) is a widely used non-steroidal 
anti-inflammatory drug (NSAID) with analgesic and antipyretic properties (Figure 
4.1). It used in the clinical management of mild to moderate pain, in the treatment of 
arthritic and soft tissue disorders and in primary dysmenorrhoea. 
H3C 
Figure 4.1. The chemical structure of ibuprofen 
Ibuprofen is a poorly soluble acidic drug with a pKa of 4.4 (Clarke, 1986) and Log P 
of 3.50 (Fini et al., 1995). The intrinsic solubility of the drug is 21 µg/mL at 37°C 
(Table 4.2). It is considered highly permeable based on oral bioavailability being > 
90% compared to a reference intravenous dose (Martin et al., 1990). Ibuprofen has 
been classified as a BCS Class II drug (Lindenberg et al., 2004). The drug is usually 
administered as the free acid form. It was chosen as a model drug to investigate 
because the low stomach pH in the fasted state (approx pH 1.2 - 2.0) is likely to 
hinder the solubility of ibuprofen in the upper GI-tract and hence result in 
dissolution rate-limited bioavailability in this region. The time to peak plasma levels 
of 1-2h (Davies, 1998) and scintigraphic monitoring of an orally administered 
formulation (Parr et al., 1987) show that ibuprofen absorption occurs in this region. 
Levine et al (1992) showed that the presence of food increased the absorption rate of 
ibuprofen, probably due to increased in vivo dissolution. 
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Thus it can be expected that in vitro dissolution tests using simple compendial 
media may not accurately predict the in vivo behaviour. The aim of these 
investigations was to carry out in vitro dissolution testing in more realistic media to 
assess the physicochemical factors affecting drug dissolution in the presence of meal 
components. This would aid the predictive nature of in vitro dissolution testing prior 
to expensive in vivo studies to ascertain an IVIVC. 
Dissolution tests on ibuprofen 400mg tablets were initially carried out in 0.1N HCI 
pH1.2, simulated intestinal fluid (SIF) pH 6.8 and O. 1N HCI + 0.25%w/v sodium 
dodecyl sulphate (HCI+SDS). This provided baseline dissolution profiles for 
subsequent comparison with more complex media. For the HCI+SDS experiment, 
0.25%w/v SDS was added to bulk HCI to lower the surface tension to that of gastric 
fluid (-35mN/m) (Finholt & Solvang, 1968; Dressman et al., 1998; Efentakis & 
Dressman, 1998). Various media have been advocated to mimic the fed state 
conditions in the GIT (Dressman et al., 1998; Galia et al., 1998). Milk was put 
forward as being nutritionally balanced (appropriate ratio of fats: proteins: 
carbohydrates) and therefore a relevant dissolution medium (Dressman et al., 1998). 
Ibuprofen is also known to be a GI irritant and is commonly taken with milk. Hence, 
a mixture of 50% milk and 50% O. 1N HCI was used as a `realistic' medium to 
mimic the fed state stomach. The fat content of the medium was varied by using 
skimmed, semi-skimmed and whole milk. Lactose and casein based media were also 
investigated given that they are significant components of milk. IDR, solubility and 
disintegration tests were carried out in the specified media and the results discussed 
in light of the dissolution data. 
4.2. Materials and Methods 
4.2.1. Materials 
Details of all materials used in the preparation of the dissolution media and in 
performing the experiments are listed in section 2.1. 
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4.2.2. Methods 
Media preparation 
SIF was prepared in accordance with United States Pharmacopoeia 28 (2005) in a5 
L volumetric flask. 
HCI + SDS (0.25% w/v) was prepared by addition of 12.5 g of SDS to a5L 
volumetric flask and making up to volume with O. 1N HCI. The pH of the medium 
was 1.2. 
For the milk media, 250 mL of the specified milk was mixed with 250 mL 0.1N HCl 
in the dissolution vessel. The pHs of the media were approximately 2.7. 
The lactose medium was composed of 4.8% w/v lactose monohydrate in 0.003N 
HCI adjusted to pH 2.7. The medium was prepared by adding 240g of lactose 
monohydrate to a5L volumetric flask and making up to volume with 0.003N FICI. 
The casein medium was a dispersion of 1.475%w/v bovine casein in O. OIN HC1(pH 
2.7) to match the casein concentration in the 50/50 milk/HC1 mixtures (see Section 
4.3.2.4. ). 7.375 g of casein was accurately weighed and transferred to each 
dissolution vessel and 500 mL of 0.01N HCl added separately. 
A further medium (casein filtrate) was prepared by filtering 5L of a 1.475% w/v 
dispersion of casein in 0.01N HC1, pH 2.7, under vaccum using the buchner 
apparatus fitted with a Whatman No. 2 filter paper (Whatman International Ltd, 
Maidstone, England). 
0.003N HCl containing 0.017%w/v of the surfactant sodium dodecyl sulphate 
(0.017% w/v SDS), pH 2.7, was used as a medium to match the surface tension and 
pH of the milk mixtures. The medium was prepared by addition of 850 mg of SDS 
to a5L volumetic flask and making up to volume with 0.003N HHC1. 
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Dissolution testing 
The dissolution tests were performed according to the method described in Section 
2.2.3 using 500 mL of dissolution medium. 
Intrinsic dissolution rate determinations 
See Section 2.2.4. 
Solubility determinations 
See Section 2.2.1. 
Disintegration testing 
See Section 2.2.2. 
4.3. Results and Discussion 
4.3.1. Dissolution in compendial media 
The dissolution of ibuprofen tablets in 500mL 0. IN IICI at p'I 1.2 (non-sink 
conditions) did not meet the typical compendial criteria for immediate release (IR) 
dosage forms of 70% in 45 min (BP) or 75% in 45 min (USP) as the medium 
became saturated with drug (Figure 4.2). At more than 1 pH unit below its pKa, an 
acidic drug is less than 10% ionised leading to a pH dependent solubility issue. The 
addition of SDS as surfactant to the dissolution medium, to match the surface 
tension of gastric fluid, increased ibuprofen dissolution but saturation was reached at 
60 min and the amount of drug dissolved was still below the required amount for IR 
dosage forms. Conversely, 94% ibuprofen dissolved within 15 min from tablets 
exposed to 500 mL of SIF at pH 6.8, where the drug is fully ionised. As anticipated, 
these results confirm that the presence of surfactant and medium pIi affect the 
dissolution of an acidic drug such as ibuprofen. The United States Pharmacopoeia 
28 (2005) criteria for the dissolution of ibuprofen tablets state that not less than 80% 
ibuprofen should dissolve in 60 min using apparatus 2 at 50 rpm. But the specified 
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medium is 900m1 of pH 7.2 phosphate buffer, which may not accurately reflect in 
vivo dissolution in the stomach where the fluid volume, pH and surface tension are 
significantly lower. 
4.3.2. Effect of milk-based media and milk components on the dissolution of 
ibuprofen tablets 
4.3.2.1. Effect of lipid content 
Figure 4.3 illustrates ibuprofen dissolution profiles in 500mL of the various 
milk/HCl media under non-sink conditions but media saturation was not reached 
within the 2h test. The mean amounts (± S. D. ) of ibuprofen dissolved at each time 
point are plotted. The mean amounts of ibuprofen dissolved after 60 min in the 
various media were compared. A one-way analysis of variance showed there was no 
significant difference between the amounts of ibuprofen dissolved in the 3 types of 
milk after 60 min (p>0.05). However, a 2-sample T-test between 0.1N HCI and each 
type of milk showed a significant difference in mean dissolution after 60 min in 
each case (p<0.05). 
These results suggest that the use of O. IN HCI as a dissolution medium may not 
adequately represent real fed stomach conditions for the dissolution of ibuprofen. 
Although the milk/HCl media were coarse representations of the fed state stomach 
environment significant differences in the dissolution profiles were evident. The 
0.1N HCl had a pH of 1.2 whereas all three milk-HC1 mixtures had pH values close 
to 2.5 (at 37°C). Whether it was solely the increased pH that improved dissolution 
was investigated by using diluted hydrochloric acid adjusted to pH 2.5. The 
dissolution of ibuprofen was slightly lower at this pH. 
The reported surface tension of whole milk of 52N/m (Fox & McSweeney, 1998b) 
is more than 100-fold higher than gastric fluid. Theoretically, mixing milk with 
gastric fluid in the stomach may alter the overall surface tension of the stomach 
contents, further influencing the dissolution of ibuprofen compared to O. iN IUCI. 
Indeed, Table 3.1 shows that the surface tension of all 3 milk/IUC1 mixtures was 
approximately 48mNlm, some 20mN/m lower than that of 0.1N HC!. 
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An interesting finding was the non-significant difference in dissolution after 60 min 
between the three types of milk. The different milks were similar in composition and 
surface tension except that, according to supplier information, the lipid content in 
skimmed, semi-skimmed and whole milk was 0.1%, 1.7% and 3.6% w/v 
respectively. Thus, increasing the lipid concentration in the dissolution medium did 
not increase the dissolution of ibuprofen. For a drug with poor water solubility, 
increased dissolution was anticipated with increasing lipophilicity of the medium. 
The unexpected result could be attributed to the complex structure of milk, which is 
also susceptible to change during processing and storage. 
Milk lipids exist as emulsified globules coated with a membrane called the milk 
lipid globule membrane (MLGM). 25-60% of the membrane weight consists of 
proteins, lipids and hexoses whilst other minor constituents make up the remaining 
weight (Keenan & Patton, 1995). Hence the composition of the MLGM may hinder 
the lipid solubilisation of ibuprofen. Furthermore, processes such as homogenisation 
lead to the adsorption of casein micelles onto the lipid globules. Approximately 30% 
of casein in homogenised milk is associated with lipid globules (Keenan & Patton, 
1995). Agitation of the milk media by the paddles may cause random additional loss 
of MLGM and some denuding of the lipid core, which could account for the large 
variation in dissolution results between the six vessels at each sampling time point 
although test conditions were kept constant. 
The dissolution profiles in Figure 4.3 suggest that some constituent of milk other 
than the lipid content is improving dissolution, Milk contains proteins and 
carbohydrates as other significant components and their effect on the dissolution of 
ibuprofen was investigated. Prior to this, a gross assessment of the effect of the other 
components in milk, such as dissolved salts, minerals and enzymes was carried out 
as described below. 
4.3.2.2. Effect of soluble non-lipid components 
To assess the effect of the other components present in milk, further dissolution tests 
on ibuprofen tablets were attempted using skimmed milk, which is virtually fat free. 
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The experiment involved increasing the milk content of the dissolution medium 
from 50% to 100% to avoid dilution of the soluble components while maintaining a 
pH of 2.5 by acidifying the medium with hydrochloric acid. The experiment was 
unsuccessful due to significant precipitation of protein that separated the milk into 
an aqueous whey layer with a heavy precipitate settling to the bottom of the vessel 
that clogged the sampling filters. 
An alternative experiment was to assess the effect of diluting skimmed milk on the 
dissolution profile of ibuprofen tablets. The pH of 100% skimmed milk was 6.8 at 
37°C. The effect of dilution was investigated using 50% skimmed milk and 50% 
water as a medium (pH 6.7 at 37°C). The dissolution profiles of ibuprofen 400 mg 
tablets in the various media are compared in Figure 4.4. Again, non-sink conditions 
caused media saturation with drug by 15 min at pH 6.8. 
The clear improvement in the initial dissolution profile of the skimmed milk/water 
medium compared to the skimmed milk/HC1 medium (Figure 4.4) may be attributed 
to a more favourable pH for ionisation (pKa of ibuprofen = 4.4. ). However, at 
similar pH values, milk concentration did not appear to have a significant effect on 
dissolution (p>0.05). This suggests that the component(s) in milk that improved 
ibuprofen dissolution is/are capable of a similar extent of reaction at half their 
original concentration, such that the mechanism of interaction is almost saturated at 
50% dilution of the reactant(s) in milk. In terms of IVIVC, if skimmed milk was to 
be used as a biorelevant medium, dilution with water in the GIT is not likely to 
hinder the effect of the milk on ibuprofen tablets. The rapid dissolution (94% in 15 
min) in SIF may be due to potassium and sodium salt formation in the phosphate 
buffer. The strong neutralising effect of Na' and K+ cations raises the microclimate 
pH around the acidic drug particles thus aiding dissolution. This result should 
caution against the possible positive deviation from true intestinal dissolution of 
acidic drugs when using SIF as an in vitro dissolution medium. 
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4.3.2.3. Effect of lactose 
Whether the dissolution profiles seen in milk/HCl are due to a drug interaction or 
excipient interaction has yet to be determined. If the component(s) in milk 
responsible can be identified first, then the nature of the interaction can be studied 
using the isolated components allowing easier manipulation of experiments and 
analyses. The major carbohydrate in milk is lactose. The typical lactose content of 
bovine milk is 4.8%w/v (Fox & McSweeney, 1998a). The milk/HCl experiment was 
repeated replacing milk with the appropriate concentration of lactose dissolved in 
0.003N HCl maintaining a pH of 2.7. 
Figure 4.5 shows the mean amount of ibuprofen dissolved after 60 min in the lactose 
medium was 3.60% (S. D. ±0.24%). Thereafter, the lactose medium was saturated 
with drug similarly to the HCI pH 2.5 medium. The non-significant increase in 
dissolution of ibuprofen compared to HCI pH 2.5 (p>0.05) up to 60 min suggests 
that the presence of lactose in milk is not responsible for the improved dissolution 
seen in milk media. 
4.3.2.4. Effect of casein 
Since casein is the major protein in bovine milk (Swaisgood, 1995), it was used to 
mimic the milk/HCJ experiment replacing the milk. A potential limitation to this 
experiment was the precipitation of casein in HCl but protein was seen to precipitate 
in the milk/HCl experiments as well, therefore, any interaction between protein 
precipitate and the tablets that may have occurred previously would be expected to 
occur in this casein investigation. The typical total casein concentration in bovine 
milk is 2.95% w/v (Swaisgood, 1995). 
The dissolution profile of ibuprofen tablets in the casein medium (Figure 4.5) 
showed approximately 9% (S. D. ± 0.84%) was dissolved after 60 min. This result 
falls within the error ranges for the dissolution data from milk/HCI experiments 
indicating that casein plays a role in the improved dissolution seen in milk media. 
Casein in bovine milk exists as micelles that are colloidal complexes of proteins and 
salt, mainly calcium (Farrell et al., 1990). In the absence of calcium as in this 
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experiment, protein submicelles are still produced. These subunits form large 
spherical casein micelles via hydrophobic interactions (Jensen et al., 1995). A 
possible explanation for the increased dissolution of ibuprofen is the solubilisation 
of the unionised drug in the casein micelles. 
The possibility that the enhanced dissolution arose from a physical erosion of the 
tablet by suspended particles of undissolved casein (casein is poorly soluble at pH 
2.5) was assessed by filtering the medium prior to use. Paradoxically, using the 
casein filtrate resulted in an increase in the rate and amount of ibuprofen dissolved 
over 30 min (Figure 4.5). This phenomenon remains unexplained. The dissolution 
profile plateau in the casein filtrate at 30 min suggests saturation was reached 
whereas the lower dissolution and later plateau at 90 min in the unfiltered casein 
medium suggests limited ibuprofen release from the tablets in the latter medium. 
Having identified casein as the likely component in milk improving the dissolution 
of the ibuprofen tablets used, the next stage of the investigation was to determine 
whether the interaction was one with the drug or formulation excipients or both. 
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4.3.3. Intrinsic dissolution rate, solubility and disintegration studies 
As mentioned in the introduction, the IDR measures the dissolution properties of the 
drug related to the dissolution medium. It is independent of formulation factors that 
may affect dissolution and thus has been used for many years to characterise solid 
drugs. For the purposes of this work, IDR experiments on ibuprofen were carried 
out to determine whether the results seen in milk media were drug or formulation 
related. 
Initial attempts to determine the IDR of ibuprofen in these media were unsuccessful. 
The amount dissolved from the single exposed surface of the disks was very low and 
consequently the U. V. absorbance of ibuprofen was below the limit of detection 
(LOD), which was 4 µg/mL. Figure 4.6 shows a 91-fold increase in the sensitivity of 
the detection method was accomplished by using fluorescence spectroscopy (LOD 
47 ng/mL). This allowed very low concentrations of dissolved ibuprofen to be 
detected and quantified in these media. 
10 ug/ml Ibuprofen Standard 
Comparison of fluorescence and UV detection 
3.00 
Minutes 
Fluorescence 
,+ (s: n = 644) 
I 
I ý!! 
1 
UV(s: n=7) 
4.00 a. oo 6,00 
Figure 4.6. Comparison of fluorescence and UV detection in the liquid 
chromatographic determination of Ibuprofen 
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Ibuprofen release was expressed as the amount of ibuprofen dissolved per unit area 
plotted versus time in Figure 4.7. In addition, linear regression analysis was applied 
to the dissolution profiles between 15 and 90 min to determine the IDRs in Table 
4.1, calculated as the slope of the regression line. The data generated enabled the 
effects of the various media on the dissolution of drug substance to be evaluated. 
The dissolution from the disks during the first 15 min was not considered in the IDR 
determinations because only a single sample was taken at 15 min. Also the initial 
ibuprofen dissolution rate in the whole milk/HCl medium was >10 fold higher than 
in the other media. However, the higher initial dissolution in the whole milk/HCl 
medium did not impact upon the IDR between 15 and 90 min, which was 
comparable to the IDR in the other milk media shown in Table 4.1. Perhaps, the 
viscosity of the whole milk and a heavier precipitate was responsible for the initial 
`burst' dissolution seen, via a greater erosive effect on the disk surface. 
Table 4.2 shows the solubility determinations of ibuprofen in the various media. The 
change in pHs of the bulk suspensions at the 1,5 and 24h sampling times were < 0.1 
pH unit. The equilibrium solubilities of ibuprofen (24h data) in all three milk based 
media were at least 6 fold higher than the O. 1N HCI, 0.017% w/v SDS and the 
casein filtrate media. However, Table 4.1 shows that the IDR in the HCl and SDS 
media between 15-90 min was higher than in the milk and casein media, which was 
unexpected based on dissolution and solubility data. This could be the result of 
variable occlusion of the exposed disk surface by precipitated fragments of milk 
media as the experiment progressed. In the casein medium, ibuprofen diffusivity 
could have been lowered by a combination of microenvironmental p1! change and 
increased viscosity of the diffusion layer at the solid-liquid interface caused by the 
dissolved casein in contact with the drug. This concept was put forward by Millar 
and Corrigan (1993) for the release of drug from ibuprofen-casein compacts into 
phosphate buffer media. 
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Table 4.1. IDR of ibuprofen in various media 
Medium 
IDR: 15-90min 
(mg/min/cm2) 
r2 value 
O. 1N HCI 0.0053 0.9829 
0.017% w/v SDS 0.0055 0.9965 
Whole milk/O. 1N HCl 0.0021 0.9181 
Semi-skimmed milk/O. 1N HCI 0.0012 0.9085 
Skimmed milk/O. 1N HC1 0.0023 0.9968 
Casein filtrate 0.0042 0.9879 
Table 4.2. Solubility determinations of ibuprofen in various media at 37°C. 
Medium pH 
Mean amount dissolved (µg/ml) ± S. D. n=2 
lh 5h 24h 
0. IN HC1 1.2 20.4± 2.1 25.7 ± 2.4 21.1 ± 3.2 
0.017%w/vSDS 2.5 34.2 ± 2.9 30.3 ± 0.9 24.7 ± 3.3 
Casein filtrate 2.5 23.7 ± 1.6 23.3 ± 0.1 24.7 ± 10.9 
Whole milk/0.1N HC1 2.4 103.8 ± 1.2 105.5 ± 3.4 132.0 ± 0.7 
Semi-skimmed milk/0.1N HCl 2.4 153.7 ± 2.4 193.6 ± 6,6 219.8 ± 17.4 
Skimmed milk/0.1N HC1 2.4 132.8 ± 3.5 157.9 ± 4.8 124.0 ± 2.4 
Overall, the IDR data suggest that the dissolution enhancements seen with tablets 
may be due to a formulation-related effect of casein on the tablets. However, the 
solubility data revealed improved ibuprofen solubility in milk media. From the 
dissolution results in Figure 4.5 it can be seen that the profile for the casein filtrate 
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medium reached a plateau by 30 min (- 15% ibuprofen dissolved) whereas the milk 
media profiles (Figure 4.3) indicated steadily increasing drug dissolution up to 120 
min (- 16% ibuprofen dissolved). This suggests that casein is somehow involved in 
improving the release of ibuprofen from the formulation, the drug is then available 
for dissolution, which is aided by higher solubility in milk, but in the casein medium 
saturation is reached accounting for the early plateau. The data for the solubility in 
casein filtrate medium do not support the previous hypothesis of solubilisation of 
ibuprofen into casein micelles. 
Disintegration studies on the tablet formulation were performed in the various media 
to further evaluate the nature of the interaction seen with the tablets. The results are 
shown in Table 4.3. 
Table 4.3. Disintegration times for ibuprofen 400mg tablets in various media. 
Medium pH 
Mean Disintegration 
Time ± S. D. (min) n=3 
0.1N HC1 1.2 2.91 ± 0.70 
0.017% w/v SDS 2.6 3.47 ± 0.06 
Casein filtrate 2.5 3.53 ± 0.48 
Whole milk/0.1N HC1 2.5 3.95 ± 0.44 
Semi-skimmed milk/0.1N HCl 2.5 3.12 ± 1.03 
Skimmed milk/0.1N HC1 2.5 2.59 ± 0.53 
The tablets disintegrated in all media in less than 4 min - an acceptable time 
according to industrial perspectives for IR dosage forms. Furthermore, there were no 
significant differences in disintegration times between the various media to warrant 
a possible binder performance issue for this dosage form in the different media. 
These findings differ from those of Abrahamsson et al (2004), who reported a delay 
in the disintegration time of several tablet formulations immersed in a multi- 
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component nutritional drink, caused by the precipitation of a casein film around the 
tablet surface. 
The question that remains unanswered is that what is casein interacting with to 
improve the drug dissolution from the tablet? Although the tablets in this study 
disintegrated in all the media to a sufficient extent to pass through the standard 
compendial mesh size, further breakdown of the agglomerates to primary particles 
still needs to occur for the dissolution process. Perhaps this is where casein exerts its 
influence by promoting desorption of drug from drug-excipient agglomerates. It is 
believed that at low pH values unionised drug is immobilised onto excipient by 
adsorption or complexation and casein interferes with this effect. 
The commercial ibuprofen tablet formulation used listed the following excipients in 
the ingredients (their functions are stated in brackets): microcrystalline cellulose 
(diluent); lactose (diluent); croscarmellose sodium (disintegrant); hydroxypropyl 
methylcellulose (binder); SDS (wetting agent); magnesium stearate (lubricant); 
French chalk (glidant/lubricant); colloidal silicon dioxide (glidant) and titanium 
dioxide (opacifier). 
The quantitative manufacturing formula was not obtainable. However, from the 
functions of the ingredients included and the typical percentages used in practice, 
the excipients likely to be involved in drug interactions can be identified. Lactose is 
a highly soluble bulking agent and not likely to affect drug dissolution. 
Microcrystalline cellulose (MCC), croscarmellose sodium, Hydroxypropyl 
methylcellulose (HPMC) and magnesium stearate may be implicated in drug- 
excipient interactions. The disintegration data exclude casein interaction with 
croscaremellose sodium and HPMC since no major differences in disintegration 
times were observed between casein-containing and casein-free media. 
Of several tablet formulations investigated, Abrahamsson et al (2004) found that a 
tablet formulation with 50% MCC exhibited the strongest food effect, taking 70 min 
to disintegrate in a fed state medium. Mixing of the individual excipients with the 
fed state medium produced a precipitate, which was shown to include caseinate by 
IR spectroscopy. Hence, it is plausible that although disintegration was not delayed 
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by casein containing media in this study, this surface-active component may interact 
with the MCC surface, either displacing or competing with ibuprofen for interaction 
at the excipient surface. 
Magnesium stearate is incorporated in low levels (0.25-5% w/w) as a tablet 
lubricant therefore unlikely to have a significant interaction with casein but it cannot 
be ruled out. Further investigations of the possible drug-excipient interactions in this 
study are required to elucidate the cause of the higher ibuprofen dissolution from the 
tablet formulation. 
4.4. Conclusion 
The dissolution of ibuprofen tablets in milk/HCI media was significantly higher than 
in typical compendial media. The bovine milk protein, casein, appeared to play a 
role in the increased dissolution seen. Lactose had no effect. Whilst the solubility of 
ibuprofen in milk/HCI media was higher than in the other media, it is not believed to 
be directly responsible for the effect seen. The improved ibuprofen dissolution in 
milk/HCI media may be the result of casein influencing the availability of ibuprofen 
for dissolution from a drug- excipient complex coupled by the higher drug solubility 
in these media. The interaction does not affect the disintegration time of the tablets 
in the various media. 
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5. NAPROXEN 
5.1. Introduction 
Like ibuprofen, naproxen ((2S)-2-(6-methoxynaphthalen-2-yl)propionic acid) is an 
NSAID with analgesic and antipyretic properties. It is indicated to treat similar 
conditions i. e. mild to moderate pain, rheumatoid and osteoarthritis, tendonitis etc. It 
is restricted to prescription supply only in the U. K. and therefore is not used by the 
general population as extensively as ibuprofen. 
MeO 
Figure 5.1. The chemical structure of naproxen 
Naproxen differs structurally from ibuprofen in that it is a naphthyl rather than a 
benzyl derivative and also has a methoxy group incorporated into the molecule 
(Figure 5.1). However this does not improve its lipophilicity based on its log P value 
of 3.18 compared to a log P value of 3.50 for ibuprofen (Fini et al., 1995). It has a 
lower intrinsic solubility of 12µg/mL (Table 5.1) at 37°C than ibuprofen (21µg/mL 
in Table 4.2). Naproxen has a pKa of 4.2 and is administered as the free acid or 
sodium salt. It is considered highly permeable based on oral absorption compared to 
an intravenous dose (Davies & Anderson, 1997). Charles and Mogg (1994) reported 
peak plasma levels of the free acid within 1-1.5h, which suggests absorption from 
the upper GI-tract. Food reduces the rate but not extent of absorption (Parfitt, 1999). 
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This NSAID was selected as a second acidic BCS Class II drug to study in order to 
compare its solubility and IDR in milk based media to that of ibuprofen. This would 
allow comparison of the dissolution behaviour of two propionic acid-derived 
NSAIDs in order to identify drug-specific or class-specific behaviour. Disintegration 
and dissolution tests were also carried out on a marketed tablet product to assess the 
effect of the medium on drug release from the formulation. The media used for the 
investigations included O. 1N HCl, 50/50 mixtures of whole, semi-skimmed or 
skimmed milk with 0.1N HCI, 0.017% w/v SDS and casein filtrate. 
5.2. Materials and Methods 
5.2.1. Materials 
Details of all materials used in the preparation of the dissolution media and in 
performing the experiments are listed in section 2.1. 
5.2.2. Methods 
Media preparation 
See Section 4.2.2. 
Solubility determinations 
See Section 2.2.1. 
Intrinsic dissolution rate determinations 
See Section 2.2.4. 
Disintegration testing 
See Section 2.2.2. 
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Dissolution testing 
See Section 2.2.3. The volume of dissolution medium used was 500 mL. 
5.3. Results and Discussion 
5.3.1. Solubility Data 
The solubility of naproxen drug substance in all the dissolution media was lower 
than that of ibuprofen. At 24h, the solubility of naproxen in all the media was 
approximately half that of ibuprofen except in semi-skimmed milk/0. IN HCl where 
it was approximately one third (Table 5.1). These results are reflected in the 
dissolution profiles (Figure 5.4), where maximum dissolution was reached for 
naproxen in milk-based media at about 16% from a 250 mg dose tablet in a 500 mL 
dissolution volume (i. e. 80gg/mL). As a result the dissolution began to plateau after 
about 60 min. In comparison, dissolution profiles for ibuprofen in milk based media 
(Figure 4.3) continued to rise until the last time point of 120 min. At this point, 15% 
of the drug had dissolved from a 400 mg tablet into 500mL of dissolution medium 
giving a concentration of 120pg/mL, just about reaching the saturation concentration 
for ibuprofen in the skimmed milk/O. IN HC1 medium. 
Table 5.1. Solubility determinations of naproxen in various media at 37°C. 
Medium PH Mean amount dissolved (µg/m1) ± S. D. n=2 
lh 5h 24h 
0.1NHC1 1.2 12.0±2.2 10.9±0.7 12.0±0.3 
0.017% w/v SDS 2.5 12.6±0.2 11.4 ±0.1 10.1±0.3 
Casein filtrate 2.5 15.0 ± 0.7 13.4 ± 0.7 11.1+0.7 
Whole milk/O. 1N HCl 2.4 67.0 ± 3.5 65.6 ± 0.8 61.0 ± 0.4 
Semi-skimmed milk/0.1N HCl 2.4 68.0 ± 3.4 63.6 ± 0.6 69.6 ± 4.7 
Skimmed milk/O. 1N HCl 2.4 70.1 ± 1.8 72.5 ± 17.2 66.3 ± 0.4 
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It is worth noting from Table 5.1 that the solubility of naproxen in casein filtrate was 
not much higher than in the 0.1N HC1 and 0.017% w/v SDS media. The same was 
true for ibuprofen solubility in these media (Table 4.2) and so, it appears that casein 
does not affect the solubility of these two propionic acid derived NSAIDs in acidic 
conditions below pH 3. 
The solubility of naproxen in all three milk-based media was in the region of 6-fold 
higher than in the casein, SDS and HC1 media. The difference in solubility between 
the three milk-based media was within a 10 pg/mL range. The skimmed milk 
medium showed a higher solubility than the whole milk, undermining the argument 
that the lipid content in milk could be responsible for the 6-fold increase in 
solubility compared to the non-milk based media. 
Interestingly, for both ibuprofen and naproxen, the highest solubilities were recorded 
in the semi-skimmed milk/O. 1N HC1 medium. It was previously mentioned in the 
ibuprofen discussion (Section 4.3.2), that in whole milk, lipid-mediated drug 
solubilisation may be limited by the MLGM. In skimmed milk the negligible lipid 
content would be unable to exert an effect in any case. However, during the 
processing procedure to produce semi-skimmed milk, partial removal of the MLGM 
and some denuding of lipid globules and other structural changes to the composition 
of milk may enhance the lipid-mediated solubilisation of the drugs. As seen for 
ibuprofen, this improved solubility in semi-skimmed milk did not translate to an 
improved tablet dissolution profile compared to the whole and skimmed milk media 
as an excipient interaction was thought to have an overriding effect. 
5.3.2. IDR Determinations 
Table 5.2 shows the calculated IDR values and coefficients of determination (r2) for 
naproxen in the various media. Six further sampling time points in the range 0-15 
min were included in this study to monitor more accurately the initial dissolution 
rate. O. 1N HCI, 0.017%w/v SDS and semi-skimmed milk/0.1NHC1 showed linear 
dissolution (Figure 5.2) whereas the casein filtrate, whole and skimmed milk/0.1N 
HC1 had more erratic release form the disk surface over the first 15 min. Hence two 
100 
IDR values are reported in Table 5.2, the second of which does not include the 
results of the first 15 min, omitted to improve the linear regression fit. However, the 
regression fits were not appreciably altered by using only the 15-120 min data as 
indicated by the coefficients of determination for the two IDR values in each 
medium (Table 5.2). Figure 5.3 shows examples of the linear regression fit applied 
to dissolution data from the naproxen disks. 
The IDR in the 0. IN HCI medium was slightly higher than the SDS medium, such 
that the addition of SDS had little effect on the wetting of the disk surface and 
consequent dissolution. 
Table 5.2. IDR of naproxen in various media 
Medium IDR: Revalue IDR: R value 
0-120n-in 0-120 min 15-120min 15-120 min 
(mg/min/cm2) (mg/min/cm2) 
0.1N HCl 0.0038 0.9932 0.0036 0.9934 
0.017% w/v SDS 0.0030 0.9838 0.0028 0.9809 
Whole milk/0.1N HC1 0.0036 0.9008 0.0040 0.9391 
Semi-skimmed milk/O. 1N HC1 0.0046 0.9951 0.0045 0.9973 
Skimmed milk/0.1N HC1 0.0008 0.3324 0.0004 0.2568 
Casein filtrate 0.0077 0.8893 0.0076 0.9413 
Despite the higher solubility of naproxen in the whole milk/O. 1N HCI medium, the 
IDR was similar to that in O. IN HCI. The rate of drug dissolution from the disk 
surface in 0.1N HCI and in semi-skimmed milk/O. 1N HCI was constant and showed 
the best linearity (r2 >0.99 for both calculations). 
Dissolution of naproxen into the skimmed milk medium was limited and thus a 
credible IDR could not be calculated from the data. This was unexpected from the 
naproxen solubility data (Table 5.1). This anomalous result requires further 
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investigation. Naproxen showed the highest [DR in the casein filtrate although its 
solubility in this medium was similar to that in O. IN HCl and SDS media. Sink 
conditions existed in all the media. What appears to be a high naproxen dissolution 
rate in the first minute in the casein and milk media (Figure 5.2) is possibly an 
interference from the naproxen assay at the low amounts dissolved. 
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5.3.3. Tablet dissolution studies 
As with ibuprofen, the dissolution of naproxen tablets was significantly greater in 
milk based media than in 0.1N HCI and 0.017% w/v SDS media. Figure 5.4 
illustrates that over the first 60 min tablets in skimmed milk showed the highest 
dissolution but there was no significant difference between the 3 types of milk 
between 60-120 min (p>0.05) as the media became saturated. Tablets in the casein 
filtrate medium showed lower drug dissolution than in the milk media, and the 
dissolution hit a plateau by 45 min with approximately 8% dissolved. Naproxen 
dissolution in the HCI-0.017% w/v SDS and HCI pH 1.2 media was significantly 
lower than in the milk and casein media, again with dissolution being limited to 
approximately 5% at 15 min due to media saturation with drug, 
Whilst the casein filtrate medium increased the dissolution of naproxen from the 
tablets compared to the O. 1N HCI and 0.017% w/v SDS media, its effect was not as 
great as that seen with the ibuprofen tablet formulation where the dissolution profile 
in casein filtrate was in the region of the profiles in milk media. 
The lower dissolution compared to dissolution in milk media is in line with the 
solubility data, which illustrates poorer solubility of naproxen in casein filtrate. 
However, the enhanced dissolution profile compared to 0.017%w/v SDS (which 
also had a slightly more favourable surface tension) did not agree with the solubility 
data, suggesting an effect of casein on drug release from the tablet formulation. 
The trends in the tablet dissolution profiles were not as clearly reflected in the IDR 
profiles. Nonetheless, dissolution rate calculations showed differences in the IDR 
values over the period 15-120 min between 0. IN HCl and the milk-based media. 
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Similarly to ibuprofen, it appears that casein influences the release of naproxen from 
the formulation. Tablet disintegration times in all media were below 4 min as with 
the ibuprofen formulation but there was a more discernible difference in the 
disintegration time of the naproxen tablets between the milk-based media and the 
other media as shown in Table 5.3. 
Table 5.3. Disintegration times for naproxen 250mg tablets in various media. 
Medium pH 
Mean Disintegration 
Time ± S. D. (min) n=3 
0.1N HCI 1.2 0.97 ±0.51 
0.017% w/v SDS 2.6 1.63±0.55 
Casein filtrate 2.5 1.50 ± 0.69 
Whole milk/0.1N HCl 2.5 3.52 ± 0.44 
Semi skimmed milk/0.1N HCl 2.5 2.98 ± 1.03 
Skim milk/0.1N HC1 2.5 2.47 ± 0.64 
It took the naproxen tablets nearly twice as long to disintegrate in the milk-based 
media compared to other media and the disintegration time decreased as the fat 
content of the milk was decreased. Anwar et al (2005) investigated the 
disintegration of tablets in biorelevant media. They reported a significant increase in 
the disintegration time of both fast and slow disintegrating tablets in whole milk 
compared to various aqueous media. These results were attributed to the slower 
penetration rate of fluid into the tablet due to the higher viscosity of the milk 
medium. Regardless, as seen in Figure 5.4, disintegration time did not have a 
bearing on the dissolution of naproxen into the milk-based media. 
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The marketed naproxen tablet brand used in this study contained the following 
inactive ingredients: polyvinylpyrrollidone (PVP) (diluent/binder), croscarmellose 
sodium (disintegrant), magnesium stearate (lubricant) and iron oxide (E172) 
(colourant). 
It was previously observed (Bettinetti et al., 1992) that mixing higher grades of 
PVP with naproxen increased the melting point of naproxen through the formation 
of crystalline microaggregates of the drug dispersed within the polymer matrix. Does 
casein somehow disrupt this sold state interaction and hence influence the release of 
naproxen from this dispersion? Indeed it has already been demonstrated that water 
soluble polymers such as PVP do form complexes with proteins (Matsudo et al., 
2003). Such protein complexes can cause change in the conformation of the polymer 
chain due to stearic repulsion, electrostatic repulsion of the charged bound proteins 
or local collapse of the surface polymer segment onto which protein is bound 
(Matsudo et al., 2003). Whilst only speculative at this stage, the possible formation 
and nature of casein-PVP complexes needs to be further investigated. 
Furthermore, magnesium stearate is hydrophobic and is reported to have retarded 
drug dissolution from oral dosage forms (Levy & Gumtow, 1963; Ganderton, 1969; 
Lerk et al., 1982; Hussain et al., 1992). However, little work has been done to assess 
such a hindrance in the dissolution of oral dosage forms in biorelevant media. Thus 
the effect of low levels (0.25-5% w/w) of magnesium stearate on the solubility and 
dissolution of naproxen in the casein medium needs to be assessed. 
Overall, whatever the nature of the interaction between casein and the formulation 
excipients, it does not override the solubility influence of the milk-based media on 
dissolution (unlike ibuprofen, where dissolution in casein filtrate and milk-based 
media was similar). In this case, once the naproxen is mobilised from the 
formulation for dissolution (e. g. via a desorption process), its higher solubility in 
milk-based media is clearly demonstrated in the higher tablet dissolution profiles 
compared to casein filtrate. 
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5.4. Conclusion 
The solubility of naproxen in the 50/50 milk/0.1N HCl media was significantly 
greater than in the other media tested. This was reflected in the enhanced tablet 
dissolution profiles in the milk-based media. The highest IDR of naproxen in the 
casein filtrate is probably the result of an erosive effect of the medium. Casein 
appears to enhance the dissolution of naproxen from the tablet studied through an 
interaction with some excipient. The possible casein-excipient interaction requires 
further investigation. Overall, the improved dissolution of naproxen from the 
marketed tablet brand studied was the result of a combined effect of enhanced 
solubility and excipient interaction. 
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6. LORATADINE 
6.1. Introduction 
Loratadine (ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]-cyclohepta[1,2-b]pyridine- 
11-ylidene)-1-piperidinecarboxylic acid ethyl ester) is a non-sedating antihistamine 
used in the symptomatic treatment of allergic disorders such as hayfever, pruritus, 
urticaria and insect bites and stings. 
cl 
Figure 6.1. The chemical structure of loratadine 
Loratadine is a poorly soluble weak base with a pKa of 5.0 and a Log P of 5.2. (Clarke, 
1986). It has an intrinisic solubility of 1.9 µg/mL at 37°C (Table 6.3a). Loratadine has 
been characterized as a highly permeable drug based on its apparent permeability 
coefficient (4.8 x 10-5 cm/s) across CaCo-2 cell monolayers and has been classified as a 
BCS Class II drug (Khan et al., 2004). After oral administration, the drug is rapidly 
absorbed under fasting conditions with peak plasma levels being reached within 1-1.5h 
(Simons, 2002), although there is a high inter-subject variability. 
One objective of this study was to investigate, in vitro, the dissolution of any 
unabsorbed drug leaving the stomach and passing into the intestine. The aim was to 
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mimic, in situ in a dissolution vessel, the change in pH that occurs during the gastro- 
intestinal transit of a tablet using a common compendial dissolution apparatus (USP 
apparatus 2). This would involve a 2h dissolution run in acidic conditions followed by 
an immediate increase in volume and pH whilst the test is continued for a further 4h. 
The second objective was to use loratadine as a model to study the behaviour of a 
poorly soluble basic drug (BCS Class II) in proposed intestinal biorelevant media and 
attempt to develop more economical surfactant based media to replace them. 
6.2. Materials and Methods 
6.2.1. Materials 
Details of all materials used in the preparation of the dissolution media and in 
performing the experiments are listed in Section 2.1. 
6.2.2. Methods 
Media preparation 
The pH of all the media was checked after preparation using a digital p1I meter 
(Delta 350, Mettler Toledo, Leicester, U. K. ) 
0.017% w/v sodium dodecyl sulphate in 0.1N HCl (HCI-0.017% SDS pli 1.2) was 
prepared by addition of 850 mg of SDS to a5L volumetric flask and making up to 
volume with 0.1N HCl. 
0.017% w/v sodium dodecyl sulphate in 0.003N HCI (HC(-0.017% SDS pit 2.5) was 
prepared by addition of 850 mg of SDS to a5L volumetric flask and making up to 
volume with 0.003N HCI. 
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0.25% w/v sodium dodecyl sulphate in O. 1N HCI (HCI-0.25% SDS pH 1.2) was 
prepared by addition of 12.5 g of SDS to a5L volumetric flask and making up to 
volume with O. 1N HCI. 
Sodium-based simulated intestinal fluid (NaSIF) consisted of phosphate buffer p116.8 
except that NaH2PO4 was used instead of KH2PO4 as suggested by Vertzoni et al (2004) 
to mimic better the cationic environment in the small intestine. Also, FaSSIF includes 
NaH2PO4 as the buffering agent. 
8L of both Fasted state simulated intestinal fluid blank (FaSSIF blank) and Fed state 
simulated intestinal fluid blank (FeSSIF blank) were prepared as per Table 1.2 without 
sodium taurocholate (NaTC) and lecithin, to be used as controls and for the preparation 
of FaSSIF and FeSSIF. 
8L of both FaSSIF and FeSSIF were constituted as per the formulae in Table 1.2. To 
obtain clear micellar solutions, 8L of FaSSIF and FeSSIF blanks were first prepared 
and the correct quantities of NaTC and lecithin (Tablet . 2) were mixed with 1.6 L of the 
corresponding blank medium to produce concentrates. These concentrates were then 
stirred overnight (at room temperature) using magnetic stirrers and the clear 
concentrates made up to volume with 6.4 L of the corresponding blank medium. 
6L of 0,059% w/v lecithin was prepared by addition of 3.54 g of lecithin to a container 
followed by 6L of FaSSIF blank. 6L of 0.295% w/v lecithin was prepared by addition 
of 17.7g of lecithin to a container followed by 6L of FeSSIF blank. 
6L of 0.165% w/v NaTC was prepared by addition of 9.9 g of NaTC to a container 
followed by 6L of FaSSIF blank. 6L of 0.825% w/v NaTC was prepared by addition 
of 49.5 g of NaTC to a container followed by 6L of FeSSIF blank. 
For surfactant-based media used in the solubility screen, 20 mL of each medium was 
prepared in a volumetric flask (except for Triton X 100 and C12AO where 200 mL 
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were prepared) according to the concentration stated in Table 6.1 in both FaSSIF and 
FeSSIF blanks. 
Table 6.1. Concentrations of the surfactants used in the loratadine solubility study 
and their cmc values. 
Surfactant cmc1'2 (mg/ml) 
Concentration used for 
solubility study (mg/mI) 
CTAB 0.36 0.73 
SDS 2.37 4.73 
Brij 35 0.13 0.26 
Triton X 100 0.15 0.30 
Cremophor EL 0.09 0.18 
Tween 80 0.02 0.04 
CHAPSO 5.05 10.10 
C12AO 0.00046 0.0092 
Values quoted at 20-25°C in water 
2 Source: Sigma Aldrich. (Detergent Properties and Applications Table) 
Solubility determinations 
See section 2.2.1. 
Dissolution testing 
See section 2.2.3. The volume of dissolution medium used was 1000 mL. 
pH-shift method: 
The dissolution test was carried out in 500 mL of an acidic medium (0. IN UUCI, liC1- 
0.25% SDS pH 1.2, HCI-0.017% SDS pH 1.2 or HCI-0.017% SDS p11 2.5) for 2h as 
normal, with 5m1 samples being taken at 15,30,45,60,90 and 120 min. After sampling 
at the 2h time point, 50 mL of IN NaOH, which was already at 37°C, was immediately 
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added to each of the six dissolution vessels. This was followed by the addition of 450m1 
of phosphate buffer pH 7.4 (also at 37°C) to each vessel. The final medium p11 was 
measured as 7.3. The dissolution run was continued during this pH shift and for a 
further 4h. 5ml samples were taken at 2h 15min, 3h, 4h, 5h and 6h. The pH was re- 
measured at the end of the run. 
Disintegration testing 
See section 2.2.2. 
6.3. Results and Discussion 
6.3.1. pH-solubility data and pH shift experiments 
The pH-solubility data for loratadine (Table 6.2) show the rapidly diminishing 
solubility of the drug between pH 1.2 (36.7 mg/mL) and pH 2.5 (639 . tg/mL). 
Thereafter the solubility continued to decrease with increasing pH. The lowest 
solubility was 1.3 p. g/ml at pH 6.8. 
Table 6.2. pH-related solubility determinations of loratadine at 37°C 
Mean amount dissolved (µg/ml) ± S. D. n=2 
Medium pH Ih 
O. INHC1 1.2 3.76x 104±1.1x103 
0.003N HCI 2.5 679.9 ± 7.9 
Acetate buffer 4.5 10.0 ± 0.1 
Phosphate buffer 6.8 1.7 ± 0.1 
5h 24h 
3.62 x 104 ± 43.6 3.67 x 104 ± 112.5 
670.5 ± 25.5 639.0 ± 1.1 
10.9±0.1 10.1 ±0.1 
1.7±0.04 1.3±0.1 
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The drastic reduction in solubility between pH 1.2 and 2.5 may have implications on 
drug absorption from the stomach, depending not only on individual pH variability but 
also on whether the individual is in the fed or fasted state. The solubility data suggest 
that dissolution and consequent absorption of loratadine will be hindered in the fed 
stomach due to the raised pH (2.5-4.5) in this state, if pH alone controls absorption. 
In relation to pH dependent solubility, the dissolution of a commercially available brand 
of loratadine 10mg tablets (Brand A) was investigated in various simple media (Figure 
6.2). The effects of pH were evident in the differences in drug dissolution after 2h 
between HCI-0.017% SDS at pH 1.2 and HCI-0.017% SDS at pH 2.5 and in NaSIF pH 
6.8 (103.51%, 31.81% and 0.09% drug dissolved respectively). However, with pH shift, 
the addition of IN NaOH and phosphate buffer to 0.25%w/v SDS pH 1.2 in the 
dissolution vessel (final pH 7.3) did not cause precipitation of the dissolved drug 
(Figure 6.2). This dissolution profile in the HCl-0.25% SDS pH 1.2 - pH 7.3 shift 
experiment shows 109% loratadine dissolved at 30 min. This high percentage of drug 
dissolution can be attributed to weight variation of the tablets leading to dose variations 
(accepted regulatory variation is 90-110% of the stated dose) and slight analytical bias. 
When the pH shift experiment was repeated without using SDS in the medium, drug 
precipitation on pH shift was evident from the dissolution profile. 
The presence of surfactant in the medium prevented precipitation as the p11 was raised. 
At a pH above 6 almost all of the loratadine would have been unionized, thus, the drug 
was probably solubilised within the hydrophobic micellar core of the surfactant. This 
result demonstrated that the incorporation of SDS to the gastric phase of this dissolution 
test to match physiological surface tension had a consequence on the prediction of the 
consecutive intestinal dissolution phase, highlighting a limitation of such an in sittt test. 
To determine the extent to which physiological surfactants forming micelles in the 
small intestine protect basic drugs from precipitation during transit requires p1l shift 
experiments to FaSSIF and FeSSIF media. 
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Alternative methods of pH shift experiments have recently been, investigated (Qiu et al., 
2003; Kostewicz et al., 2004; Gu et al., 2005; Kreutzwald et al., 2005) that avoid 
having to transfer the dosage form from one medium to another, which is the 
compendia) procedure for enteric-coated products (Section 1.3.8.3). The transfer 
procedure is also the basis of the Bio-Dis® system (USP apparatus 3) that allows 
sequential immersion of the dosage form into different media (Section 1.3.1.3). The 
flow through apparatus (USP apparatus 4) has also been suggested to mimic the in vivo 
pH shift during dissolution investigations (Looney, 1997) by switching the medium 
reservoir at a set time or addition of buffer. Some of these methods suffer from the fact 
that the dosage form is exposed to fresh medium instead of allowing mixing of the 
medium of first exposure with a second medium. In vivo, all the stomach contents 
empty into the duodenum over time. Hence, such methods do not allow monitoring of 
precipitation of dissolved but unabsorbed basic drug caused by the pH shift during 
gastric emptying into the intestine. Also, methods involving transfer of the dosage form 
are not practical for disintegrating dosage forms. 
The in situ pH shift addresses these issues. Although the pH shift experiments in this 
study utilize simple media as a starting point, if viable the method can be developed 
further using biorelevant dissolution media, food components, enzymes and include an 
absorption compartment. However, sampling and drug extraction may prove 
challenging as the medium becomes more complex. The effect of additives on the 
buffer capacity of the medium may also make it difficult to maintain a constant pH over 
several hours. 
In terms of practicality for this set of experiments, the increased number of stages 
during testing compared to compendia) tests increases the risk of human error during 
the test. For routine application, operator and inter-lab variability may be increased 
depending on the complexity of the test. 
With regard to predicting the dissolution behaviour of a drug during transit through the 
GIT, such a test can lend insight into the physicochemical properties of the medium 
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affecting drug dissolution. Of course, this hinges on how closely the medium resembles 
the respective in vivo environments through gastro-intestinal transit. Also, experimental 
factors such as agitation speed can affect the result. The true utility of such a test needs 
to be determined through correlation with in vivo studies. 
6.3.2. Solubility and dissolution in FaSSIF, FeSSIF and constituents 
Table 6.3a shows that the solubility of loratadine in FaSSIF was much higher than in 
the individual constituent and blank media - approximately 5 times higher than lecithin 
and 7 times higher than NaTC and FaSSIF blank at 24h. Loratadine showed the lowest 
solubility in FaSSIF blank (pH 6.4), which was similar to that in the phosphate buffer 
pH 6.8 (Section 6.3.1). Comparison of the data in Table 6.3a to Table 6.3b shows that 
drug solubility in the fed state media was higher. This is attributed to pH difference and 
the higher concentration of bile salt (NaTC) and lecithin compared to the fasted state 
media. 
The inclusion of the NaTC and lecithin as solubilisers is of particular interest. At the 
higher pH of 6.5 little difference in loratadine solubility was seen between the lecithin 
and NaTC media. This was a combined effect of the low but still physiologically 
relevant concentrations of lecithin and NaTC used (0.059% w/v and 0.165% w/v 
respectively) and the higher pH. At a relatively more favourable pH and at much higher 
concentrations of lecithin and NaTC (0.295% w/v and 0.825% w/v respectively), 
matching those reported in the fed state human intestine, solubility in NaTC (+s 64 µg/ 
mL) was at least 4 times higher than in lecithin (Table 6.3b). However the higher 
solubility in the NaTC medium was still appreciably lower than in the complete FeSSIF 
medium containing both components. This synergistic effect when both components 
were present was attributed to the formation of mixed micelles. Incorporation of 
lecithin into the bile salt micelle decreases the eme, increases the micelle size and 
enhances the solubilisation capacity (Charman et al., 1997; Horter & Dressman, 2001). 
Thus the omission of lecithin from these proposed biorelevant dissolution media to 
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make them more cost effective may potentially compromise the prediction of in vivo 
product performance. 
Two readily available suppliers of NaTC were also compared to test the variability in 
solubilizing behaviour. No discernable differences were noted at the low NaTC 
concentration (fasted state). However, at the higher NaTC concentration loratadine 
solubility was approximately 10% higher in the NaTC obtained from Lancaster (97% 
purity) than in the NaTC obtained from Sigma (95% purity). 
Table 6.3a. Solubility determination of loratadine in fasted state media at 37°C 
Medium pH 
Mean amount dissolved (µg/ml) ± S. D. n=2 
Ih 5h 24h 
FaSSIF 6.4 9.1 ±0.3 15.2±0.01 14.0±0.2 
FaSSIF blank 6.4 1.8 ± 0.04 1.8 ± 0.1 1.9 ± 0.2 
0.059% w/v lecithin 6.5 2.3 ± 0.3 3.1 ± 0.1 3.3 ± 1.0 
0.165% w/v NaTC (Sigma) 6.4 2.1 ± 0.01 2.2 ± 0.02 2.2 ± 0.03 
0.165% w/v NaTC (Lancaster) 6.5 2.1 ± 0.03 2.2 ± 0.1 2.2 ± 0.03 
Table 6.3b. Solubility determination of loratadine in fed state media at 37°C 
Medium pH 
Mean amount dissolved (µg/ml) ± S. D. n=2 
Ih 5h 24h 
FeSSIF 5.0 144.6 t 0.8 146.6 t 1.7 155.1 t 6.5 
FeSSIF blank 5.0 5.8 ± 0.1 6.2 ± 0.2 5.2 ± 0.6 
0.295% w/v lecithin 5.0 6.6 ± 0.2 10.7 ± 1.2 15.6 ± 3.6 
0.825% w/v NaTC (Sigma) 5.0 61.6 ± 0.1 63.2 ± 0.04 63.8 ± 0.6 
0.825% w/v NaTC (Lancaster) 5.0 66.1 ± 0.2 68.1 ± 0.5 68.7 ± 0.3 
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The dissolution profiles of loratadine 10 mg tablets (Brand A) in FaSSIF, FeSSIF and 
0.825% w/v NaTC are illustrated in Figure 6.3. In line with the solubility data, a 
significant difference (p<0.05) existed, using a 2-sample T-test between the dissolution 
profiles in FESSIF and 0.825% w/v NaTC between 30-120 min. The extent of the 
difference in the dissolution profiles between FaSSIF and FeSSIF seen in Figure 6.3 is 
an anomaly, caused by a disintegration issue with Brand A loratadine tablets that further 
delayed drug release from the formulation at pH 6.5 (Table 6.6). This issue is discussed 
further in section 6.3.4. 
6.3.3. Solubility screen and dissolution in surfactant based media 
The incorporation of bile salts and lecithin into dissolution media significantly increases 
the cost of dissolution tests. Furthermore, the preparation of these more complex media 
is time consuming and labour intensive. These factors have limited the utility and 
adoption of the proposed FaSSIF and FeSSIF media during product development stages 
in industry. Thus, attention has been already been focused on finding alternative 
synthetic surfactants to replace bile salt and lecithin whilst these relatively new 
biorelevant media continue to be developed to more accurately match the in vivo 
environment. 
In this study, a number of surfactants of different type were screened for their ability to 
solubilise loratadine. They included CTAB (cationic), SDS (anionic), Brij 35 (neutral), 
Triton X 100 (neutral), Cremophor EL (neutral), Tween 80 (neutral), CHAPSO 
(zwitterionic) and C12AO (zwitterionic). As a starting point, the concentration of each 
surfactant used was twice the quoted cmc from literature (Table 6.1). It is accepted that 
cmc values may be affected by temperature and electrolytes. In the case of ionic 
surfactants, electrolytes in the dissolution medium decrease the cmc whilst temperature 
has little effect (Florence & Atwood, 1988; Malmsten, 2002) . Conversely for neutral 
surfactants, electrolytes have little effect on the cmc whilst raising the temperature of 
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the dissolution medium decreases the cmc (Florence & Atwood, 1988; Malmsten, 
2002). Hence, for the purposes of this study, using surfactants at twice their cmcs was 
considered appropriate to form micellar solutions. The results of the solubility 
experiments are given in Tables 6.4a and 6.4b. The enhancement in loratadine solubility 
in synthetic surfactant media relative to NaTC for SDS, CTAB and CHAPSO was 586, 
46 and 32 fold respectively in FaSSIF blank and 25,1.8 and 1.3 fold respectively in 
FeSSIF blank. The other synthetic surfactants used did not significantly enhance 
loratadine solubility relative to NaTC. The decrease in magnitude of drug solubility 
enhancements in the synthetic surfactants when moving from FaSSIF blank to FeSSIF 
blank was due to the higher concentration of NaTC in the FeSSIF medium. 
Table 6.4a. Solubility determination of loratadine in FaSSIF blank- surfactant media. 
Medium pH 
SDS 
CTAB 
CHAPSO 
Cremophor EL 
Brij 35 
Triton X 100 
Tween 80 
C 12AO 
Mean amount dissolved (tg/ml) ± S. D. n=2 
Ih 5h 24h 
6.7 1194.4± 12.9 1186.9 ± 15.9 1290.0 ±41.3 
6.6 102.4±0.04 102.5±0.1 101.4±0.3 
6.7 68.7±0.4 71.6±0.5 71.2±0.3 
6.7 5.5±0.1 5.3±0.1 3.4±0.5 
6.7 5.3±0.04 5.5±0.04 4.5 ± 0.1 
6.7 3.2±0.2 3.2±0.1 1.5±0.1 
6.7 1.8 ± 0.02 1.7±0.1 1.7±0.2 
6.7 1.7±0.04 1.6±0.1 1.5±0.1 
Table 6.4b. Solubility of loratadine in FeSSIF blank- surfactant media. 
Medium 
SDS 
CTAB 
CHAPSO 
Brij 35 
Triton X 100 
Cremophor EL 
C12AO 
Tween 80 
pH 
Mean Solubility (µg/ml) ± S. D. n=2 
Ih 5h 
5.0 1467.3 ± 10.0 1550.0 ± 67.1 
4.9 107.9 ± 7.3 107.6 ± 3.3 
5.0 80.7t3.2 81.1±1.9 
4.9 10.8 ± 0.2 12.8 ± 2.3 
5.0 10.3±0.6 12.4±2.3 
5.0 10.0±0.6 10.0±0.4 
5.0 5.6t1.5 5.1t0.1 
5.0 4.9±0.2 5.2±0.6 
24h 
1637.3 ± 124.8 
119.0 t 7.1 
83.2: t 1.5 
10.9 t 0.1 
9.4 ± 0.04 
9.1 t 0.8 
4.8 t 0.04 
4.8 t 0.1 
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The solubilising capacity of a micelle is defined as the number of moles of solubilisate 
per mole of micellised surfactant (i. e. C- cmc) (Rosen, 1989). The moles of loratadine 
solubilised in the synthetic surfactants were calculated from the 24h data in Table 6.4a 
and 6.4b. The solubilising capacities of the synthetic surfactants are shown in Table 6.5. 
From Table 6.5 it can clearly be seen that SDS was the best at solubilising loratadine. 
CTAB showed the second highest solubilising capacity. The significantly lower 
loratadine solubility in the neutral surfactant media at higher pH (Table 6.4a) and their 
respective capacities (or lack of) in Table 6.5 showed that these surfactants were poor 
solubilisers of the drug. Where solubilising capacities were not calculated in Table 6.5 
it was because loratadine solubilities in the synthetic surfactants were similar to that in 
the FaSSIF and FeSSIF blanks i. e surfactant mediated solubility enhancement did not 
occur. The higher solubilising capacities at pH 5 compared to pH 6.7 may be attributed 
to electrolyte effects enhancing micelle formation in FeSSIF. 
Table 6.5. Solubilising capacity of synthetic surfactants for loratadine at 37°C 
based on 24h solubility data. 
Surfactant Solubility' (mole 
drug/mole surfactant) 
pH 5.0 pH6.7 
SDS 0.52 0.41 
CTAB 0.29 0.25 
Cremophor EL 0.28 0.11 
Brij 35 0.14 0.07 
Triton X 100 0.05 --- 
CHAPSO 0.03 0.02 
Tween 80 --- --- 
C 12AO --- --- 
1Data corrected for non-mice llar loratadine solubility by subtracting the solubility of loratadine 
in FaSSIF and FeSSIF blanks at 24h (Tables 6.3a and 6.3b respectively) from the solubility 
in the surfactant media at 24h (Tables 6.4a and 6.4b) 
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It was decided to select one surfactant from each class for further study in dissolution 
tests of loratadine tablets. CTAB, SDS, Cremophor EL and CHAPSO were chosen 
because they showed the highest loratadine solubility at the concentrations selected. 
However, the cost per weight of CHAPSO was considerably greater than the other 
surfactants. It was calculated that the quantity required for a standard six-vessel 
dissolution test would cost more than NaTC, which would defeat the objective of the 
study. A plot of loratadine solubility versus CHAPSO concentration is illustrated in 
Figure 6.4. The data revealed that decreasing the CHAPSO concentration from that 
used in the solubility study (10 mg/mL) to 5 mg/mL caused a five-fold decrease in 
loratadine solubility at pH 5.0 and seven-fold decrease at pH 6.5. Further reduction in 
CHAPSO concentration to 2.5 mg/mL further reduced loratadine solubility. These 
results meant that CHAPSO could not be used in lower, cost effective, concentrations 
for dissolution tests without affecting the drug dissolution profile compared to FASSIF 
and FeSSIF. Hence, CHAPSO was omitted from the dissolution study. 
Initial dissolution profiles were generated using Brand A loratadine 10mg tablets. 
Dissolution in Cremophor EL media was considerably lower than in other media at 
similar pH (Figure 6.5). Dissolution in CTAB and SDS media was more promising in 
terms of matching the dissolution profiles generated in FaSSIF and FeSSIF. It was 
decided to develop media using these two surfactants in an attempt to match the FaSSIF 
and FeSSIF derived dissolution profiles. The results are discussed in Section 6.3.5. 
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6.3.4. Disintegration behaviour of different tablet brands 
As mentioned previously in Section 6.3.2, a delay in the disintegration of Brand A 
loratadine tablets was observed during the dissolution tests. Disintegration tests 
were carried out on Brand A tablets and two further brands of loratadine (Brands B 
and C) at three relevant pHs (Table 6.6). The results show that the disintegration of 
Brand A tablets was delayed as the pH was increased to 5.0 and 6.5. Brand B was 
only slightly affected whilst the disintegration time of Brand C was almost doubled 
as the pH was increased. However, the disintegration time of Brand C was still 
below 10 minutes at pH 6.5, and was therefore allowable for an immediate release 
dosage form. 
Table 6.6. Disntegration times of three marketed loratadine tablet brands at 
various pH values. 
Loratadine Tablet Brand 
Mean Disintegration Time (min)t S. D. n=3 
Medium (37°C) Brand A Brand B Brand C 
FaSSIF blank pH 6.5 53.9±2.2 3.310.1 6.410.9 
FeSSIF blank pH 5.0 25.9 ± 0.8 2.0: t 0.4 6.0 ± 0.5 
0.1NHC1pH 1.2 6.2±0.1 1.2±0.1 3.5±0.4 
All three brands listed the same excipients: lactose monohydrate (filler), maize 
starch (disintegrant), pregelatinised maize starch (binder) and magnesium stearate 
(lubricant). The variation in disintegration time between the three products must 
therefore be due to differences in the quantity of excipient used (e. g. 
binder/disintegrant), the grade of excipient and/or manufacturing processes (e. g. 
mixing time/ drying time). 
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6.3.5 Dissolution profile matching using loratadine brands B and C 
Loratadine dissolution profiles were generated in FaSSIF and FeSSIF using Brand B 
and C tablets and the profiles compared to those previously obtained for Brand A in 
Figure 6.6. A pronounced difference in in vitro dissolution between the three 
marketed products was evident for the first hour in FeSSIF and throughout the test 
in FaSSIF. The data suggest that if FaSSIF and FeSSIF are biorelevant, then 
dissolution testing in these media during in vitro bioequivalence studies would be 
more discriminating than compendia) media towards product performance. 
Furthermore, bio-data needs to be sought for the three loratadine products from the 
manufacturers or regulatory authorities to determine whether the three products are 
in effect bioinequivalent or whether the FaSSIF and FeSSIF media were not 
biorelevant in this case. 
Further dissolution tests were carried out using Brands B and C only. In an attempt 
to match the FaSSIF and FeSSIF profiles generated for Brand B using CTAB and 
SDS, the concentrations of CTAB and SDS were adjusted until the best fit was 
obtained. The matched profiles are illustrated in Figure 6.7 and 6.8 for CTAB and 
SDS respectively. The cost reductions through the use of the synthetic surfactants 
are shown in Table 6.7. 
Table 6.7. Comparison of the cost of dissolution testing media' 
FaSSIF 
£85 £0.10 £0.60 
FeSSIF 
Replacement for FaSSIF 
CTAB SDS 
(0.1365 mg/mL) (0.225 mg/mL) 
Replacement for FeSSIF 
CTAB 
£410 901 
(1.82 mgJmL) 
> 
£1.10 
Figures for typical test: n=6, dissolution volume 1000ml 
SDS 
(1 mg/mL) 
£2.60 
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After finding the CTAB and SDS concentrations required to match loratadine 
dissolution in the biorelevant media, dissolution tests were repeated using these 
same surfactant concentrations but with Brand C tablets. The results were compared 
to the respective FaSSIF and FeSSIF profiles for Brand C in Figures 6.9 and 6.10. 
Dissolution in the synthetic surfactant media no longer matched dissolution in 
FaSSIF and FeSSIF. Although there was a difference in disintegration time between 
brands B and C (Table 6.6), disintegration was sufficiently rapid for this not to be a 
significant factor. Again, it is possible that differences in the manufacturing formula 
and/or processes influenced the deaggregation and thus the drug dissolution into 
these media. 
In moving from Brand B to C, changes in the loratadine dissolution profile between 
the biorelevant and surfactant media were observed that need to be explained. Some 
property of the formulation seems to influence loratadine solubilisation into both 
biological and synthetic surfactants. The results with Brand B indicate that there is 
scope for developing surfactant media to mimic FaSSIF/FeSSIF media. However, 
the correlation between in vitro dissolution profiles in the different media is product 
specific, therefore, caution should be exercised when investigating "similar" generic 
formulations (i. e. same qualitative formulae) as dissolution differences have been 
demonstrated. Formulation or process changes during development would require 
adjustment of surfactant concentrations to match the affected FaSSIF/FeSSIF 
dissolution profiles if the synthetic surfactant media were to be used as a surrogate 
for biorelevant media. 
The location of the drug molecule within the micelle of the biological and synthetic 
surfactants is an important consideration in searching for surrogate dissolution 
media. Variation in location of solubilisate between different micellar systems may 
lead to discriminate changes in drug dissolution observed in these media under 
certain circumstances such as formulation changes. The chemical structures of the 
ionic surfactants are given in Figure 6.11. It is generally accepted that for ionic 
micelles the solubilisate would be located in the hydrocarbon core (Florence & 
Atwood, 1988). A polar solubilisate would be oriented such that the polar groups 
would be amongst the micellar charged head groups and the non-polar groups would 
extend into the hydrophobic micellar core. Neutral polyoxyethylated 
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surfactants (i. e. Brij 35, Cremophor EL and Tween 80) solubilise polar molecules in 
the polyoxyethylene shell around the micelle rather than in the core (Florence & 
Atwood, 1988). Since the shell is highly hydrated this may account for the 
differences in loratadine solubility and dissolution seen between the ionic and 
neutral surfactants tested. 
. 74 H3Gý-CF[3 
CH2 
ýH2 
'aýro 
0 
-cH, 
HOU' 
),, ý3: ý., wH 0 
ý, /V/1i/_ 
Sodium taurocholate (NaTC) 
(anionic) 
Phosphatidylcholine (Lecithin) 
(zwitterionic) 
(p' H3C(H2C)15-N+_CH3 `Sv 
CH3 CH3(CH2)1 0CH20' ONa 
Cetyltrimethylammonium bromide (CTAB) Sodium dodecyl sulphate (SDS) 
(cationic) (anionic) 
Figure 6.11. Chemical structures of surfactants used in FaSSIF, FeSSIF, 
CTAB and SDS dissolution media. 
CH3 Br' 
I 
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Confirmation of the inclusion of unionized loratadine within the hydrophobic core 
of the biological and synthetic surfactants could be attained through studying 
changes in the size and aggregation number of micelles before and after addition of 
the drug to the surfactant solutions. Given that a change in the size and shape of 
micelles results in changes in optical density, light scattering or turbidity 
measurements can be used to detect drug solubilisation or formation of mixed 
micelles between bile salt and phospholipids (Andrieux et al., 2004). Micelle size 
has been measured by static and dynamic light scattering methods (Chaibundit et al., 
2002; Andrieux et al., 2004). Aggregation number determinations commonly 
involve time-resolved fluorescence quenching (TRFQ) studies (Benrraou et al., 
2003; Griffiths et al., 2004). Recently, small-angle neutron scattering (SANS) 
studies using appropriate models, have been used to study the morphology and 
interaction of aggregates formed in mixed surfactant solutions (Arleth et al., 2003; 
Griffiths et al., 2004; Penfold et al., 2005). 
6.4. Conclusion 
The precipitation of a poorly soluble basic drug, loratadine, on transit from the 
acidic stomach to the intestine of higher pH, has been simply demonstrated by in 
vitro dissolution testing using an in situ pH-shift method and compendial apparatus. 
The addition of the synthetic surfactant SDS, commonly used in dissolution media 
can mask the precipitation effect. 
The neutral and zwitterionic synthetic surfactants investigated were found to have 
poor solubilising capacities for loratadine and thus were not suitable for replacing 
NaTC and lecithin. SDS and CTAB were more promising in this respect and for one 
brand of loratadine tablet, FaSSIF and FeSSIF dissolution profiles were adequately 
matched by media based on these surfactants. Further work is required to elucidate 
formulation-related or process-related differences affecting the nature of micelles 
and drug solubilisation in both biological and synthetic surfactant systems. 
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7. TRIMETHOPRIM 
7.1. Introduction 
Trimethoprim (5-[(3,4,5-trimethoxyphenyl)methyl]-2-4-pyrimidinediamine) is an 
antibacterial drug used primarily in the treatment and prophylaxis of urinary tract 
infections. Trimethoprim is also used to treat gastro-enteritis, respiratory tract 
infections and malaria. 
OCH3 
H2N ýN" 
I- 
OCH3 
OCH3 
Figure 7.1. The chemical structure of trimethoprim 
Trimethoprim is described as a `very slightly soluble' (1 in 2500 parts water) weak 
base with a pKa of 7.2 and a Log P value of 0.91 (Clarke, 1986). It has an intrinsic 
solubility of 0.4 mg/mL at 37°C (Table 7.1) and is completely absorbed from the 
GIT after an oral dose with peak plasma concentrations being reached between 1-4h 
after administration (Parfitt, 1999). High drug permeability was maintained in the 
bio-data of Klepser et al (1996) who reported a mean oral bioavailability of 102% 
compared to a reference intravenous dose. Trimethoprim has been placed in TICS 
Class II in a classification of the World Health Organisation's Model list of 
Essential Medicines (Lindenberg et al., 2004). 
It was intended to use this drug as a second basic model compound to monitor 
precipitation on pH shift and dissolution behaviour in biorelevant and synthetic 
surfactant based media. 
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7.2. Materials and Methods 
7.2.1. Materials 
Details of all materials used in the preparation of the dissolution media and in 
performing the experiments are listed in section 2.1. 
7.2.2. Methods 
Solubility determinations 
See Section 2.2.1. 
Dissolution testing 
See Section 2.2.3. The volume of dissolution medium used was 1000 mL. 
7.3. Results and Discussion 
Preliminary trimethoprim dissolution data in simulated intestinal fluid (SIF) p1i 6.8 
(Figure 7.2) were unexpectedly high. Therefore, the BCS solubility classification of 
trimethoprim was investigated to address the dissolution results. The findings and 
their implications are discussed below. 
Solubility studies of trimethoprim were carried out at pH 1.2,5.0,6.2,6.8,7.2,7.5 
and 8.2 in appropriate buffers as per the FDA BCS guidance for determining the 
drug substance solubility class (CDER, 2000). The results are shown in Table 7.1. 
According to the guidance, the solubility class is determined by calculating the 
volume of aqueous medium sufficient to dissolve the highest dose strength (200 mg 
in this case) in the pH range 1-7.5 (the dose: solubility ratio). For a drug substance 
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to be classified as `highly soluble' it must have a dose: solubility ratio S 250 mL 
over the pH range 1-7.5. 
Table 7.1. pH related solubility determination of trimethoprim at 37°C. 
Mean amount dissolved (mg/mL) ± S. D. 
(n=3) 
Medium pH lh 5h 24h 
Dose: Solubility 
ratio (mL) 
0.1NHC1 1.2 8.2±0.2 8.5±0.1 6.7±0.3 30 
Acetate buffer 5.0 3.7 ± 0.2 3.9 ± 0.01 4.1 ± 0.1 49 
Phosphate buffer 6.2 2.6 ± 0.1 2.7 ± 0.02 3.7 ± 0.6 54 
Phosphate buffer 6.8 1.6 ± 0.01 1.6 ± 0.003 1.9 ± 0.1 108 
Phosphate buffer 7.2 1.0 ± 0.01 1.0 ± 0.02 1.1 ± 0.1 184 
Phosphate buffer 7.5 0.8 ± 0.01 0.7 ± 0.01 0.6 ± 0.03 303 
Phosphate buffer 8.2 0.5 ± 0.01 0.5 ± 0.02 0.4 ± 0.01 476 
From the results it can be seen that trimethoprim exceeds the solubility class 
boundary at pH 7.5 with a dose: solubility ratio of 303 mL. This explains its `poor 
solubility' classification according to the BCS. Consequently, the dissolution of 
trimethoprim was higher than one would expect for a basic BCS Class II compound 
at intestinal pH. Approximately 100% of the drug dissolved from a tablet in 15 min 
and 80% of powdered drug substance (50 µm) dissolved in Ih in 1000 mL 
phosphate buffer at pH 6.8 (Figure 7.2). The 115% dissolution at 30 min from the 
tablets can be explained by the fact that tablet products can contain a maximum of 
110% of the stated drug dose and excipient interference in the analytical method. 
The dissolution volume and pH used are typically used to mimic intestinal 
conditions. 
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Based on the dose: solubility ratios (Table 7.1), if it was argued that 1000 mL was too 
large a volume to be physiologically relevant, using 500 mL as the dissolution volume 
would still ensure adequate trimethoprim solubility at pH 6.8 so as not to limit drug 
dissolution from the dosage form. 
The solubility and dissolution results imply that the BCS solubility classification 
boundary is too stringent for characterising drug dissolution behaviour. As already 
mentioned in Section 1.5.1, numerous suggestions have been put forward to improve the 
applicability of the BCS (Polli, 2004), which include increasing the solubility class 
boundary to 500m1 and changing the pH range to 1.2-6.8. A narrower pH range would 
be more appropriate for basic drugs with pKa values z 7.0. Drug solubility would be 
expected to decrease significantly at pH values higher than the pKa when the unionised 
proportion of drug increases, but these higher pH values are unlikely to be experienced 
in the small intestine. 
Conversely, Yazdanian et al (2004) demonstrated that increasing the solubility class 
boundary from 250 to 500 mL and limiting the pH range to 1.2. -6.8 had little impact on 
the BCS classification of 15 acidic NSAIDs. When only the solubility at pil 7.4 was 
considered, the solubility classification of all 15 compounds changed from Class 11 
(poorly soluble) to Class I (highly soluble). The results of these workers were not 
unexpected considering the pKa values of the compounds studied were ; -> 3.5. The poor 
drug solubilities that persisted at pH 1.2 required dissolution volumes > 500 niL. 
Instead, Yazdanian el al (2004) suggested narrowing the p1l range to 5.0-7.4, which is 
the pH range in the small intestine where most drugs are absorbed. The widely accepted 
pH range in the small intestine is 4.5-6.8. For weakly basic compounds having pKa 
values in this pH range, increasing the solubility class boundary to 500 niL may still be 
appropriate. 
It has emerged through the widespread implementation of the ICS in pharmaceutics 
research, that certain criteria for drug classification may be too restrictive resulting in a 
physiologically inaccurate assessment of the predicted drug behaviour in vivo. The 
increasing amount of experimental data to exemplify this and general consensus 
amongst pharmaceutical scientists lends support for future proposed amendments by the 
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FDA to extend the applicability of the BCS through scientifically justified changes to 
the criteria. This will facilitate regulatory implementation of the BCS in the 
pharmaceutical industry to apply for biowaivers after SUPAC and for new generic 
products, which at present is not preferred to in vivo bioequivalence studies due to lack 
of certainty in regulatory outcome. 
7.4. Conclusion 
It was not feasible to continue the study with trimethoprim owing to its high solubility 
resulting in a low discriminating power for dissolution differences in various media. 
The classification of trimethoprim as a BCS Class II compound is inappropriate based 
on its solubility and dissolution behaviour at physiologically relevant pHs. Recognition 
should be given to this during solubility class determinations of basic drugs with pKa 
values >_ 7. Increasing the dose: solubility ratio from 250 mL to 500 mL for the solubility 
class boundary and/or narrowing the pH range from 1.2-6.8 may provide a more 
accurate classification for these types of compounds. 
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8. GENERAL DISCUSSION 
8.1. Dissolution testing in physiological conditions 
Dissolution testing has received a lot of attention in recent years as its role has 
shifted from a simple quality control tool to a more predictive test for in vivo 
performance. Drug dissolution from oral dosage forms depends not only on the 
inherent drug and excipient/formulation properties but also on the physiological 
conditions in the GIT such as the presence of food, gastric motility, transit time, pH, 
buffer capacity, osmolality, surface tension, viscosity and liquid volume. These 
combined physiological factors are assessed during pharmacokinetic studies in 
fasted and in fed healthy human subjects. However, if an IVIVC could be 
established between drug dissolution from the dosage form and absorption, it would 
reduce the size, number and therefore cost of human studies required to select an 
appropriate candidate drug product through more accurate preclinical in vitro 
dissolution tests. A crucial factor to correctly predict in vivo performance using 
dissolution tests is to employ a physiologically relevant dissolution medium. 
Various workers have investigated a range of dissolution media such as milk 
(Machcras et al., 1986; Macheras et al., 1987; Macheras et al., 1989; Galia et al., 
1998), nutritional liquid meals and lipid emulsions (Ashby el al., 1989; Buckton et 
al., 1989) and fasted and fed state simulated intestinal fluids (Dressman et al., 1998) 
in an attempt to identify those which were more physiologically relevant. This 
evolution of biorelevant in vitro dissolution testing media was the main driver for 
the investigations of this research project. The aim was to extend the development of 
such media by evaluating more fully the variables affecting in vitro dissolution of 
oral dosage forms such as surface tension, presence of meal (milk), reduced volume 
and pH. These effects were investigated to evaluate whether they originated from an 
interaction between the medium components and the drug and/or the formulation 
excipients, 
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The need to develop biorelevant dissolution test conditions was further emphasiscd 
by the regulatory introduction of the BCS and the biowaver concept for SUPAC and 
generic products (ANDAs), where in vitro dissolution tests could be used as a 
surrogate for in vivo bioequivalence studies for rapidly dissolving Class I drugs. 
Although the current BCS biowaver criteria require dissolution data in media having 
pHs 1.2,4.5 and 6.8, the use of more accurate biorelevant media is a future prospect, 
particularly if biowavers were to be extended to Class II drugs. In consideration of 
proposed biorelevant media, the in vitro dissolution discriminating ability of FaSSIF 
for three loratadine tablet products was demonstrated in this work (Figure 6.6), of 
which the in vivo significance requires bio-data. 
8.2. Surface tension considerations of dissolution media 
A key variable that needs to be measured when comparing different dissolution 
media is the surface tension. Differences in surface tension between media can 
potentially be the cause of changes in drug dissolution through altered wetting 
phenomena and result in inaccurate deductions regarding the effect of media 
components. Thus the surface tension of the media investigated in this project were 
measured in Chapter 3 and were borne in mind during interpretations of the data 
generated. 
The surface tensions of FaSSIF and FeSSIF (46-49mN/m) were considerably higher 
than that of the comparable synthetic surfactant media (27-35mN/m). Except for the 
CTAB 1.82mg/mi medium, the concentrations of these synthetic surfactant media 
were below their cmc values. Consequently, drug dissolution into these media was 
attributed to improved wetting rather than solubilisation as is considered the case in 
FaSSIF and FeSSIF. This has important implications in trying to find cheaper 
synthetic alternatives to the proposed biorelevant media containing bile salts and 
lecithin. If drug dissolution is influenced by a different process (i. e. wetting versus 
solubilisation) in the replacement media, then the altered media may not accurately 
represent in vivo behaviour or correctly discriminate between differences in product 
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performance. This issue could possibly be addressed if the synthetic surfactants 
utilised had similar structures and micelle forming characteristics to NaTC and 
lecithin. 
8.3. Dissolution of ibuprofen and naproxen tablets in milk-based 
media 
The use of milk-based media to investigate the dissolution of poorly soluble acidic 
drugs (Chapter 4 and 5) revealed some interesting phenomena. The work 
highlighted that the effect of a milk protein, casein, on the dissolution performance 
of the ibuprofen and naproxen tablets tested was associated with an interaction with 
the formulation excipients. For naproxen, enhanced drug solubility in milk media 
also played a role. 
Most excipients for oral dose formulations are characterised according to their 
applicable physical and chemical properties, stability and incompatibilities in the 
relevant literature (for example, Rowe et al., 2003). Formulators can also consult the 
FDA's Inactive Ingredient Database, which lists the maximum amounts of inactive 
substances permitted for a particular dosage form and route based on FDA approved 
drug products. However, there is limited data available regarding food-excipient 
interactions, particularly for excipients typically used in IR oral dosage forms. For 
this reason, excipients need to be screened not only for toxicity and drug interaction 
but also for their interaction with major food components (e. g. dietary proteins, 
lipids and carbohydrates) and physiological secretions (e. g. bile salts, phospholipids 
and enzymes) if in vitro dissolution testing is to be used as a predictive tool for ill 
vivo product performance. 
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8.4. Loratadine dissolution 
Anecdotal evidence suggests it is not uncommon for patients to complain about the 
lack of effectiveness of loratadine tablets purchased over the counter in relieving 
allergic symptoms. Whether this is a pharmacokinetic or pharmacodynamic issue is 
a point of debate. The pH-solubility profile for loratadine (Chapter 6) suggests that 
a raised stomach pH may hinder drug dissolution and absorption. The p11 in the 
stomach may be raised due to individual variation, administration of drugs or the 
presence of food. In the latter case, drug absorption may be improved by taking 
loratadine in the fasted state. 
At present there is no recommendation to patients to take loratadine on an empty 
stomach, obviously based on the pharmacokinetic data submitted to regulatory 
authorities prior to granting a product licence. Nevertheless, Simons (2002) and 
Khan et al (2004) have shown high inter-subject variability during pharmacokinetic 
studies. Consequently, for a proportion of the population it is possible that loratadine 
bioavailability will be poor. For poorly soluble basic drugs with rapidly diminishing 
pH-solubility profiles and a risk of precipitation on intestinal transfer, it may 
improve the treatment outcome if manufacturers recommended a conservative 
measure of fasted state dosing. 
The differences in the disintegration times and dissolution profiles of the three 
brands of loratadine tablets (Chapter 6) emphasize that caution should be exercised 
if using `similar' generic products for these types of investigations because of the 
variability in manufacturing formulae and process controls, both of which are not 
often released by the manufacturer. In such a situation, it can prove difficult to 
isolate formulation variables responsible for certain effects seen during in vitro 
testing. More insight into formulation based dissolution differences in biorelevant 
media would be acquired if the dosage form were manufactured in-house. Being 
able to alter controllably the excipients, concentrations and processes in response to 
dissolution data would enable the identification of problem excipients that may 
interact with food and/or physiological components and allow the formulation of 
more robust products. 
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8.5. Development of biorelevant intestinal dissolution media 
The higher loratadine solubility in FaSSIF and FeSSIF in Chapter 6, compared to 
the individual component media, illustrated the importance of phospholipids in 
forming mixed micelles with NaTC and the higher solubilising capacity of these 
mixed micelles. However, FeSSIF is not truly representative of the fed state 
environment although it contains physiological concentrations of bile salt and 
lecithin, which are believed to be the major components affecting drug dissolution 
through solubilisation. To represent the fed state more accurately, meal components 
such as digested lipids, proteins and carbohydrates need to be included in FeSSIF. 
In addition, it is important to note that lecithin-bile salt mixed micelles are involved 
in dietary lipid solubilisation. Thus, in the presence of digested lipid in FeSSIF, the 
proportion of the formed mixed micelles available for drug solubilisation may 
change. Also, the presence of meal components in FeSSIF may affect the 
composition, nature and solubilising capacity of the mixed micelles or the kinetics 
of their formation, resulting in changes in the in vitro dissolution profile, which may 
actually be a closer correlation to the in vivo occurrence. 
8.6. Solubility categorization of drugs in the BCS 
Based on the trimethoprim discussion in Chapter 7 and references therein, the I3CS 
solubility classification criteria should be used with appropriate caution if adopted in 
the drug development stages so as not to exclude promising candidates erroneously. 
The BCS was essentially developed as a regulatory tool to aid the review process 
and accordingly incorporates stringent specifications. Nonetheless, it can be argued 
that the criteria for placing drugs in a solubility class are not justified for the 
prediction of in vivo performance. 
It is well known for ionisable drugs that the p1i of the medium and the pKa of the 
drug will influence solubility. At present the BCS requires solubility data throughout 
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the pH range 1.2-7.5 and dissolution data at pH values of 1.2.4.5, and 6.8, 
regardless of whether the drug is acidic or basic. For biorelevancc, increasing the 
solubility class boundary to 500ml and changing the pH range to 1.2-6.8 may be 
appropriate for basic drugs. For acidic drugs, increasing the solubility class 
boundary to 500 ml and changing the pH range to 4.5-6.8 may be appropriate if it 
can be justified that the drug in question has the most significant absorption in the 
intestine and dissolution and absorption in the stomach is not critical to the 
pharmacokinetics. Hence, it is proposed that two separate solubility and dissolution 
criteria should be applicable in the BCS for acidic and basic ionisable drugs 
reflecting in vivo drug dissolution more realistically. 
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9. GENERAL CONCLUSIONS AND FUTURE WORK 
9.1. General Conclusions 
The utilisation of milk-O. IN HCL mixtures as biorelevant gastric dissolution media 
led to some interesting findings during the solubility, disintegration, dissolution and 
IDR investigations of ibuprofen and naproxen. This work has identified casein, the 
major bovine milk protein, as a food component that may increase the dissolution of 
ibuprofen and naproxen from tablet formulations during residence in a fed state 
stomach environment. The effect was attributed to an interaction of casein with the 
formulation excipients, which requires further elucidation. These findings have 
demonstrated that the use of more complex, alternative dissolution media to 
represent realistic gut conditions has the potential to reveal changes in product 
dissolution performance that may occur in vivo and alter the previously predicted 
bioavailibility. Hence the elucidation of interactions between food constituents and 
formulation excipients will enable the development of more robust oral dose 
products. Furthermore, the inclusion of meal components into in vitro dissolution 
testing media will provide more accurate dissolution data and improve IVIVCs. The 
physicochernical properties of the medium such as pH, buffer capacity, osmolality, 
surface tension and viscosity will also influence drug dissolution from oral dosage 
forms and must be representative of physiological conditions. 
Oral absorption of poorly soluble basic drugs can potentially be problematic if 
precipitation occurs on transit to the small intestine- a major site for drug absorption. 
pH-solubility profiles and in vitro pH-shift dissolution experiments can be useful to 
predict such problems if the media used are physiologically representative. At 
present simple buffer systems are used and more biorelevant conditions need to be 
applied to account for factors such as in vivo solubilisation by bile salts. However, 
the inclusion of synthetic surfactants in the gastric phase of a p11-shift experiment 
may affect the results. 
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Anionic (SDS) and cationic (CTAB) synthetic surfactants were found to be better 
solubilisers of loratadine than the neutral and zwitterionic surfactants for the future 
development of more cost effective media to replace the proposed biorelevant 
media. Loratadine dissolution profiles in FaSSIF and FeSSIF were successfully 
matched using SDS and CTAB based media for one tablet brand but the correlation 
did not hold when the tablet brand was replaced. The solubilisation behaviour of 
FaSSIF, FeSSIF, SDS and CTAB media was highly specific for the product under 
test suggesting that drug solubilisation was sensitive to formulation factors. Hence, 
if these surfactant media were to be used to replace biorelevant media, any 
formulation and process changes would require adjustment of the surfactant 
concentrations to re-match the dissolution profiles in the biorelevant media. 
Whilst FeSSIF is representative of the physiological bile salt and phospholipid 
concentrations it needs to be developed further to mimic the fed state. In particular, 
it lacks food constituents that could affect drug dissolution and solubilisation. The 
addition of monoglycerides, digested proteins, carbohydrates and pancreatin would 
be appropriate. 
The solubility criteria for categorization of drugs into the BCS have received 
considerable comment in literature and in this project. The FDA is reviewing 
suggestions from industry and future changes to the classification are imminent. 
9.2. Recommendations for Future Work 
> The present research highlighted interactions of casein with the excipients 
used in the ibuprofen and naproxen tablets. These interactions require further 
investigation through analysis of solid and liquid mixtures of casein with the 
individual excipients using methods such as DSC and NMR 
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> Ensure Pluse with 0.45% pectin has been reported to adequately match fed 
state stomach after administration of the FDA standard breakfast (Klein et 
aL, 2004). It would be useful to investigate excipient and drug interactions 
with this medium that could affect drug release and dissolution in clinical 
trial subjects. Taking into account that the FDA breakfast has been criticiscd 
for not being representative of the daily breakfast consumed by many 
populations, the utility of media matched to this breakfast may be 
compromised. Although milk composition can suffer from natural 
variability, the general population consumes it whereas only specific patient 
groups use nutritional liquid meals such as Ensure Plus. It is advocated to 
develop a biorelevant milk medium by addition of physiological 
concentrations of pepsin, bile salts refluxed from the intestine and pectin to 
adjust the viscosity of the medium. Other physicochemical factors such as 
pH and surface tension should also be considered. 
> The pH-shift dissolution experiments for poorly soluble basic drugs carried 
out thus far usually involve simple buffer media. The use of more 
biorelevant media in both the gastric and intestinal phases of such a test 
would provide a more accurate prediction of in vivo dissolution behaviour. 
> None of the synthetic surfactants commonly used in the pharmaceutical 
industry have structures similar to those of bile salts. Hence, the nature and 
extent of interactions between bile salts and drugs/excipients may not be 
adequately represented by surrogate surfactant media. For this reason, less 
expensive compounds with similar structures to taurocholate need to be 
screened for their use in biorelevant media. Furthermore, micelle formation 
and drug solubilisation phenomena in these physiological and synthetic 
surfactant environments need to be explored using light scattering methods, 
NMR, TRFQ and SANS. 
¢ The dissolution data acquired in FeSSIF needs to be compared to dissolution 
data in a modified FeSSIF medium containing monoglycerides, digested 
proteins, carbohydrates and pancreatin. 
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> Overall, the in vitro dissolution tests suggested above need to be assessed for 
their biorelevance through in vivo studies where the pharmacokinetic data 
could be used to derive IVIVCs. 
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APPENDICES 
Appendix 1: Attendance at Conferences and Seminars 
1. British Pharmaceutical Conference. 
September 2002. Manchester, U. K. 
2. British Pharmaceutical Conference. 
September 2003. Harrogate, U. K. 
3. Biolnternational 2003: Towards harmonisation in bioavailibility and 
bioequivalence. 
October 2003. London, U. K. 
4. Faculty of Science Post graduate Research Seminars and Poster Session. 
(Chairperson) 
March 2004. Liverpool John Moores University, U. K. 
5. European Conference on Drug Delivery and Pharmaceutical Technology. 
May 2004. Seville, Spain. 
6. British Pharmaceutical Conference. 
September 2004. Manchester, U. K. 
7. Biopharmaceutics Considerations for Oral CR/MR Formulations. 
February 2005. London, U. K. 
8. AstraZeneca Annual PhD Seminar Session. 
September 2005. Alderley Edge, U. K. 
9. British Pharmaceutical Conference. 
September 2005. Manchester, U. K. 
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